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THESIS ABSTRACT

The dopamine receptor complex and the dopamine transporter system (DAT) are
implicated in neuropsychological disorders. The aim of our research project was to
design, synthesise and evaluate high affinity and selective (over D2 receptor subtype)
dopamine D4 receptor subtype ligands, as well as dopamine reuptake inhibitors.
Preliminary D4 and D2 pharmacophore studies led to the synthesis of minimal ligands
based on the readily available tetrahydroisoquinoline structure with N-propyl, N-butyl
and N-phenethyl substituents. These minimal ligands were proposed based on the
minimal features necessary for D4 binding of the aromatic group at a distance of 3.8 Å
from the basic nitrogen. Further refined D4 and D2 receptor pharmacophore modelling
studies led to the design and synthesis of new molecules of the tetrahydroisoquinoline
class based on a refined D4 pharmacophore. These compounds featured the further
addition on nitrogen of bulkier hydrophobic groups, namely 2-(trans-2-phenyl-1cyclopropyl)methyl-1,2,3,4-tetrahydroisoquinoline

11,

(E)-2-cinnamyl-1,2,3,4-

tetrahydroisoquinoline 23 and (E)-2-(4-stilbenyl)methyl-1,2,3,4-tetrahydroisoquinoline
24. These compounds had D4 receptor affinities (Ki) of 930 nM, 880 nM and 880 nM
respectively.

Following the availability of data on other structurally diverse high

affinity and selective D4 (over D2) ligands in the literature, a new second generation D4
over D2 selective pharmacophore was developed with a wider set of training set
compounds than was available for the initial preliminary and refined D4
pharmacophores.

This new D4 pharmacophore model was different from others

reported in the literature and was validated using known D2 and D4 not used in the
training set, as well as through the synthesised and tested tetrahydroisoquinoline

iv

analogues.

This second generation pharmacophore showed reasonable predictive

capability for D4 binding.
With a view to the design of new DAT inhibitors, a DAT pharmacophore model was
generated. Following the preliminary DAT pharmacophore studies using only one class
(tropane) of training set compounds, further work led to the generation of a refined,
less-biased DAT pharmacophore using a structurally diverse training set compared to
the other reported DAT pharmacophores in the literature. Compared to reported DAT
pharmacophore models in the literature, our refined DAT pharmacophore was unique
since it was generated using structurally diverse training set compounds.

A new

compound based on the 6,7-dehydrotropane structure was designed similar to the
benztropine class of compounds.

This new compound, 3α-[1-(4-chlorophenyl)-1-

phenyl]methoxy-8-methyl-8-azabicyclo[3.2.1]oct-6-ene 32, showed high DAT affinity
with a Ki value of 49 nM.

Another quite different new compound, 1-(3-chloro-

[1]benzothiophene-2-carbonyl)-4-phenylpiperazine

39,

a

benzothiophene-based

analogue, was also synthesized and was shown to have a moderate DAT affinity of 320
nM.

This compound is a promising new lead for the potential development of

structurally different DAT inhibitors for combating cocaine abuse.
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1 CHAPTER 1
GENERAL INTRODUCTION
1.1

OVERVIEW

This chapter gives a general introduction to the two main areas of research on
dopaminergic systems in this thesis: the dopamine receptor complex and the dopamine
transporter (DAT) system.

There is great interest in dopamine receptors1 and the

continuing design and synthesis of selective ligands, particularly antagonists, for these
receptors, including the D4 receptor subtype which is implicated in the modulation of
emotional, motivational and cognitive processes.2 The dopamine transporter (DAT)
proteins are involved in the reuptake of the released neurotransmitter, dopamine, and
therefore are physiologically important as they terminate the process of synaptic
transmission.3 Cocaine’s ability to bind to the DAT is believed to be a key factor in its
reinforcing and addictive properties.

Research is therefore focused on developing

different classes of compounds which can act as cocaine antagonists and bind to the
DAT, thereby preventing or delaying cocaine addiction.

1.2

DOPAMINE RECEPTOR COMPLEX

Dopamine was found to exist in the brain in 1958,4 but it took another 15 years to
establish that dopamine was a neurotransmitter. The name dopamine is derived from its
chemical name dihydroxyphenylethylamine.4

It is a major catecholamine

neurotransmitter within the central nervous system and dopaminergic pathways are
involved in the control of emotion, movement, learning,5 memory and prolactin
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secretion.6,7 It also plays a crucial role in incentive motivation and reinforcement
learning and its release is evoked by rewards.8

Dopamine

Dopamine mediates its effects via G-protein coupled receptors.9 This general receptor
type constitutes 80% of all hormone and neurotransmitter receptor subtypes and
includes dopaminergic, adrenergic, serotonergic, and muscarinic10 receptors, together
with receptors for peptides, odorants and opsins.

Their function is to mediate

communication between cells by first receiving messenger signals from extracellular
neurotransmitters, hormones, photons, odorants, or pheromones and then transducing
those signals by activating intracellular G-proteins.11,12 There is a need to understand
the mechanism of ligand binding and selectivity to different dopamine receptor
subtypes in order to design and synthesise high affinity and selectively targeted
compounds.

For example, in the treatment of schizophrenia, dopamine receptor-

selective antagonists are needed in order to eliminate the extra-pyramidal side effects
and also help in the early diagnosis of schizophrenia.13 Potentially, this can be achieved
in a variety of ways, including chemical modification14 of the receptor binding site and
site-specific mutagenesis,15 as well as by developing high dopamine receptor affinity
selective ligands. High resolution X-ray structural data has recently been published for
the human dopamine D3 receptors,37 although this structural analysis was done by
modifying the D3 receptor by introducing a point mutation in the transmembrane
domain to enhance thermal stability.
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The first evidence for the existence of dopamine (DA) receptors in the CNS came in
1972 from biochemical studies showing that DA was able to stimulate adenylyl cyclase
(AC).16 In 1978, DA receptors were first proposed, on the basis of pharmacological and
biochemical evidence, to exist as two discrete populations, one positively coupled to
AC and the other one independent of the adenosine 3,5-cyclic monophosphate
(cAMP)-generating system;17 in 1979, Kebabian and Calne16 summarized these
observations and suggested the designation D1 for the former and D2 for the latter.
Since that time, further DA receptor subtypes have been identified.

After the

introduction of gene cloning procedures, three novel DA receptor subtypes were
characterized. These have been called D318, D419 and D5/D1b20,21 thus taking the total
number of receptor subtypes to 5: D1, D2, D3, D4 and D5.

Although the

pharmacological properties of ligands for D1-like (D1 and D5) and D2-like (D2, D3 and
D4) dopamine receptors23 are quite different, the number of selective ligands for each of
the five receptors subtypes is small. Homology dopamine receptor models have also
been proposed22 that have helped in the design of ligands.

1.3

DOPAMINE RECEPTOR SUBTYPES

As noted above, there are two subfamilies of dopamine receptor complex: the D1-like
and D2-like families. The D1-like family includes D1 and D5 receptor subtypes,23 and the
D2-like family includes D2, D3 and D4 subtypes (see Table 1.1). The D1 and D5
receptors share homology in their transmembrane domains.24,25 There are five variants
of the human D2 receptor subtype. Three of these (A, S, C) occur in only 0.5% to 4%
of the population, while the other two variants are D2short and D2long, both of which are
present together in different proportions (mostly the long form) in different cells.4 The
short form has one exon less (corresponding to 29 amino acids) than the long form.
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Table 1.1 includes the classification of the dopamine receptor complex covering
information on genetic differences in the amino acid sequence as well as examples of
high affinity ligands (Kd values refer to Table 1.1, Kd is the dissociation constant to
describe the affinity between a ligand and a protein to form the ligand-protein complex)
that bind to each receptor subtype.

Many drugs used to treat neurological and neuropsychiatric disorders like Parkinson's
disease, restless leg syndrome and schizophrenia have affinities for dopamine receptors.
Such medications are not without limitations so the development of novel selective
dopamine receptor ligands is of importance for improved therapeutic approaches for
these diseases.26
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Table 1.1 : Dopamine receptor subtypes from gene cloning.27
“They are divided into D1-like and D2-like groups to reflect amino acid homology, functional similarity, and pharmacological properties. Under amino acids, (h) and
(r) refer to human and rat sequences, respectively. D 2(short) and D2(long) refer to different alternatively spliced forms of the D2 receptor gene. The homology values
27
are for the transmembrane-spanning region.” Table taken from The RBI Handbook of Receptors, 2001.

D2(short/long)

D2-like
D3

477 (h)
475 (r)
SCH23390 (0.30)
Dopamine (228)

414/443 (h)
415/444
Spiperone (0.05)
Raclopride (1.8)
Clozapine (56)
Dopamine (1705)

400 (h)
446 (r)
Spiperone (0.61)
Raclopride (3.5)
Clozapine (180)
Dopamine (27)

387 (h)
368 (r)
Spiperone (0.05)
Raclopride (2.37)
Clozapine (9)
Dopamine (450)

100
44

82
49

44
100

44
76

42
54

Caudate/putam
en, nucleus
accumbens,
olfactory
tubercle,
frontal cortex
Adenylyl
cyclase 
None

Hippocampus,
Hypothalamus

Caudate/putamen, nucleus
Nucleus accumbens,
accumbens, olfactory tubercle, olfactory tubercle,
cerebral cortex (low)
islands of Calleja,
cerebral cortex
(low)

Adenylyl cyclase 

Adenylyl cyclase 

Adenylyl cyclase 

Frontal cortex,
midbrain,
amygdala, medulla
(all low),
cardiovascular
system, retina
Adenylyl cyclase 

None

Yes

Yes

Yes

Short

Short

Long

Long

Long

Long

Long

Short

Short

Short

D1
Amino Acids

446 (h,r)

Pharmacological
characteristics (Kd, nM)Ligands

SCH23390
(0.35)
Dopamine
(2340)

Homology
With D1 receptor
With D2 (short)
receptor
Localization

Response
Introns in gene
Organization of amino
acid sequence
Putative third
intracellular loop
Carboxyl terminal tail

D1-like
D5/D1b

D4
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1.4

SCHIZOPHRENIA AND DOPAMINE RECEPTOR THEORY

Schizophrenia is a severe psychiatric disorder characterised by hallucinations,
delusions, eccentric or violent behaviour, and social withdrawal, but the actual
triggering cause (or causes) has not been identified. Although the disease runs in
families, searches for a schizophrenia gene have been unsuccessful. However several
clues point to the involvement of the dopamine system as the majority of patients with
schizophrenia

are

behaviourally

supersensitive

to

dopamine-like

drugs

like

amphetamines.1 The therapeutic potencies of antipsychotic drugs directly correlate with
their affinities to dopamine D2 receptors.28 The fact that antipsychotic drugs that blunt
symptoms have been shown to bind preferentially to the dopamine receptors and block
them implicates dopamine receptors in schizophrenia.29 It is believed that the dopamine
system is over-activated in schizophrenia but it is not known why and whether the fault
lies in the receptors or in some other molecule(s), or how the overactivity could produce
the symptoms of schizophrenia. To add to the complexity, the only dopamine receptor
subtypes known until 1993, the D1 and D2 types, had features that seemed at odds with
what is known about the disease. Both the subtypes are concentrated in the basal
ganglia-knots of neurons involved in controlling movement.

But schizophrenia is

marked by cognitive and emotional effects, not by effects on movement. Furthermore,
the net effect of dopamine on D2 receptor-carrying neurons is to activate psychomotor
pathways in the brain. Over-activation of those pathways result in what is known as the
positive symptoms of schizophrenia, namely hallucinations, delusions and paranoia.
But patients also exhibit negative symptoms, such as withdrawal and lack of emotional
response, that are harder to explain by D2 receptor theory.29
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Most researchers believe that a number of neurotransmitters are involved in
schizophrenia, but the dopamine receptor system has an important role in this severe
mental illness, based on the high levels of dopamine in the brains of schizophrenics
compared with the brains of people without the condition.30 These high levels could be
associated with abnormal dopamine synthesis or enhanced dopamine release from nerve
terminals, impaired dopamine metabolism or dopamine transporter expression, or
increased numbers or sensitivity of dopamine receptors.

Conventional antipsychotic drugs like chlorpromazine and haloperidol31 can be
classified as dopamine D2 receptor antagonists. These neuroleptics have been partially
successful as they improve the positive symptoms of schizophrenia,32 however the
negative symptoms, which have a major effect on the quality of life and social function
of patients with schizophrenia, were not improved in these patients. The usefulness of
conventional neuroleptics was also severely limited by major movement disorders, also
known as extrapyramidal side effects, particularly tardive dyskinesia90 (repetitive
involuntary movements), presumably related to their D2 receptor antagonistic activity.

The D3 and D4 receptor subtypes are also thought to be involved in schizophrenia and
are concentrated in the part of the brain where the symptoms of schizophrenia are
thought to originate: the limbic system, which controls cognition and emotion.29 Since
then research has focussed on the role of these two subtypes in schizophrenia. The D3
receptor subtype has gained significant importance as drugs selective for this subtype
could fill the gaps in the current therapies18 by alleviating the negative symptoms
associated with schizophrenia.33
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Several studies have demonstrated an association between the dopamine D3 receptor
and schizophrenia, however most of these studies did not include a large test cohort. A
more recent study34 involved examining single nucleotide polymorphisms in the
Japanese population and found no link between the D3 receptor subtype and
schizophrenia. In contrast to this, Cariprazine, a D3/D2 partial antagonist was used in a
multi-centred clinical trial (732 patients) and it showed promising results in managing
positive and negative symptoms of schizophrenia.35 Extensive medicinal chemistry
efforts have led to the design of D3 selective antagonists that had fewer side effects
compared to some clinically used drugs in the treatment of schizophrenia.36 These high
affinity compounds, however, were lipophilic and displayed poor bioavailability. In an
attempt to better understand the pharmacological specificity within the dopamine
receptors, the crystal structure for the dopamine D3 receptor was reported recently.37

With respect to the dopamine D4 receptor subtype, the association of this receptor with
schizophrenia was shown by Seeman et al.4

Moreover, the atypical antipsychotic

clozapine (Section 1.5), a D4 receptor antagonist, has high affinity38 for the D4 receptor
subtype with a 20-fold selectivity over the D2 subtype.39 The location of the D4 subtype
in the brain and the high affinity and selectivity of clozapine for the D4 receptor seems
to strongly implicate the dopamine D4 receptor subtype in schizophrenia.

Clozapine, which is capable of treating both the positive and negative symptoms, binds
to the dopamine D4 receptor subtype with moderate selectivity over the D2 subtype, and
does not induce extrapyramidal side effects.40 It demonstrated superior efficacy to
conventional antipsychotics in patients with treatment-refractory schizophrenia.41
Unfortunately clozapine may induce potentially life-threatening emergencies like
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agranulocytosis, seizures and cardiomyopathy42 in some patients and therefore its use is
limited therapeutically. Some research has been directed towards the synthesis of a
family of clozapine analogues43 that would be virtually devoid of such side effects.
Thus selective D4 receptor ligands, with more favourable safety profiles might have
potential as effective antipsychotics without the undesirable side effects.

1.5

USE OF D4 SELECTIVE LIGANDS IN THE TREATMENT OF
SCHIZOPHRENIA
The ability of Clozapine to bind with high affinity to
several additional non-dopaminergic receptors like
the muscarinic ACh receptors, 5-HT receptors and
2 –adrenoceptors makes it difficult to identify the
contribution of D4 receptor function to clinical
Clozapine

efficacy. Investigation of D4 selective agonists or

antagonists is therefore necessary to determine the biological significance of this
receptor subtype.28

A number of synthetic targets have been investigated for their ability to bind with high
affinity to the dopamine D4 receptor subtype with considerable selectivity over other
dopamine receptors.

One such group are the chiral aporphine alkaloids. They were

investigated for their possible role in the treatment of schizophrenia but (-)-aporphines
cause stereotypy (excessive repetition and patterns of speech), hallucinations and
delusions in both animals and humans, whereas (+)-aporphines lack pharmacological
activity and block stereotyped activity induced by the (-)-aporphines.44 With these
findings, the aporphine class of compounds was not investigated further and
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Kulagowski79a et al at the Merck Sharp and Dohme Research Laboratories in the USA
investigated a series of piperazinylazaindoles and piperazinylindoles (Figure 1.1) for
their affinity and selectivity for the dopamine D4 receptor subtype. These studies
resulted in compounds with a 1000-fold improvement in the affinity for the D4 receptor
and 2200-fold selectivity relative to the D2 receptor subtype.

Clozapine

JHH12

Compound 7

JHH6

Compound 13

Compound 36

Compound 45

Fananserin

Compound 14

Figure 1.1 : Some high affinity and selective D4 ligands
Note: The compound names or numbers used are those employed in the original references
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Table 1.2 : D4/D2 receptor affinities for known D4 ligands; ligand names are from
Figure 1.1. D4 selectivity as D4 Ki/D2 Ki.
Ligands

D4 affinity

D2 affinity

Ki (nM)

Ki (nM)

D4

Reference

Selectivity

Clozapine

9-25

60

6

44

Compound 7

15

4200

280

76

JHH12

0.51

>1700

3333

79a

JHH6

1.58

870

550

89

Compound 36

1.4

1100

786

90

Compound 45

2.5

>1700

680

90

Compound 13

1.3

141

108

90

Fananserin

2.93

726

248

90

Compound 14

4.4

1716

390

76

Piperazinylindoles like JHH12 (Figure 1.1) have very high affinity and selectivity for
the D4 receptor over the D2 receptor (Table 1.2), and JHH12 was also a suitable
candidate for radio-isotopic labelling.79a Another series of compounds incorporating 3methoxy-2-naphthyl esters like JHH6 (Figure 1.1) were reported by Boyfield89 et al.
and very high D4 selectivity was obtained. Several mixed 5-HT2/D2 and D4/D2 ligands
(e.g. Fananserin, Figure 1.1) were investigated by a research team in Rhone-Poulenc
where the drug Fananserin (RP 62203) was initially developed as a 5-HT2 antagonist
but it also demonstrated a high D4 affinity and is an antagonist at this receptor.90
Meltzer et al. also studied the biological profiles of a series of neuroleptic agents and
suggested that compounds with D2/5-HT2 binding ratios > 1, such as risperidone45,46 and
tiopirone,47 have potential for the treatment of schizophrenia and lead to a low incidence
of extrapyramidal side effects.
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Various structural analogues of piperazine-related compounds have been reported in the
literature.48 The amide, compound 13 (Figure 1.1), for example, showed high affinity
and selectivity for the D4 receptor over the D2 and adrenergic α1 receptors. Isochroman
derivatives of substituted phenylpiperazines88 (Compound 36, Figure 1.1) also showed
high selectivity and affinity for the D4 receptor subtype (Table 1.2).

In 2003, a highly D4 selective isochroman-based antagonist, sonepiprazole, was tested
in a human clinical trial at three different doses to investigate if the drug was effective
and well-tolerated in the treatment of schizophrenia.49 This multicentre, multinational,
randomized, double-blind, placebo controlled trial showed that sonepiprazole was
ineffective as an antipsychotic in treating hospitalised patients with schizophrenia.

Sonepiprazole

However, the ineffectiveness of this compound may have been a result of poor blood
brain barrier penetration.

It is thus considered still worth pursuing the design and

synthesis of selective and high affinity dopamine D4 receptor ligands for the treatment
of schizophrenia and other neuropsychiatric disorders.
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1.6

D4 SELECTIVE LIGANDS FOR RADIO-ISOTOPIC LABELLING

The applications of positron emission tomography (PET) and single photon emission
computed tomography (SPECT) to investigate the brain functions in normal and
diseased states, are well documented50,51,52 and are used extensively. They are nuclear
imaging techniques, which differ significantly from other imaging modalities, such as
computed axial x-ray tomography (CAT) and magnetic resonance imaging (MRI).
CAT and MRI generally provide fine structural anatomic information while PET and
SPECT provide information about regional biochemistry and pharmacology53 (e.g.
regional metabolism and neurotransmitter binding site density). The radionuclides (e.g.
oxygen-15, nitrogen-13, carbon-11 and fluorine-18) that are used for PET have a short
half-life which is an attractive feature of this imaging technique due to minimal
radiation exposure to the subject under investigation.

SPECT uses low cost

radionuclides53 (e.g. technetium-99m and iodine-123) that have a longer half-life and
these tracers emit gamma radiation that is measured directly.

The development of quantitative methods for studying dopamine and its receptors in the
living brain has also been undertaken extensively.54

Seeman et al.55 used two

radiolabelled ligands, [3H] nemonapride and [3H] raclopride, to indirectly measure the
D4 receptor density, with [3H] raclopride binding to D2 and D3 receptors while [3H]
nemonapride bound to D2, D3 and D4 receptors. The difference in binding of these two
radio-ligands was then attributed to the number of D4 receptor sites. In vivo studies
were carried out on 32 schizophrenic brains, normal brain samples and also individuals
suffering from Alzheimer’s and Huntington’s disease.

The D4 receptor densities

increased by 6.6 fold in schizophrenic brains, whereas the combined D2 and D3 receptor
densities showed only a 10% increase. Six of the 32 schizophrenic brains were drug-
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free and even they showed a significant increase in the D4 receptor density, indicating
that the dopamine D4 receptor density increase was not just due to the antipsychotic
drugs.55
One of the aims of the current work was to potentially assist in the longer term with
more precise D4 receptor density studies.

1.7

DOPAMINE TRANSPORTER SYSTEM

Apart from the receptors, another important facet of the dopaminergic system is the
dopamine transporter, particularly with respect to drug abuse. The continuing negative
impact of drug abuse on the medical and social well being of our society emphasizes the
need to put forth significant effort toward prevention and treatment. In particular, the
relative ease of accessibility to pure and inexpensive cocaine has propelled the abuse of
this illicit drug worldwide56 and has become a serious health and social concern.
Dopamine neuron density and/or DAT sites are involved in a number of neurological
disorders, as well as in drug abuse. Cocaine is known to have multiple effects on
endogenous central neurotransmitter systems and binds with moderate and equipotent
affinity to all three of the monoamine transmitter transporters and subsequently inhibits
the reuptake of dopamine, serotonin and noradrenaline into presynaptic neurons57
(Figure 1.2). However the euphoric and reinforcing effects of cocaine are believed to
be primarily due to its binding to the dopamine transporter (DAT) and inhibition of the
uptake of dopamine.57
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Figure 1.2 : Cocaine interaction with dopamine transporter (from Reference 58)

The function of the DAT is to transport dopamine from the synaptic gap back into the
cytoplasm of the presynaptic neuron. The uptake of dopamine is coupled to the flow of
sodium and chloride ions and is inhibited by many structurally different compounds.60
While there are diverse ligands known that bind to the transporter and inhibit the uptake
of dopamine thereby increasing the dopamine concentration in the synapse, the lack of
an X-ray structure for the DAT has hindered a detailed molecular understanding of the
interaction of these compounds with the transporter.3,59

Some information can be

obtained indirectly through the design and synthesis of compounds that probe the
interaction of substrates with the DAT and this information may prove vital in the
development of a mechanistically based therapeutic for cocaine abuse. The binding
potencies of cocaine at the DA binding site on the transporter have been shown to
correlate with the reinforcing properties of cocaine in animal models.60

Recent advances in molecular biology have identified the amino acid sequences of the
DAT,61 but no experimental 3D structural data have been obtained for this transporter as
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yet. Probes for the DAT may be useful as a marker for the dopaminergic terminals in
some neurodegenerative diseases like Parkinson’s disease,3 where there is a loss of
dopaminergic neurons in the brain (substantia nigra).

The lack of experimental

structures makes it difficult to employ a structure–based design strategy for the
discovery of novel DAT inhibitors as cocaine antagonists.62

It has been hypothesized56 that there are high and low binding affinity sites on the
dopamine transporter, to which cocaine (Figure 1.3) and numerous other cocaine
analogues have access. There is evidence to suggest that the increase in locomotor
activity induced by cocaine and other dopamine uptake inhibitors may be mediated via
the high affinity sites. Certain compounds that bind to the transporter but do not
produce the behavioural effects of cocaine are thought to bind to the low affinity site. 56
Currently research is focused on developing compounds similar to cocaine
neurochemically but not as reinforcing or potentially addictive, thereby preventing the
craving for cocaine. They are also designed to have a slower onset of action and be
longer lasting so they can prevent the craving for a longer time.

Compounds that are capable of inhibiting dopamine transport, and of binding to the
transporter, display remarkable variations in structure, including tropane analogues, 1,4dialkylpiperazines, mazindol analogues, phencyclidine analogues and methyl phenidate
analogues (Figure 1.3).
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Cocaine

WIN 35,428

Methyl phenidate

Mazindol

GBR-12935

Figure 1.3 : Structural classes of ligands that bind DAT

In spite of the structure-activity relationship studies carried out on these classes of
dopamine uptake blockers, there is still no effective treatment for cocaine abuse
available clinically.62

1.8

COMPUTER AIDED DRUG DESIGN (CADD)

In the search for high affinity dopamine D4 receptor and transporter (DAT) ligands,
powerful molecular modelling techniques have been useful in designing lead targets.
Ligand based drug design is also used as an alternative to homology modelling specially
where there is no X-ray crystal structure of the receptor known and the drug design is
based on mapping and orientation of certain features of a molecule that could form the
basis for its high binding affinity and selectivity. This method depends on utilising the
knowledge of other molecules that bind to the biological target (e.g the dopamine
receptor) of interest.
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The basic idea behind molecular modelling is to use computer generated models of the
molecular system under investigation to predict and explain physical properties of the
system that can be experimentally measured. The models are the result of evaluating
mathematical equations that can estimate the 3D orientation of molecular conformers
and is made up of two basic components: Computation and Visualisation. Computation
involves simulation of molecules by the use of quantum and classical physics equations.
Evolution of the modern graphics workstation has enabled real time graphics and fast
computational speeds in the one relatively inexpensive unit, and has provided the
platform for the development of combined visualisation and computational tools.

1.8.1

Ligand-Based Drug Design (Pharmacophore Mapping Approach)

Ligand-based drug design or pharmacophore mapping is one of the most popular
approaches in computer aided drug design when the 3D structural data on the receptor is
not known and when a series of compounds has been identified that show varying levels
of binding affinity63 and selectivity to that particular receptor. The pharmacophore is an
important and unifying concept in rational drug design, which embodies the idea that
molecules are active at a particular receptor because they possess a number of key
features (functional groups) that interact favourably with this receptor and which
possess a geometry complementary to it.64

In order to use this approach, one should have training set data for ligands grouped into
three main categories: high affinity ligands, a range of intermediate affinity ligands, and
ligands with low affinity. The aim of such a method is to identify common features or a
pharmacophore representing the geometry of the receptor-binding site as a collection of
functional groups in three-dimensional space.65 Since the bioactive conformation of a
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particular active compound is not known, the training set should contain a set of low
energy conformations for each compound. This is also desirable as the lowest energy
conformer doesn’t necessarily have to be the active conformer but the energy of the
active conformer is usually not much greater in energy than the global minimum
conformer.

The pharmacophore generation involves identifying common features of the training set
ligands (considering all conformers of each training set ligand) like aromatic rings,
hydrophobic groups, hydrogen bond donors and/or acceptors (OH, OCH3 etc), positive
ionisable nitrogen and their 3D orientation in the space. These pharmacophore models
can be a good guide in designing new structural targets and mapping all their
conformers to get an estimate of their affinities. The models can also be an extremely
useful tool in understanding the features necessary for targeting a particular receptor
subtype over another, provided a pharmacophore model for the other subtype is also
generated. This helps, particularly, in designing synthetic targets to have features not
only for high binding affinity, but also for avoiding certain features that would make
these targets bind to other receptors.

Due to the structurally diverse classes of compounds reported in the literature with
varying affinities for D4 and D2 receptors, there was a need to generate ligand-based
dopamine D4 and D2 pharmacophore models to guide the design and synthesis of
ligands with high D4 affinity and selectivity (over D2).

Also, the ligand-based DAT pharmacophore studies in the literature were generated
using very specific types of structurally similar compounds. There was, therefore, a
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need to generate a DAT pharmacophore with a broader training set in order to develop
new DAT inhibitors which potentially could later find clinical application.

This approach of pharmacophore modelling in the design and synthesis of ligands was
adopted in this current work.

1.9

PROJECT AIMS

With advances in the understanding of neurodegenerative associated disorders, there is
also a continuous need to develop high affinity and selective ligands that can add value
in providing possible mechanisms involved in their interactions with the biological
receptor and transporter systems. Structure-activity relationship studies of these target
ligands can also provide valuable insights into the features necessary to avoid side
effects. The general aims of this project were thus to design and synthesise high affinity
and selective dopamine D4 receptor ligands (antagonists) and dopamine uptake
inhibitors with an additional possibility for radio-isotopic labelling which could prove
useful in the early detection and treatment of schizophrenia and other neurodegenerative
disorders, and in the study and mitigation of cocaine abuse.

Specific Aims:
A. The first aim of this project was to design, synthesise and evaluate high affinity
D4 receptor target compounds by generating ligand-based pharmacophore
models for the dopamine D4 and D2 receptor subtypes.

Due to a lack of

structural information on the D4 and D2 receptors, preliminary 3Dpharmacophore modelling was planned for the dopamine D4 and D2 receptors by
using common structural features of known training set ligands. “Minimal”
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compounds (low molecular weight compounds with few structural features),
were to be designed initially based on these preliminary pharmacophores in
order to test the idea of the minimum features necessary in a molecule to bind
selectively and with considerable affinity to the dopamine D4 receptor. Results
obtained from synthesis and in vitro pharmacological evaluation of these
minimal compounds would then be used to validate the pharmacophore models
and also to refine these models in order to design more strongly and selectively
binding compounds.

Comparison between the D4 and D2 refined

pharmacophore models was expected to help in designing D4 targets by avoiding
D2 pharmacophore model features and trying to map all the features of the D4
model.

B. The second aim of this project was to design, synthesise and evaluate high
affinity cocaine antagonists binding to the dopamine transporter (DAT) protein.
Although high DAT affinity cocaine antagonists have been synthesised, there is
a need for more research to synthesise structurally different compounds. The
compounds planned would be larger than cocaine and thus unlikely to act as
agonists, and potentially be free from any side effects and be more effective in
the treatment of cocaine addiction. Hence we decided to develop new DAT
selective compounds, which would be suitable for radio-labelling to understand
the mechanism of action and the fate of the target ligand in vivo.

The work related to Aim A is described in Chapters 2 and 3. Preliminary and refined
dopamine D4 and D2 pharmacophores are discussed in the first part of Chapter 2. The
second part of Chapter 2 includes the synthesis of designed target compounds based on
these pharmacophores that were predicted to bind selectively to the D4 receptor. The
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third section of Chapter 2 covers in vitro testing results and comparison between
predicted and experimental D4 and D2 receptor binding affinities. Second generation D4
and D2 pharmacophore studies are discussed in Chapter 3. The D4 and D2 receptor
pharmacophore generation evolved from preliminary studies with very few training set
ligands to a refined pharmacophore with more high affinity and selective D4 receptor
ligands, and then finally to the second generation pharmacophore which was based on a
much larger and structurally diverse ligand training set.

The design, synthesis and testing of DAT selective target compounds are discussed in
Chapter 4. Conclusions and future directions are discussed in Chapter 5 while the
Experimental discussion is given in Chapter 6. References are given in Chapter 7.
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2 CHAPTER 2
DESIGN, SYNTHESIS AND TESTING OF
SELECTIVE DOPAMINE D4 RECEPTOR
LIGANDS
2.1
2.1.1

LIGAND BASED PHARMACOPHORE STUDIES
Introduction

While a large number of selective dopamine D4 receptor ligands (agonists or
antagonists) have been published in the literature,79a,

111

there is still considerable

interest in the development of further ligands with greater receptor subtype selectivity
and high binding affinity. Very few of the known D4 compounds have been reported to
be designed based on pharmacophore models. Molecular modelling involving ligandbased drug design may add significant value in the synthesis of selective dopamine
receptor ligands. This technique is particularly valuable where there are only a few
subtle structural differences in the receptor subtypes, for example, between the
dopamine D4 and D2 subtypes. This widely used design approach utilises the common
features of the biologically active ligands that are known to bind to these dopamine
receptors to design a pharmacophore model. It was the aim of this section of the project
to achieve this using CATALYST® computer software.72

The pharmacophore model is generally created using a training set of structurally
diverse ligands with varying affinities for the dopamine receptors. The 3D orientation
of the functional groups of a ligand of interest is of primary importance. Molecular
flexibility is taken into account by considering each compound as a collection of
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conformers representing different areas of conformational space available to a molecule
within a given energy range. For the purpose of the present research on dopamine
receptor ligands, the orientation of functional groups with respect to the basic ionisable
nitrogen is considered to be of importance. The basic amines carry a lone pair of
electrons, which would be protonated at physiological pH and are involved in crucial
binding interactions with carboxylate anions (aspartate) in the receptor. This is true in
the case of most amine-based G-protein coupled receptor ligands; examples of these are
evident in the case of adrenoceptor ligands. 22, 66

In all the pharmacophore development studies, a basic assumption was that the active
ligands and the designed ligands would bind to the same receptor site.

The

superimposition of the training set ligands on the pharmacophore model gave an idea of
the features necessary for high affinity to the receptor.72 These models were validated
by superimposition of other known ligands from the literature with a range of known
receptor binding affinities and which were not part of the training set of the
pharmacophore. The next step involved the design of possible target ligands to map as
closely as possible on all the features of the pharmacophore. An ideal candidate will
map all the features of the pharmacophore72 and will therefore be predicted to bind with
high affinity.

Functionalities like a basic amine (that can accept a proton under physiological
conditions), H-bond donor or acceptor groups, an aromatic ring centroid (with the plane
of the ring also constrained), a hydrophobic feature, and tolerances around each feature
form the basis of the pharmacophore model.

The relative fit values of the best

energetically available conformer of a ligand that tries to map all, or a maximum
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number, of features of the model help to estimate the affinity of that ligand. This in turn
is compared with the actual in vitro binding activities. A similar pattern is followed for
all the training set ligands to establish a correlation of the true and estimated activities
of a ligand and this correlation is used to validate and evaluate different pharmacophore
hypotheses.

Validation of the pharmacophore model is very important.

The generated

pharmacophore models are tested by superimposition of non-training set ligands on
these models in 3D space. The training set should ideally include structurally diverse
compounds that cover a range of activities from the least to the most active.68,72
Comparison of predicted with experimental affinities of designed ligands also provides
valuable information on the quality of the generated pharmacophore models and thus
provide direction for further refinement of these models. The statistical validation is
then done before choosing the model (Section 2.1.3) for analysis based on the relative
cost analysis of the hypothesis generated in comparison to the null hypothesis.

This chapter includes four main sections of pharmacophore studies, beginning with the
‘Preliminary pharmacophore’ studies (Section 2.2) and then refining these studies to
generate ‘Refined pharmacophores’ (Section 2.3) as new data on high affinity and
selective dopamine D4 ligands were published. The third Section 2.4 covers a
comparison between the literature and the refined D4 and D2 pharmacophore models.
Section 2.5 includes superimposition of the preliminary and the refined D4 and D2
pharmacophore models to identify key differences between the two. The synthesis of
the designed dopamine D4 target compounds is discussed in Section 2.7, followed by
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Section 2.9 covering testing of these compounds along with a comparison of predicted
versus experimental binding affinities.

2.1.2

Training set selection and conformation generation

All training set ligands used to generate dopamine D2 and D4 ligand pharmacophores
were antagonists at these receptors and were compiled from their published Ki values.
The training set compound structures and their corresponding D2/D4 binding affinities
are included in different tables in this chapter. Only ligands with at least a 4-fold
selectivity for the D4 receptor over D2 receptor subtype were selected to generate the
preliminary D4 pharmacophores.

The refined (Section 2.3) and second generation

(Chapter 3) dopamine D2 and D4 pharmacophore training sets were comprised of a wide
range of activities in order to generate unbiased and robust pharmacophore models.

Conformers for each of the training set molecules were generated using the standard72
20 kcal/mol limit (relative to the lowest energy conformer found) and the best
conformer search option.

This energy limit of 20 kcal/mol was chosen as it was

recommended by CATALYST® 72 to ensure a large spread of conformers. The software
uses a poling algorithm67,70,71 to ensure effective sampling of conformational space.

Rigid ligands generate few conformations while flexible ligands generate a higher
number of conformations. It should be noted that the number of conformers for each
molecule is restricted to 250 in this program.
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2.1.3

Generation of hypotheses

CATALYST® generates ranked hypotheses consisting of features. These features are
displayed as colour coded round mesh balls, which represent an area in space relative to
other features.

This forms the basis of each pharmacophore72 that maps the

characteristic feature groups in each training set compound in 3D space and thereby
estimates the activity of the compound.
Hypotheses are generated by CATALYST® with emphasis on a group of molecules that
are the most active from the training set. In order to ensure the hypotheses generated
are structure unbiased, the compounds in the training set were selected in such a way
that there were a few structurally dissimilar compounds within the most active group.
The activities of the most active compounds fall into a certain activity range, the upper
limit of which is defined by CATALYST® to be a product of the uncertainty value
multiplied by the activity of the most active compound in the training set. The lower
limit is the binding affinity of the most active molecule.68
CATALYST® uses molecular mechanics (force field) calculations69 and a particular
way to handle conformational space sampling.70,71 The geometry of compounds is built
with the CATALYST® builder and optimised by using a CHARMM-like force field
implemented in the program.69

CHARMM (Chemistry and HARvard School of

Macromolecular Mechanics) is the name of a widely used set of force fields for
molecular dynamics. CATALYST® provides two numbers to assess the validity of a
hypothesis:
(i)

The cost of an ideal hypothesis which is the lower bound on hypothesis costs
of the simplest possible hypothesis that still fits the data perfectly.
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(ii)

The cost of the null hypothesis, which assumes that there is no statistically
significant structure in the data and that the experimental activities are
normally distributed about their mean.

Typically CATALYST® generates ten ranked hypotheses that are arranged in a
hierarchical manner according to the CATALYST® cost analysis, which takes into
account various factors including training set size. According to the assessment criteria,
a generated hypothesis with a score that is substantially below the cost of the null
hypothesis is likely to be statistically significant. If this resultant cost is over 60 bits,
then the hypothesis is deemed statistically significant (with over 90% chance that the
hypothesis is a true correlation), while a resultant cost of 40-60 bits translates to a 75%90% statistical probability and with a resultant cost below 40 bits, the probability drops
below 50%.72

The selection of the best hypothesis was made based on the cost of a particular
hypothesis with respect to the null hypothesis cost and also the mapping of the features
necessary for binding (visual inspection). For example, in all the pharmacophores
generated, a positive ionisable nitrogen feature or a positive charge feature was
considered important in the design of target compounds and structural orientation of
different groups relative to this positive ionisable or positive charge group.

2.2

PRELIMINARY PHARMACOPHORE STUDIES

The aim of the preliminary pharmacophore modelling was to design a "minimal ligand"
having the minimal features necessary for selective affinity for the dopamine D4
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receptor over the D2 receptor subtype. In the longer term, it was then planned to refine
the minimal ligand by adding various groups to this with the aim of improving binding
affinity and selectivity for the dopamine D4 receptor subtype.

Common feature hypotheses were generated using CATALYST® for both of the
preliminary D2 and D4 pharmacophore models. Unlike the quantitative CATALYST®
hypothesis generation, the common feature hypothesis generation does not utilise the
activity data of the training set ligands but instead uses the structural functions that are
common to all the training set ligands. The preliminary pharmacophore models were
generated by the “Common Feature Hypothesis” because of the lack of a suitable
published training set of ligands showing affinity for the particular receptor subtype,
especially in the case of the dopamine D2 receptor. Most ligands in the literature had
reported affinities for D2-like or D2 receptors in general, which meant that the reported
value was not only the D2 subtype affinity but could also be the D2 and D4 (D2-like)
combined affinity. Due to this problem, it was decided to generate a common feature
hypothesis for the preliminary D2 and also for the D4 pharmacophores (in order to
compare the two models). Since the common feature hypothesis method does not take
into account the biological data of the training set ligands, it is not intended to predict
biological affinity.

2.2.1

Preliminary D2 Model

The features used for generating the preliminary D2 pharmacophore were positive
ionisable nitrogen, ring aromatic group, hydrophobic group and hydrogen bond acceptor
and donor groups. Since the compounds used in the training set had a basic nitrogen
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group, an aromatic ring, and groups that may act as hydrogen bond acceptors or donors,
these features were used for generating the hypothesis along with a broad feature in the
hydrophobic group.

2.2.1.1 Training Set Input
At the time the preliminary models were generated, there were very few ligands which
were reported to have selective D2 over D4 receptor affinity. Also, although there were
several reported dopamine D2 receptor ligands at the time, these were not selected in the
training set for preliminary pharmacophores because their reported in vitro mammalian
cell line binding affinities were broadly for the D2-like receptor (including D2, D3 and
D4 subtypes). This made it difficult to incorporate more ligands in the preliminary D 2
specific training set.

The "Common Feature Hypotheses" function was used to generate 10 hypotheses.
This feature was used since the two ligands, SNO92385 and U-91356A85 (Figure 2.1)
did not have the specific D2 subtype receptor binding value recorded in the literature but
only the broad D2 receptor family affinity (which included D2 and D4 receptor
subtypes). Hence the Ki values (specific binding affinity data) for these compounds,
were not used to generate the pharmacophore while only the common features of the
training set were mapped. The ligands SNO923, U-91356A, Naxagolide85, and JHH
1079a (Figure 2.1) were chosen as they were all structurally different. The purpose for
choosing these structurally different compounds was to identify the common features
amongst these four training set ligands.

30

S

Naxagolide

SNO923

U-91356A

JHH10

Figure 2.1: Preliminary D2 pharmacophore training set

All the conformations within a range of 20 kcal/mol of the global minimum conformer
were used for each of the 4 training set ligands. The software selects the conformer that
best fits the hypothesis (not necessarily the global minimum). All four ligands of the
training set were given a "Principal" value of 2 in order to ensure that all chemical
features in each of the training set ligands were considered when generating hypotheses
and at least one mapping for each generated hypothesis was found. The "Maximum
Omit Feature" function was used in order to establish a mapping relationship between
the hypothesis features (e.g.: hydrophobic, ring aromatic, positive ionisable nitrogen,
etc) and the chemical features in the training set. A "Maximum Omit Feature" value of
0 was given to the two most active compounds, Naxagolide and JHH 10, and a value of
1 to the remaining two.
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2.2.1.2 Analysis
Out of the 10 hypotheses generated, the hypothesis ranked 1 was selected as it mapped
the positive ionisable nitrogen feature. The model mapped the following four features:
a positive ionisable nitrogen, hydrogen bond acceptor, and two hydrophobic groups and
the superimposition of the training set ligand SNO923 on the model is shown in Figure
2.2. The mapping of a hydrogen bond acceptor (at a distance of 6.3 Å from the positive
ionisable nitrogen) in the D2 pharmacophore is an important feature. Thus a ligand
having functional groups such as OH or OCH3, which can map on the hydrogen bond
acceptor site will be predicted to bind strongly to the D2 receptor.

Figure 2.2 : Superimposition of compound SNO923 on the preliminary D2
pharmacophore model
Red sphere: positive ionisable nitrogen, small green sphere: hydrogen bond acceptor group,
large green sphere: possible direction and region of the receptor interaction, and blue spheres:
hydrophobic groups.
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2.2.2

Preliminary D4 model

In order to maintain consistency of pharmacophore generation, the features used to
generate the preliminary D4 pharmacophore were the same as for the preliminary D2
pharmacophore.

2.2.2.1 Training Set Input
With a view to ensuring better D4/D2 ligand discrimination, the training set was selected
based on the literature reports of high affinity and selective dopamine D4 receptor
subtype ligands (over D2 subtype) and not the broad D2-like high affinity ligands.
However, there were only a limited number of such D4 selective ligands published at the
time and hence the preliminary D4 pharmacophore training set was comprised of a small
number of compounds. Six out of eight training set ligands were high affinity and D 4
selective compounds. All the training set ligands had at least a 100-fold selectivity over
the D2 receptor subtype. The antipsychotic compounds, N-propyl norapomorphine (R)NPA and clozapine (Figure 2.3) showed significant D4 affinity over the D2 subtype and
formed the remaining two training set ligands.

As discussed in Section 2.2, this

pharmacophore was a model based on the ‘common feature hypothesis’, which enabled
comparison of predicted and experimental affinities.
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(R)-NPA

JHH8

JHH15
Clozapine

JHH6

JHH7

JHH3

JHH12

Figure 2.3 : Preliminary D4 pharmacophore training set input
Note: The compound names are the actual names given by authors in the relevant publications
(see Table 2.1) and are referred to by these names in this chapter.
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2.2.2.2 Analysis
Ten ranked hypotheses were generated. The orientation of positively ionisable nitrogen
with respect to other groups was considered the main objective of this preliminary
pharmacophore as a literature report73 indicated the importance of a protonated basic
nitrogen in ligand binding via a salt bridge to the receptor. Therefore the hypothesis
(ranked no.1) that mapped the positive ionisable nitrogen, ring aromatic and
hydrophobic groups was selected for further studies (Figure 2.4).

None of the

hypotheses mapped hydrogen bond donor or acceptor groups even though most of the
training set molecules had such groups present. Also mapping of a ring aromatic
feature at a distance of 3.8 Å from a positive ionisable nitrogen was a unique to the
preliminary D4 pharmacophore (Figure 2.4). This, therefore, was a distinctive property
of the preliminary D4 pharmacophore model over the corresponding D2 model.

3.8 Å

Figure 2.4 : Most active compound, JHH12 mapped on the preliminary D4
pharmacophore model
(Brown sphere - ring aromatic group (mesh indicates the plane and arrow indicates possible
receptor interaction site), red sphere - positive ionisable nitrogen and blue spheres - hydrophobic
group)
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The most active ligand in the training set was compound JHH12 with a D4 receptor Ki
of 0.5 nM and a selectivity of 3000 fold over the D2 subtype. The mapping of this
compound on the preliminary D4 model is shown in Figure 2.4. The pharmacophore
maps three of the four features, the ring aromatic feature, positively ionisable feature
and one of the two hydrophobic features.
Table 2.1 : Preliminary D4 training set comparison between experimental and estimated
Ki values
Compounds

Experimental D4
Activity

Estimated
Activity

Reference

Ki (nM)

Ki (nM)

JHH8

8

7

79a

JHH15

8

5.9

79b

JHH7

25

12

79b

JHH6

8.2

3.1

89

JHH3

7.7

10

89

JHH12

0.5

0.5

79a

(R)-NPA

25

5.7

74

Clozapine

10

7.1

79a

Although the binding affinity data was not used to generate the common feature-based
preliminary D4 pharmacophore, the predicted D4 binding affinity for all training set
ligands showed a good correlation with their experimental activity (Table 2.1). This
was probably due to the structurally similar training set ligands that were used to
generate the pharmacophore model.
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2.2.3

Design of “Minimal Ligands”

The short distance of 3.8 Å between the positive ionisable nitrogen and an aromatic
group, as mapped in the D4 pharmacophore but not the D2 pharmacophore, then formed
the basis of our ‘minimal ligand’ approach in the design of D4 receptor ligands. The
initial aim of this approach was to investigate D4 receptor affinity of a molecule that had
only these two minimal features.
The position of an aromatic ring close to the positively ionisable nitrogen was critical in
all the training set molecules (distance of 3.8 Å) (Figure 2.5). Using this distinctive
property, the 1,2,3,4-tetrahydroisoquinoline (THIQ, 1; see Section 2.8.2) analogues: Npropyl THIQ 2, N-butyl THIQ 3 and N-phenethyl THIQ 4 were designed and they were
mapped on this D4 model in order to estimate their respective affinities for the D4
receptor. The reason for choosing the tetrahydroisoquinolines was that these analogues
had a constrained basic nitrogen relative to the aromatic ring centre at a distance of 3.8
Å, which was suggested to be important for D4 receptor affinity from the preliminary D4
model.

Also these synthetically accessible analogues (Figure 2.5) had limited

flexibility, which would possibly reduce competitive binding to other dopamine
receptor sites.
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Figure 2.5 : Minimal ligands (THIQ) for D4 receptor
Mapping of two features: positively ionisable nitrogen (shown by the dot on nitrogen) and ring
aromatic (shown by the dot on the THIQ aromatic ring) was critical in the design of the minimal
ligands.

All three THIQ analogues mapped the two important features of the D4 pharmacophore
model: the aromatic ring and the positive ionisable nitrogen at a distance of 3.8 Å,
which was not observed in the preliminary D2 model. We therefore decided to focus on
these two features and synthesise the THIQ analogues in order to prove the validity of
the idea that for selective binding, it is desirable to have an aromatic system close to the
basic amine and undesirable to have any functionality capable of accepting a hydrogen
bond at a distance of around 5.2 Å from the basic amine (see preliminary D2 model,
Section 2.2.1). The synthesis and testing of these tetrahydroisoquinoline analogues with
N-propyl, N-butyl and the N-phenethyl groups are described in Sections 2.8 and 2.9
respectively.
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2.2.4

Limitations of the preliminary D4 model

The training set had a very limited number of ligands without much variation in the
binding affinity values. The selection of the training set ligands was based on their
selectivity for the D4 receptor subtype over D2. The pharmacophore that was then
generated was called the preliminary D4 model and pharmacophore generation was
based on mapping of common features of the training set ligands and not the binding
affinity data of these ligands.

2.3

REFINED PHARMACOPHORE STUDIES

In order to overcome the limitations of the preliminary pharmacophore models, new
quantitative pharmacophores for D2 and D4 receptor ligands were designed.
Pharmacophore models, each for ligands binding to D2 and D4 receptors, were obtained
using the following two sets of features:
1. ring aromatic, hydrogen bond acceptor, hydrophobic group, hydrogen bond
donor and a positive charge.
2. hydrophobic aromatic, hydrogen bond acceptor, hydrophobic group, hydrogen
bond donor and positive charge.
Unlike

the

preliminary

models

(common

feature

hypothesis),

the

refined

pharmacophore models were generated using the binding affinity data for all the new
training set ligands along with a few ligands used to generate the preliminary
pharmacophore. The reported Ki values for all the training set ligands were used to
generate all pharmacophores discussed in this chapter. The Ki refers to the equilibrium
dissociation constant of a ligand determined in inhibition studies usually involving
competitive radioligand binding.75
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This enabled us to get estimated affinities for the test set ligands making it easier to
design new targets. The positively ionisable nitrogen was not always a feature mapped
in all the ten ranked hypotheses generated in the preliminary pharmacophore models,
which made it difficult to analyse such hypotheses. In order to overcome this mapping
problem of the positively ionisable nitrogen feature, it was decided to use the positive
charge feature instead. Hypotheses generated using this feature mapped the positive
charge group in almost all the hypotheses generated.

All the training set ligands

containing a basic nitrogen were used in their protonated forms.

Both sets of features were the same except for the hydrophobic aromatic feature instead
of the ring aromatic feature. Pharmacophore models generated using the ring aromatic
features are more restrictive, and therefore more specific and more desirable, because
the plane of the aromatic ring system is constrained as well as the ring centroid.
Additionally, a projected location constraint is calculated for the interacting system on
the receptor. However, in the event, the hydrophobic aromatic feature did not prove to
be of any additional use as the software tried to map the hydrophobic aromatic feature
generating many hypotheses without the positive charge feature. We were mainly
interested in the relative orientation of chemical features with respect to the positively
charged nitrogen, therefore the positive ionisable nitrogen or the positive charge feature
was used for all further hypothesis development.

Hypothesis Log file
The hypothesis generation log file has the entire data for all hypotheses and the fits of
all training set ligands, their conformers used and how strongly a feature on the
conformer fits on a particular pharmacophore feature (e.g. a basic nitrogen of a
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compound mapping a positive ionisable feature of the pharmacophore, or the protonated
nitrogen mapping the positive charge feature). As an example, the log file (Figure 2.6)
for hypothesis ranked 5 for the refined D2 pharmacophore is discussed below. The
initial section of the log file includes the features of hypothesis ranked 5 followed by
their weights (total of all five feature weights gives the maximum fit value for this
hypothesis), tolerances, coordinates and then a table of distances between features.

Figure 2.6 : Log file for refined D2 hypothesis ranked 5

The next section of the log file covers all the data for each of the training set ligands
including name, fit value on the pharmacophore features, the conformer that is used to
map, and a mirror image (under Enan) used if any (a ‘–’ sign indicates that a mirror
image was used for that compound). The mapping columns indicate the hypothesis
functions that mapped for each compound and the numbers identify a particular instance
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of a feature on the conformer providing optimum fit, and an asterisk means that it was
not mapped. The Est column is the estimated activity for each compound on this
hypothesis which is compared to the Act, the experimental activity for each. If Act/Est
value is greater than 1 then it is indicated by a negative value in the Error column. The
Uncertainty (Unc) is given in the last column. CATALYST® puts a value of 3 by
default for Uncertainty. At the bottom of the log file is the total cost for the hypothesis
(98.7396).

RMS and correlation are measures of the regression derived by

CATALYST® in fitting the estimated activity to the measured experimental activity.

2.3.1

Refined D2 model

Since the preliminary pharmacophore generation, more antagonist compounds became
available in the literature that were selective for the dopamine D2 receptor. In order to
increase the training set ligands with a range of binding affinity data, it was decided to
generate a refined D2 pharmacophore by incorporating these new high affinity D2
receptor ligands in the training set.

2.3.1.1 Training Set
The refined D2 training set consisted of 15 known ligands (Figure 2.7) in contrast to just
4 in the preliminary D2 training set. The range of activities (Ki) was between 0.05 nM
and 3500 nM (Table 2.2). The D2/D4 selectivity of training set ligands ranged from
340-fold for Cmpd 12, one of the high D2 affinity training set ligands, to 4-fold
selectivity for Cmpd 2a (Figure 2.7). With structurally diverse training set ligands with
a wide range of affinities, the pharmacophore generated was likely to be less biased. An
ideal training set, however, would have at least 17 ligands in the training set with a
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range of affinities from high to poor. Structurally different ligands should form a set of
at least four ligands having a similar activity range. This means that an affinity of
around 0.5 nM (high affinity) should be represented by at least four ligands, followed
by moderate level affinity represented by another set and poor affinity by another set. It
is very important that an ideal training set should have at least two ligands with poor
affinity. Thus an ideal training set would have at least five such sets covering a wide
range of activities. This prevents biased pharmacophore generation, since each set is
well represented by structurally different ligands.
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JHH10
Raclopride

Compound 3

Spiperone

Haloperidol
(+)-Butaclamol

Nemonapride

Cmpd12

Cmpd22

Naxagolide

Cmpd5

Cmpd2a

Figure 2.7 : Refined D2 pharmacophore training set
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Cmpd19

Quetiapine

Cmpd3d

Figure 2.7 (continued): Refined D2 pharmacophore training set
Note: The names beginning with ‘Cmpd’ were given during pharmacophore generation and the number after ‘Cmpd’
is from the relevant reference and the rest are the names used in the respective literature

2.3.1.2 Analysis
In the case of the refined D2 pharmacophore model, the first two and the fourth
hypotheses did not map the positively charged nitrogen as a feature, hence these two
hypotheses were discarded. As hypothesis no. 5 was more specific due to the more
restrictive or rigid constraints on the plane of the aromatic system, and since it mapped
the positive charge function as well as the aromatic group, it was decided to select this
hypothesis for all the calculations (Figure 2.6).
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Table 2.2 : Refined D2 pharmacophore training set with experimental and estimated D2
Ki values
Compounds

Experimental
Activity

Estimated
Activity

Reference

Ki (nM)

Ki (nM)

Raclopride

3

5.3

76

Compound3

10.4

4.7

77

(+)-Butaclamol

1.1

13

78

JHH10

2.4

1.4

79a

Spiperone

0.05

0.04

76

Haloperidol

1.4

2.5

86

Nemonapride

0.16

0.33

80

Cmpd12

9

2.1

77

Cmpd22

0.67

100

81

Cmpd5

7

7

82

Cmpd19

1.4

0.77

76

Cmpd2a

560

110

83

Cmpd3d

3500

84

84

Naxagolide

1.5

11

85

Quetiapine

310

36

86

The most active ligand from the training set, spiperone, was predicted to bind with an
affinity of 0.04 nM and its reported experimental affinity was 0.05 nM (Table 2.2). The
second best ligand, nemonapride, was predicted to bind with a Ki of 0.3 nM and its
reported affinity was 0.16 nM. The predicted affinities for all the training set ligands
had a good correlation (R value of 0.72) with their experimental affinities except for
46

Cmpd22 which had a reported Ki of 0.67 nM and was predicted to bind with a Ki of 100
nM. This can be explained by the fact that the software used for pharmacophore
generation selects the most active ligand in the training set (spiperone in the case of the
D2 model) and maps the hypothesis features as per its chemical features. Although
Cmpd22 has a high affinity of 0.67 nM, it has a different structure as compared to
spiperone; Cmpd22 is not a spiro compound like spiperone and it lacks a suitably
positioned hydrogen bond acceptor group, and hence it mapped poorly on the D2 model.
The good mapping of the protonated piperidine nitrogen in spiperone on the positive
charge site in the D2 pharmacophore is shown in Figure 2.8.

Figure 2.8 : Protonated spiperone mapped on the D2 refined pharmacophore

Most training set molecules, with an actual/experimental affinity of 100 nM and over
are predicted (by the pharmacophore hypothesis no. 5) to bind with an affinity of 100
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nM which suggests that if the predicted affinity was around 100 nM, then a compound
would bind poorly to the D2 receptor. It was observed that compounds with predicted
affinities of 100 nM fitted only two of the four features of the pharmacophore. There
was a reasonable general correlation (R value = 0.72) for estimated and experimental
activities for the training set (Figure 2.9).

Figure 2.9 : Experimental and estimated activity (Ki [nM]) correlation (0.72) of the
training set ligands for the refined D2 pharmacophore
The green line represents the ideal situation where the experimental (true activity) and
estimated activities are the same.

Protonated spiperone was the most active molecule of the training set. It closely fitted
all the four features of the pharmacophore and was therefore predicted to bind with an
affinity of 0.01 nM (experimental affinity 0.03 nM, Table 2.2). If a compound had
groups that mapped three out of four features of the pharmacophore, then it was
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predicted to have a binding affinity of around 1 nM (100 fold lower), and thus a fit of
two features gave a predicted affinity of around 100 nM.

2.3.1.3 Statistics
During the hypotheses generation, CATALYST® calculates the cost of two theoretical
hypotheses, one in which the Error cost is at a minimum (where all compounds fall
along a line of slope = 1), and one where Error cost is high (all compounds fall along a
line of slope = 0). The difference in cost values of these two hypotheses is a useful
guide for estimating the chances for a successful experiment.

The greater the

difference, the higher the probability of finding useful pharmacophore models. The
hypothesis significance is based on the magnitude of the difference between the cost of
any returned hypothesis and the cost of the null hypothesis.

The total fixed cost for hypothesis no 5 was 67.07 and the Null hypothesis cost was
103.79. A difference of 60 is ideal. The difference between the null cost and the fixed
cost of the hypothesis no. 5 is 36.7, which means that although the hypothesis generated
was not ideal, it still had a high probability (75% - 90%) of representing a true
correlation in the data. The difference between the costs of hypothesis 5 and hypothesis
1 was very small (hypothesis 1 had a difference between the null and fixed costs of 37.2
as compared to 36.7 of hypothesis 5) and thus we decided to use hypothesis ranked 5 for
all comparisons for the new designed ligands (Section 2.9.2.1).
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2.3.2

Limitations of refined D2 pharmacophore

Due to the small number of high affinity, structurally diverse D2 selective ligands
reported in the literature at the time, the training set for the refined D2 model still had
only 15 ligands. Statistically, as discussed earlier, a training set should have at least 17
compounds to get a reasonable pharmacophore model.

2.3.3

Refined D4 pharmacophore

In order to overcome limitations of the preliminary D4 pharmacophore, a refined D4
model was generated using a much larger set of training ligands, which became
available at the time, and with a range of activities and with at least two compounds
within each range.

2.3.3.1 Training Set
The training set ligands (n=24) for the refined D4 pharmacophore studies are shown in
Figure 2.10. These compounds ranged in D4 binding affinity from the most active
(JHH12; Ki 0.51 nM, Compound 51; Ki 0.67 nM) to poor (Compound 14c; Ki 333 nM,
Compound 1d; Ki 120 nM) (Table 2.3). The high affinity D4 ligands used in this
training set were also highly selective (at least 10-fold) over the D2 receptor subtype.
The objective of the choice of this wide range was to reduce bias during pharmacophore
generation. There was thus a suite of new compounds with different structural features
added to the refined training set compared to the preliminary pharmacophore training
set.

These ligands included variously substituted piperazines, piperidines,

tetrahydroazepines and pyrrolidines.
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JHH12

Rcmpd10d

PD-172760

API-104

A-01-49

Rcmpd10a

Compound 8c

API-103

Compound 12

Compound 3b

PD-141977
Compound 46

Compound 36

Compound 47

Figure 2.10 : Refined D4 pharmacophore training set structures
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Compound 1d
Compound 14c

Compound 12c

JL-13-47

CP-293019
Fananserin

Compound 5c
JHH6

Compound 7
Compound 51

Figure 2.10 (continued): Refined D4 pharmacophore training set structures
Note: Compound names beginning with ‘API’ were given during pharmacophore generation and the rest are from the
relevant reference.
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2.3.3.2 Analysis
The refined D4 pharmacophore differed from the D2 preliminary or refined
pharmacophore in that it mapped four features: positive charge, 2 hydrophobic groups
and a ring aromatic group unlike the D2 pharmacophore which mapped a hydrogen bond
acceptor group along with a ring aromatic group, hydrophobic and positive charge
groups.

Of the ten ranked hypotheses produced, hypothesis no. 2 mapped the ring aromatic
group and was chosen for all calculations, as it appeared to be more restrictive than
hypothesis no.1, which did not map the ring aromatic group. There was only a small
difference between the costs of these two hypotheses (a difference of 0.7) hence it was
decided to use hypothesis 2 for further analysis and comparisons.

Figure 2.11 : Most active training set ligand, JHH12 mapped on the refined D4
pharmacophore
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The most active compound in the training set, JHH12 had an experimental activity of
0.51 nM and the estimated activity was 0.49 nM (Table 2.3). As this molecule mapped
all four features of the pharmacophore (Figure 2.11), it was predicted to bind strongly to
the D4 receptor. A mapping of three features was hypothesised to bind with an affinity
of 50 nM and if only two features are mapped, D4 affinity was estimated to be of the
order of 5000 nM.
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Table 2.3 : Training set ligand activities for the D4 receptor pharmacophore
Compounds

Experimental
Activity

Estimated Activity

Reference

Ki (nM)
Ki (nM)
JHH12

0.51

0.49

79a

Rcmpd10a

8.8

5.9

87

Rcmpd10d

12.4

12

87

Compound8c

6.95

3.1

88

PD-172760

4.3

10

90

API-103

5

7

90

API-104

6.3

5.7

90

Compound12

8

7.1

90

Compound 3b

8.5

5

84

Compound 46

1.3

1.4

90

PD-141977

26

10

90

Compound 36

1.4

12

90

Compound 47

3.8

6.8

84

Compound 51

0.67

3.2

80

CP293019

3.4

10

90

Compound 7

25

7

90

Compound 5c

2.1

4.1

80

Compound1d

120

260

83

Compound 12c

110

6.1

80

Compound14c

333

14

87

JHH6

1.58

6.8

89

A-01-49

6.75

3.5

90

JL-13-47

164

130

90

Fananserin

2.93

8.3

90

Note: All compound names in the table above and in Figure 2.10 are as they are referred to in the respective
publications (unless prefixed API) and have not been given separate numbers for discussions in this chapter.
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2.3.3.3 Statistics
Out of the ten ranked hypotheses, hypothesis ranked 2 was selected for all calculations.
The total fixed cost for this hypothesis was 93.17 while the Null Hypothesis cost was
108.79. In this case the difference was only 15.6, which was quite small compared to
the ideal value (>60). This means that statistically there was only a 50% chance that
this hypothesis represented a true correlation.72 The training set correlation between
experimental and predicted D4 affinity was 0.68 (Figure 2.12). However due to the
range of structurally different ligands chosen for this pharmacophore and with the
previous knowledge (preliminary pharmacophore studies) of the minimum features
necessary for D4 receptor affinity, it was decided to use this hypothesis for further
exploration of other features necessary for D4 receptor binding.

Figure 2.12 : Experimental and estimated activity (Ki [nM]) correlation (0.68) of the
training set ligands for the refined D4 pharmacophore
The green line represents the ideal situation where the experimental
(true) and estimated activities are the same.
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2.3.4

Limitations of the refined D4 pharmacophore

In the refined D4 pharmacophore training set there were structurally different
compounds, and although the experimental binding affinities (Ki) of the top two ligands
were very similar (JHH12 – 0.51 nM, Compound 51 – 0.67 nM), their predicted D4
receptor affinities were different. The amide compound, compound 51, was predicted
to bind with an affinity of 5.3 nM. Although this ligand is the second best in the
training set, it is still under-estimated. This could possibly be explained by the fact that
the pharmacophore generation uses the most active ligand in the training set
preferentially and maps the rest accordingly. This can be a problem, especially if there
are structurally diverse compounds in the training set with similar activity. Also, many
of these compounds fall in the activity range of 0.1 nM – 25 nM with few ranging well
over 100 nM. These inactive ligands are over-estimated in activity compared to their
actual experimental value. For statistical reasons, the affinities of the training set
compounds should ideally be equally spaced over four orders of magnitude.
In order to validate the refined D4 pharmacophore model, the designed and synthesised
ligands in this work were superimposed on the refined D4 pharmacophore and the
predicted and experimental affinity comparisons are discussed later in Section 2.9.2.2.

2.4

COMPARISON BETWEEN LITERATURE
PHARMACOPHORE MODELS

AND

REFINED

D4

Boström91 et al. reported a D4 ligand (antagonist) pharmacophore model by using
conformational analyses (MM3 forcefield) and least squares molecular superimposition
studies. This is a very different approach to that taken in the CATALYST ® program.
The GB/SA (Generalized Born augmented with the hydrophobic solvent accessible
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surface area SA) continuum model92 involved conformational analysis in an aqueous
phase. A set of eighteen structurally diverse high affinity D4 antagonists were used as a
training set. A D4 pharmacophore model was designed following successful results
from the previous D2 pharmacophore model generated by Boström et al.

The main

conclusion drawn by Boström following this D2/D4 pharmacophore comparison was
that the bioactive conformations of antagonists at the two receptor subtypes are virtually
identical. Thus the D2 / D4 selectivity of a compound cannot be rationalized in terms of
differences in bioactive conformations at the two receptor subtypes with respect to those
parts of the molecules described by the pharmacophore elements/features. Moreover
receptor essential volumes seen in the D2 pharmacophore are also present in the D4
pharmacophore. The D4 pharmacophore, however, mapped a feature not present in the
D2 pharmacophore.

Boström et al. designed a preliminary D4 model (similar in approach to that previously
used by the same group to generate the D2 model) consisting of the following four
features: two aromatic ring features (A and B), an ammonium nitrogen feature (C) and a
site point in the protonated nitrogen direction (D) (Figure 2.13). Additionally, two
receptor essential regions (E and F) were proposed which were common to both the
receptor subtypes. Any substituents like a methyl group that could occupy these regions
decreased the affinities for both the subtypes. High D4 and D2 affinities of the most
active training set ligands are proposed to be due to aromatic ring and hydroxy
substituent group interactions with the receptor. The final proposed D4 model had three
aromatic ring features (A, B and G) along with the rest of the features, D, E and F
(Figure 2.13). It was concluded from the above results that the D2 / D4 selectivity of a
ligand was increased because of poor D2 affinity and not due to high D4 affinity. It was
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suggested that the D2 affinity was largely dependent on the electronic properties of the
aromatic ring corresponding to the ring A of the pharmacophore.

Figure 2.13 : Dopamine D4 pharmacophore model taken from Boström et al.91
A, B and G correspond to aromatic rings, C: ammonium nitrogen, D: site point in the
N+-H direction, E and F: receptor essential regions.

In conclusion, Boström et al proposed an identical pharmacophore model for the D4 and
D2 receptor subtypes and attributed the high D2 / D4 selectivity to poor D2 binding
instead of higher D4 affinity. They proposed that the difference in the binding profile
(D2/D4 selectivity) was attributed to the electronic and/or steric properties in parts of the
molecule corresponding to the aromatic ring feature G of the D2 and D4 receptor
subtype pharmacophores. Any changes to these electronic properties in the features
corresponding to A, B and G may affect the selectivity of the ligands due to decreased
D2 receptor affinity, as the D4 receptor affinity was shown to be generally unaffected.91
In contrast to this, our D4 pharmacophore model was considerably different from our D2
model and the structural features and their relative orientation could explain the
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differences in D4 affinity of certain training set ligands as well as for the designed
minimal D4 targets compared to the D2 receptor binding. Our designed pharmacophore
models may thus provide valuable information on specific structural features and their
orientation that may be necessary for high D4 receptor binding affinity. In addition our
models provide some insight into the D2 binding features that should be avoided in a
target molecule and therefore improve D4 selectivity. Although the basic features of an
aromatic ring and positively charged nitrogen were common to the Boström group’s
model, our D4 model had additional features of two hydrophobic groups, one of which
invariably maps the distant aromatic ring of most active D4 ligands (see Figure 2.11).
The biggest difference in our D4 and D2 pharmacophore models is that the D4
pharmacophore model does not map a hydrogen bond acceptor group, a feature which is
a distinctive characteristic of our D2 pharmacophore model. This difference provided
the possibility for designing novel D4 ligands with significant selectivity over the D2
subtype.

Thus, in contrast to the differences in the D4 and D2 affinities being attributed to the
electronic properties of the aromatic ring (proposed by Boström et al), our refined
models suggested that an ideal D4 ligand should avoid a hydrogen bond acceptor group
at a distance of about 4 Å - 5 Å from the basic nitrogen and have two aromatic groups,
one roughly at a distance of 3.4 Å - 3.8 Å and the other at 6.8 Å - 7.0 Å from the basic
nitrogen plus another aromatic or a heteroaromatic or aliphatic group or even an alkyl
side chain at a distance of 4.5 Å – 5.4 Å from the nitrogen. The Boström model did not
include the distances or bond angles, thereby making the comparison with respect to
distances difficult.
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In other related work, Lee et al. published a D4 pharmacophore based on
isoxazolylpiperazine inhibitors93 using CATALYST software. The training set included
18 molecules from only one class of isoxazolylpiperazine compounds. The mapping
features used were: two hydrogen bond acceptor, one hydrophobic-aromatic and one
ring aromatic. This was different from our refined D4 pharmacophore which included
structurally diverse training set ligands and mapping of a positive ionisable nitrogen
feature and the 3D orientation of the hydrophobic group and ring aromatic group was
considered a critical pharmacophore feature for predicting high D4 receptor affinity.

The test set compounds used for validation in the Lee et al. pharmacophore model
showed a good correlation but these were of the same isoxazolylpiperazine class of
compounds. Structural diversity in the pharmacophore generation and validation was
not explored.

This possibly may explain the strong correlation between the

experimental and estimated D4 affinities of the training and test set compounds in their
case.

A comparative tabular summary of D2/D4 pharmacophore features is given in Table 2.4.
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Table 2.4 : D2/D4 pharmacophore feature comparison
Pharmacophores

D2

D4

Key Observation

Boström model
features

2 aromatic rings,
protonated
nitrogen. Extra
features include
two essential
receptor regions
(volumes)

Same features as Difference in the
D2
D2/D4 binding
profile attributed to
electronic
properties of
aromatic ring and
tolerated receptor
volume.

Lee et al model

No D2
pharmacophore

4 features: 2
hydrogen bond
acceptor groups,
ring aromatic
and
hydrophobicaromatic

No mapping of
positively ionisable
nitrogen feature.
Only one class of
training and test set
compounds.

Refined
pharmacophore
features

Positive charge,
hydrophobic group,
ring aromatic and
hydrogen bond
acceptor

Positive charge,
2 hydrophobic
groups and ring
aromatic group

Relative orientation
of aromatic ring
and hydrophobic
groups with respect
to positively
charged nitrogen
and avoiding a
hydrogen bond
acceptor group may
provide selective
high affinity D4
receptor ligands
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2.5

SUPERIMPOSITION OF REFINED
PHARMACOPHORE MODELS

D4

AND

REFINED

D2

Overlay of our D4 and D2 pharmacophore models made the design of final ligand targets
clearer based on the features necessary for D4 binding and avoiding features necessary
for D2 binding (Figure 2.14).

Figure 2.14 : Superimposition of D4 and D2 pharmacophore models
(features to the right hand side are common to both pharmacophores and the features to
the left are unique to each)

The ring aromatic (brown sphere), hydrophobic region (blue sphere) and the positive
charge (red sphere) are the three features common to both the pharmacophores and are
very similar in their orientation. The features that are important with respect to high
affinity and selectivity are the remaining two features.

The hydrophobic (second

hydrophobic group of the D4 model) group (blue sphere), at a distance of 5.6 Å-7.6 Å
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from the positively charged group (red sphere) was unique to the D4 pharmacophore
whereas the hydrogen bond acceptor group (green spheres) was unique to the D2
pharmacophore.

From these observations, it was decided to design target D4 compounds that may map
the desired hydrophobic group of the model.

2.6

DESIGN OF REFINED D4 PHARMACOPHORE MODEL-BASED D4SELECTIVE TARGET COMPOUNDS

Based on the refined D2/D4 pharmacophore models, two tetrahydroisoquinoline
derivatives, 9 and 11 (Figure 2.15) were designed in an attempt to modify the structural
features of the previous minimal THIQ ligands (2, 3 and 4; see Figure 2.5) to map the
refined D4 pharmacophore selectively. The trans stereochemistry of compound 11 was
specified during the conformational generation. The intermediate amides of 9 and 11, 8
and 10 (Figure 2.15) respectively, were also mapped on the refined D4 pharmacophore
to investigate the influence of the lack of a positive ionisable nitrogen in these amides
on the predicted D4 affinity. The N-allyl substituted compound 12 was also designed as
the double bond would make the side chain less flexible than the N-propyl 2 and Nbutyl 3 substituted analogues. The synthesis and testing of these target compounds is
discussed in Sections 2.8.4, 2.8.6 and 2.9.2.

The refined D4/D2 pharmacophore models were also used to design additional new D4
target

compounds

(21,

22,

23

and

24)

(Figure

2.15),

building

on

the

tetrahydroisoquinoline-based minimal ligands. These compounds were selected as they
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mapped at least three of the four features of the refined D4 pharmacophore model and
also because they lacked any functional groups positioned such that they could
potentially map hydrogen bond acceptor sites in the refined D2 pharmacophore model.

8

10

11

9

12
*

*

21

22

23

24

Figure 2.15 : D4 receptor ligand targets
* stereogenic carbon.

The 1-substituted THIQ target compounds 21 and 22 with a stereogenic centre (both R
and S isomers were used in mapping of these compounds on the pharmacophores) were
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modelled using a feature that allows all conformations of the two enantiomers to map,
where the stereochemistry of the compound is unknown. The new stilbene target
compounds, 21 and 24, were predicted to bind to the D4 receptor with an affinity (Ki) of
10 - 11 nM, while the corresponding cinnamyl analogues, 22 and 23 had predicted Ki
values of 7 nM (Table 2.5). The predicted D2 affinities for all four ligands were over
100 nM.

Predictions for both D2 and D4 binding were based on the refined

pharmacophore models. The synthesis of these compounds is discussed in Section 2.8.

Table 2.5 : Estimated Ki values of target ligands (refined pharmacophore)
Cmpd.
No.

Designed Ligands

Estimated

Estimated D4
over D2
Selectivity

Ki (nM)
D2

D4

2

N-propyl THIQ

100

58

1.7

3

N-butyl THIQ

100

110

0.9

12

N-allyl THIQ

100

55

1.8

4

N-Phenethyl THIQ

27

49

0.5

8

2-pyridyl amide

110

260

0.4

9

2-pyridyl amine

80

24

3.3

10

Trans-cyclopropyl phenyl amide

150

250

0.6

11

Trans-cyclopropyl phenyl amine

21

6.5

3.2

21

(E)-1-(4-stilbenylmethyl) THIQ

1200

11

109

22

1-cinnamyl THIQ

550

7

78

23

(E)-2-cinnamyl THIQ

670

7

96

24

(E)-2-(4-stilbenylmethyl) THIQ

1150

10

115
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2.7

INTERACTION OF TARGET D4 COMPOUNDS WITH ADRENERGIC
RECEPTOR SUBTYPES

Like the dopamine receptors, adrenergic receptors also belong to the G-protein coupled
receptor family94 and the endogenous ligands for these latter receptors (adrenaline,
noradrenaline), being 2-arylethylamines, are structurally similar to dopamine. It was
therefore of interest to make a preliminary assessment of whether the designed D4 target
compounds might not also interact with some of the adrenergic receptor subtypes (α1A,
α1B or α1D), whose ligand-based pharmacophore models (Figure 2.16) were accessible
from other work in our group.95 Interaction with these subtypes in vivo may result in
undesired side effects. The proposed D4 ligand target compounds (Table 2.6, Table 2.7
and Table 2.8) were superimposed on the pharmacophores for the three adrenergic
receptor subtypes: α1A, α1B and α1D.
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Figure 2.16a

Figure 2.16b

Figure 2.16c
Figure 2.16 : α1 Adrenergic receptor ligand pharmacophore models95
Figure 2.16a) α1A pharmacophore model; Figure 2.16b) α1B pharmacophore model
(purple spheres: hydrogen bond donor group); Figure 2.16c) α1D pharmacophore model
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Table 2.6 : Estimated affinities of proposed D4 target ligands from the α1A
pharmacophore model.94
Cmpd.
No.

Compound name

2
3
4
8
9
10
11
12
21

N-propyl THIQ
N-butyl THIQ
N-phenethyl THIQ
2-pyridyl amide
2-pyridyl amine
Trans-cyclopropyl amide
Trans-cyclopropyl amine
N-allyl THIQ
(E)-1-(4stilbenylmethyl)THIQ
1-cinnamyl THIQ

22
23
24

(E)-2-cinnamyl THIQ
(E)-2-(4stilbenylmethyl)THIQ

Estimated
Affinity
Ki (nM)
20
20
3.1
250
3.3
2.8
2.8
21
24
2.8
2.8
19

The α1A pharmacophore model (Figure 2.16a) mapped only three features (positive
ionisable, ring aromatic and hydrogen bond acceptor) as compared to four features
(positive ionisable, ring aromatic, hydrophobic and hydrogen bond donor) of α1B
pharmacophore model. The proposed D4 target ligands mapped two out of the three
features of the α1A receptor pharmacophore and were therefore predicted to bind with
moderate affinity to the α1A receptor subtype (Table 2.6). The training set for the α1A
pharmacophore model consisted of very high affinity ligands with 85% of the ligands
having affinities in the range of 0.04 nM - 0.2 nM. Hence an affinity of around 3 nM
can be considered average or poor compared to the training set of the pharmacophore
model.
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Table 2.7 : Estimated affinities of proposed D4 target ligands from the α1B
pharmacophore model.95
Cmpd.
No.

Compound name

Estimated
Affinity
Ki (nM)

2

N-propyl THIQ

140000

3

N-butyl THIQ

5600

4

N-phenethyl THIQ

6200

8

2-pyridyl amide

6200

9

2-pyridyl amine

5500

10

Trans-cyclopropyl amide

5400

11

Trans-cyclopropyl amine

5600

12

N-allyl THIQ

520000

21

(E)-1-(4-stilbenylmethyl)THIQ

8400

22

1-cinnamyl THIQ

5300

23

(E)-2-cinnamyl THIQ

5300

24

(E)-2-(4-stilbenylmethyl)THIQ

14000

The α1B pharmacophore model (Figure 2.16b) contains four features including a
hydrogen bond donor group. The proposed D4 targets did not have a hydrogen bond
donor group and also the hydrophobic group of α1B pharmacophore was in a different
orientation compared to the D4 receptor pharmacophore. Thus out of the four α1B
pharmacophore features, only two were mapped by the proposed D4 ligands and hence
were predicted (Table 2.7) to bind poorly to the α1B receptor subtype.
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Table 2.8 : Estimated affinities of proposed D4 target ligands from the α1D
pharmacophore model.95
Cmpd.
No.

Compound name

Estimated
Affinity
Ki (nM)

2

N-propyl THIQ

320

3

N-butyl THIQ

180

4

N-phenethyl THIQ

190

8

N-pyridyl amide

190

9

N-pyridyl amine

180

10

N-trans-cyclopropyl amide

180

11

N-trans-cyclopropyl amine

180

12

N-allyl THIQ

300

21

E-1-(4-stilbenylmethyl)THIQ

330

22

1-cinnamyl THIQ

180

23

(E)-2-cinnamyl THIQ

180

24

(E)-2-(4-stilbenylmethyl)THIQ

310

A similar observation was made on comparing D4 target compounds on the α1D
pharmacophore model. This pharmacophore mapped three features – positive ionisable,
hydrophobic and hydrogen bond acceptor. The proposed D4 targets are estimated to
bind with moderate affinity to the α1D receptor subtype since they mapped two of the
three features. This mapping was similar to that on the α1A pharmacophore, but since
the training set of α1A pharmacophore had very potent ligands, the predicted D4
affinities would appear to be better. However, in comparison with the α1A training set,
the predicted D4 affinities on the α1D pharmacophore were moderate to low (Table 2.8).
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Based on these comparison models, it can be concluded that the proposed D4 target
compounds were predicted to have reasonable selectivity for binding to dopamine
receptors over α-adrenergic receptors, apart possibly from the α1A receptor.

2.8

2.8.1

SYNTHESIS OF DESIGNED DOPAMINE D4 - SELECTIVE RECEPTOR
LIGANDS
Introduction

One aim of this project was to synthesise the designed minimal dopamine D4 ligands
using synthetically accessible 1,2,3,4-tetrahydroisoquinoline as the template structural
molecule. Various analogues of tetrahydroisoquinolines have been synthesised and
assessed as ligands for dopamine receptors.96 The rationale for the selection of 1,2,3,4tetrahydroisoquinoline as a base structure was that it is readily available and also is an
endogenous amine found in mammalian brain.97 Its exact role is not fully understood,
but recent studies in rat models have shown that this compound may play a
neuroprotective role.97

The N-propyl 2 and N-butyl 3 analogues of 1,2,3,4-tetrahydroisoquinoline have been
reported earlier and have been tested for dopaminergic activity, 98 however their D4
receptor affinity over the dopamine D2 subtype has not been reported. The purpose of
synthesising these simply substituted compounds was mainly to test the idea of the
minimal pharmacophore features necessary for dopamine D4 receptor binding, and then
to use this information to add more groups to increase selectivity and affinity analogous
to the recent fragment based approach99 in drug design. The synthesis of these ligands
is described in the following section.
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2.8.2

N-substituted tetrahydroisoquinolines

It was planned to access most of the targets by N-alkylation of the commercially
available 1,2,3,4-tetrahydroisoquinoline (THIQ) 1 with the appropriate alkyl halide in
the presence of a base (Scheme 2.1).

R-X / K2CO3
ethanol / reflux
1

R-X = 1-iodopropane
1-iodobutane
allyl bromide

R
propyl (2)
butyl (3)
allyl (12)

Scheme 2.1 : N-alkylation of THIQ

The first minimal ligand, N-propyl-1,2,3,4-tetrahydroisoquinoline 2, was synthesised in
high yield by reaction of 1-iodopropane with 1,2,3,4-tetrahydroisoquinoline in the
presence of potassium carbonate as a base. Complete alkylation was achieved after
heating the solution in ethanol and 2 was isolated by column chromatography. High
resolution mass spectrometric data on 2 was in agreement with the molecular formula
and molecular weight of the desired compound. A characteristic 1H NMR single signal
at 4.20 ppm was assigned to the 1-position methylene protons, consistent with
assignments reported98 for other 2-substituted 1,2,3,4-tetrahydroisoquinolines.

Similarly the N-butyl analogue 3 was synthesised by the reaction of 1-iodobutane with
1,2,3,4-tetrahydroisoquinoline in ethanol to afford 3 in high yield (87%) upon
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recrystallisation of the crude product.

1

H and

13

C NMR spectroscopic analysis

confirmed the structural assignment.

The reaction between 1,2,3,4-tetrahydroisoquinoline and allyl bromide in the presence
of base gave the N-allyl analogue 12 as colourless needles. Electrospray ionisation
(ESI+) and electron impact (EI+) high resolution mass spectra substantiated the
molecular formula of the desired compound 12. Characteristic multiplets at 5.8 – 5.98
ppm and 5.08 – 5.17 ppm for the terminal allylic protons in the 1H NMR spectrum
supported the formation of the desired compound 12; further support was forthcoming
from the 13C NMR data, with new signals at 135.7 and 125.5 ppm being consistent with
the presence of an N-allyl group.

A direct N-alkylation procedure (Scheme 2.2) was also used in the synthesis of
compound 4. Reaction of 1 with phenylethyl bromide in 1-butanol in the presence of
potassium carbonate, gave the desired product 4 in good yield (77%).

phenethyl bromide / K2CO3
NH
1

1-butanol / reflux

N
4

Scheme 2.2 : Direct N-alkylation

The CI mass spectrum confirmed the expected molecular weight for 4 with an MH+ ion
at m/z 238 and a fragment ion at m/z 146 corresponding to loss of the terminal benzylic
group (and a hydrogen atom); it is probable that the ion at m/z 146 corresponds to the
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stabilised N-methyl-3,4-dihydroisoquinolinium ion. The high resolution mass spectrum
(CI+) on the hydrochloride salt of 4 also afforded evidence for the molecular formula
and molecular weight of the desired compound, and this was confirmed by elemental
microanalysis.

While further alkylation of the tertiary amine products to give quarternary salts can be a
problem with the N-alkylation approach to these amines, this was not a significant
problem in the above cases using equimolar quantities of 1 and the appropriate halide.
In one case, further alkylation of the N-allyl derivative 12 was deliberately explored.
Heating of 12 at reflux in tetrahydrofuran for 24 h in the presence of allyl bromide was
required to afford a high yield of the quarternary salt 2,2-bisallyl-1,2,3,4tetrahydroisoquinolinium bromide 19.

2.8.3

Synthesis of N-substituted tetrahydroisoquinolines via the intermediate
amides

An alternative approach to N-substituted tetrahydroisoquinolines is via initial amide
formation followed by reduction of this functionality to the tertiary amine (Scheme 2.3).
Although not noted here specifically as a potential D4 receptor ligand, the viability of
the intermediate amide approach was assessed initially with m-bromobenzyl amide 6.
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K2 CO3 / R (R -COCl (5)
(R)

T HF / warm (2h)
1

6, 10

1. H3 B-SMe2 / T HF
2. methanol / K2 CO3 / reflux / 4h

6, 7 : R =

10, 11 : R =
(R)
(racemic)
7, 11

Scheme 2.3 : Synthesis of N-substituted THIQ analogues through intermediate amides

For the synthesis of the amide 6, the appropriate acid chloride, m-bromophenylacetyl
chloride 5 (R = m-BrPhCH2), was first prepared from the reaction of m-bromophenyl
acetic acid with an excess of thionyl chloride and then reacting the acid chloride formed
with 1 in dry tetrahydrofuran in the presence of potassium carbonate. This afforded 6 in
68% yield. Optimum yields were obtained by controlling the reaction temperature
between 60 ˚C and 65 ˚C with stirring; at higher temperatures (>80 ˚C) the reaction
proceeded rapidly but resulted in a red coloured charred mass, probably due to in situ
base-induced ketene formation from the acid chloride and subsequent reactions.

Reduction of the amide 6 was then achieved by using an excess of borane-dimethyl
sulfide in tetrahydrofuran, which was added slowly via a syringe to a stirred solution of
6 in tetrahydrofuran and then subsequently heating at reflux (Scheme 2.3). The reaction
was then quenched by the addition of ethanol and concentrated in vacuo to give a
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residue, which was then dissolved in methanol and heated at reflux in the presence of
base. Filtration and removal of the volatiles gave the crude amine, which was then
purified by column chromatography to give the pure amine 7 (70%). 1H and 13C-NMR
spectroscopic data were consistent with the structure with characteristic signals for the
benzylic substituent methylene group being apparent at 3.68 ppm and 61.6 ppm in the
respective spectra.

This successful amide approach was then extended to the N-substituted THIQ
analogues, 10 and 11.

2.8.4

Synthesis of trans-2-(2-phenyl-cyclopropanecarbonyl)-1,2,3,4tetrahydroisoquinoline 10 and the amine 11

The amide 10 was synthesised as outlined in Scheme 2.3. The acid chloride 5 (R' =
cyclopropylphenyl) of trans-2-phenyl cyclopropane carboxylic acid was first prepared
from thionyl chloride and was then reacted with 1,2,3,4-tetrahydroisoquinoline in dry
THF on warming the mixture with stirring for 2 hours.

Work up afforded the

corresponding amide 10 in 86% yield. The HR-MS (EI+) data was consistent with the
mass of 277.1456 calculated for C19H19NO. In the 1H NMR spectrum, the cyclopropane
protons appeared as multiplets at 1.22 ppm – 1.31 ppm, 1.56 – 1.61 ppm, 1.82 – 1.91
ppm and 2.52 – 2.58 ppm. The 13C NMR of the amide also revealed the presence of a
signal ascribed to the amide carbonyl group at 178 ppm and three quaternary carbons at
139.6 ppm, 138.1 ppm and 134.4 ppm ascribed to C8’, C4’ and C-13 respectively (for
atom numbering see Section 6.2.2.9). Signals at 41.8 ppm (C-10), 25.3 ppm (C-12) and
17.3 ppm (C-11) in the 13C NMR spectrum were attributed to the cyclopropyl group.
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Reduction of 10 with an excess of borane-dimethyl sulfide in tetrahydrofuran (Scheme
2.3) afforded the amine 11 in good yield (84%). Since column chromatography was not
successful in purifying compound 11, the crude product was subjected to an acid/base
extraction sequence to give 11 as an oil.

The base was then converted into its

hydrochloride salt by the procedure outlined below in this section (Section 2.8.5). The
mixture was then filtered through celite and the precipitate was dried under vacuum and
was recrystallised from diethyl ether to afford the pure hydrochloride salt of 11. The CI
mass spectrum of this salt gave an MH+ at m/z 264 which was consistent with the
molecular weight of the desired product. The HR-MS (ESI+) gave evidence for the
mass 264.1754 calculated for C19H22N (MH+). In the 1H NMR spectrum of this salt,
appearance of a triplet assigned to the methylene group (between the nitrogen and the
cyclopropyl group) at 3.72 ppm supported the structure of the reduced compound 10.

2.8.5

Formation of hydrochloride salts

The amines 2, 3, 4, 11 and 12 were converted to their water soluble hydrochloride salts
prior to pharmacological testing. Formation of these salts was achieved by passing
hydrogen chloride gas through a solution of each of the above compounds in anhydrous
diethyl ether and separating the precipitated hydrochloride salt by filtration.

2.8.6

Preparation of 2-[2-(2-pyridyl)ethyl]-1,2,3,4-tetrahydroisoquinoline 9

A different approach was used to first synthesise the amide 8 (Scheme 2.4) compared to
the previous acid chloride route (Scheme 2.3).
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DCC
1-hydroxybenzotriazole
THF

1

8

1. BH 3 / SM e2 / THF
2. ethanol / K 2CO3 / reflux / 4h

9

Scheme 2.4 : Synthesis of 2-[2-(2-pyridyl)ethyl]-1,2,3,4-tetrahydroisoquinoline 9
through DCC coupling

Synthesis of 2-(2-pyridyl) acetyl-1,2,3,4-tetrahydroisoquinoline 8 was achieved by a
direct 1,3-dicyclohexylcarbodiimide (DCC)-mediated coupling of an excess of 2pyridyl acetic acid and 1,2,3,4- tetrahydroisoquinoline in dry THF (Scheme 2.4) to give
the crude amide 8 as a brown powder. The use of dry THF and warming the reaction
mixture with stirring were critical factors for complete acylation. The TLC analysis of
the crude amide showed two components present (one for the amide 8 and one other
component) with little difference in their Rf values. The CI-mass spectrum of the crude
amide gave evidence mainly for the amide with an MH+ at m/z 253 together with
dicyclohexyl urea (C13H24N2O) as expected from the dehydration reaction. Separation
of the amide from the urea by-product was achieved using column chromatography.
The CI mass spectrum of 8 gave evidence for the structure with an MH+ ion at m/z 253.
High resolution MS (EI+) was consistent with the mass 252.12618 calculated for
C16H16N2O. Key 1H NMR signals, including a doublet signal ascribed to the H-15
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proton (adjacent to the pyridyl ring nitrogen) downfield at 8.44 ppm, were consistent
with the desired compound. The

13

C NMR gave further evidence for the structure by

the key carbonyl carbon signal at 169.2 ppm as well as the signals at 149.2 ppm and
146.4 ppm, ascribed to the C-11 and C-15 carbons (adjacent to nitrogen of the pyridyl
ring) respectively.

Reaction of the amide 8 with an excess of borane-dimethyl sulfide in THF resulted in
amide reduction to give the desired amine 9. The crude product was then purified by
column chromatography to give the amine 9 as off-white flakes (48%). The CI mass
spectrum of 9 gave an MH+ signal at m/z 239 that was consistent with the molecular
weight of the desired product, and the HR-MS of the hydrochloride salt, used for
pharmacological testing, was consistent with the molecular formula of 9. In the 1H
NMR of 9, a triplet signal at 3.68 ppm was assigned to H-9. The

13

C NMR spectrum

also clearly showed the appearance of a methylene carbon at 39.8 ppm and
disappearance of the carbonyl carbon (C-9) that appeared at 169.2 ppm in the amide 8.

2.8.7

Synthesis of (E)-2-cinnamyl-1,2,3,4-tetrahydroisoquinoline 23 and (E)-2-(4stilbenylmethyl)-1,2,3,4-tetrahydroisoquinoline 24

The bulkier 2-substituted analogues (compounds 23 and 24) of THIQ were mapped on
the refined D4 and D2 pharmacophores and were predicted to bind with a higher affinity
and selectivity to the D4 receptor than the previous N-substituted minimal ligands
(compounds 2, 3 and 4). Hence it was decided to synthesize the 2-substituted THIQ
analogues with (E)-cinnamyl or stilbenyl groups via N-alkylation (Scheme 2.5 and
Scheme 2.6 respectively).
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1

13
EtOH

K2CO3
reflux/ 16h

23

Scheme 2.5 : (E) - cinnamyl group substitution via N- alkylation

N-Alkylation (Scheme 2.5) of 1 with commercially available (E)-cinnamyl bromide 13
gave the target compound 23 in good yield. The CI-MS spectrum gave an m/z signal for
MH+ at 250 which was consistent with the molecular weight of the desired compound.
The 1H NMR spectrum of 23 provided good evidence for the structure with the vinylic
proton signals being ascribed to a multiplet at 6.31 – 6.42 ppm and a doublet (J = 18.2
Hz) at 6.62 ppm, plus a singlet signal at 3.72 ppm being consistent with the C-1
methylene group.

Direct alkylation of 1 in which commercially acquired (E) – 4-chloromethylstilbene 14
was reacted with 1 in the presence of potassium carbonate afforded 24 in good yield
(Scheme 2.6).
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14

1
EtOH

K2 CO3
reflux/ 16h

24

Scheme 2.6 : Introduction of the stilbenyl group via N-alkylation

The HR-MS (EI+) data for 24 was consistent with the molecular formula C24H23N for
the cation. In the 1H NMR spectrum of 24, a characteristic singlet signal ascribed to the
C-1- methylene group appeared at 3.96 ppm. The trans stereochemistry in the stilbenyl
moiety was confirmed by the appearance of doublets at 6.42 ppm and 6.64 ppm (J =
18.2 Hz) for the vinylic protons.

2.8.8

Attempted

synthesis

of

(E)-1-(4-stilbenylmethyl)-1,2,3,4-

tetrahydroisoquinoline 21
Some 1-substituted analogues of THIQ were also mapped on the D4 pharmacophore and
compound 21 was predicted to bind with high affinity to the D4 receptor subtype. The
proposed synthetic route to the amine 21 is outlined in Scheme 2.7. It involved a four
step synthetic approach. The first step involved the DCC-mediated coupling of βphenethylamine and 4-bromophenylacetic acid to give 15, followed by BischlerNapieralski cyclisation of 15 to give 16. Sodium borohydride reduction of 16 to the
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racemic compound 1-(4-bromobenzyl)-1,2,3,4-tetrahydroisoquinoline 18 was proposed
in Step 3.

Step 1
DCC
R.T / 1h

15

Step 2
PCl5/ CHCl3

Et 2O
R.T. 6h

Step 3
NaBH 4 EtOH
R.T. 16h

18
16
Step 4
BOC
protection

i) Pd(OAc)2
Ph3P
styrene
triethylamine
DM F
ii) CF3COOH

21

Scheme 2.7 : Proposed Bischler-Napieralski cyclisation route to amine 21
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Finally, it was expected that Heck coupling of styrene and the N-BOC derivative of 18
using palladium acetate and triphenyl phosphine, followed by BOC group deprotection,
should afford the target amine 21.
2.8.9

Synthesis of N-(2-phenylethyl)-p-bromophenyl ethanamide 15

The first step of the synthesis was the 1,3-dicyclohexylcarbodiimide (DCC) coupling,
and the expected amide 15 was isolated in 86% yield. The HR-MS (ESI+) of 15 was
consistent with the molecular formula C16H1579BrNO. The 1H NMR multiplet signal at
3.21-3.37 ppm was assigned to the methylene group attached to nitrogen and a broad
singlet signal at 3.81 ppm was ascribed to the benzylic methylene group adjacent to the
amide carbonyl. The

13

C NMR spectrum was consistent with the expected compound

structure with a signal apparent at 168.9 ppm for the carbonyl carbon and signals at
134.7, 134.2 and 131.4 ppm, ascribed to the three aromatic quarternary carbons.

2.8.10 Attempted Bischler- Napieralski cyclisation of 15
Several attempts to cyclise 15 to 16 were made, however none of these were successful.
In the first attempt at the Bischler-Napieralski cyclisation,100 mild conditions involving
stirring with PCl5 in CHCl3 at room temperature were used. When this reaction did not
give the desired cyclised product, another method101 was attempted. This involved
reaction with POCl3 in butyronitrile and heating at reflux. This, however, did not give
evidence for formation of the desired dihydroisoquinoline product.

Finally a

combination of P2O5 and POCl3 was used in the presence of xylene but this reaction
also did not give the desired product. Usually, an activated aromatic ring with a
hydroxy or methoxy substituent is required to facilitate the intramolecular electrophilic
aromatic substitution involved in the Bischler-Napieralski cyclisation, but compound 21
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was specifically designed in order to avoid such substituents which can act as hydrogen
bond acceptor groups and thereby reduce the D4 receptor affinity and possibly increase
the D2 affinity.
It was therefore necessary to assess an alternative strategy for the synthesis of target
compound 21, which involved the preparation of the tetrahydroisoquinoline 18 from a
preformed isoquinoline intermediate.

2.8.11 Alternative synthetic approach to the tetrahydroisoquinoline 18
The proposed alternative synthetic approach to 18 involved a zinc-mediated
nucleophilic attack at C1 on the preformed 3,4-dihydroisoquinoline 17 which was
expected to give 18 (Scheme 2.8). It was then envisaged that the N-BOC protected
derivative of 18 could be used in the Heck coupling reaction to afford 21 after BOC
deprotection (Scheme 2.8).
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dichloromethane
NBS
1.2 h

1

17

Zn / T HF
42h

4-bromobenzyl bromide

18

Scheme 2.8 : Zinc mediated nucleophilic addition

The 3,4-dihydroisoquinoline 17 required was readily synthesised from 1,2,3,4tetrahydroisoquinoline 1. Several oxidants have been reported for the oxidation of 1 to
3,4-dihydroisoquinoline 17, including mercuric acetate,102 sodium hypochlorite103 and
N-bromosuccinimide.104

Due

to

the

toxicity

of

mercuric

compounds,

N-

bromosuccinimide was chosen as the oxidising agent. The 3,4-dihydroisoquinoline
17104 was obtained as a colourless oil in 86% yield, after Kugelrohr distillation, from
commercially available 1,2,3,4-tetrahydroisoquinoline 1 by oxidation with a slight
excess of N-bromosuccinimide in dichloromethane (Scheme 2.8). Freshly distilled 3,4dihydroisoquinoline 17 was used in the next step since it was unstable and tended to
polymerize if stored for a longer period.

There are various methods reported105 in the literature for alkyl group addition to imines
at the imine carbon. The methods include the use of alkylzinc reagents, Grignard
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reagents or alkyllithium reagents. In our work, it was decided to be use alkylzinc-based
chemistry for the nucleophilic addition.

The organozinc complex required was

generated in situ by the treatment of 4-bromobenzyl bromide with activated zinc in dry
tetrahydrofuran. The 3,4-dihydroisoquinoline 17 was then added slowly to this cooled
solution and the reaction mixture was then stirred at room temperature for 40 hours
under nitrogen. TLC analysis of the reaction mixture showed one major product spot
and a few minor spots. Column chromatography afforded the required racemic product
18 as a light brown powder in moderate yield. The CI-MS of 18 showed an MH+ peak
at m/z 302 which was consistent with the molecular weight. The high resolution mass
spectrum (ESI+) gave further evidence for the formation of the desired compound 18.
In the 1H NMR spectrum of 18, the appearance of a triplet signal integrating for one
proton at 3.68 ppm (C1-H) confirmed the addition of a substituent at the 1-position.
Since the organozinc complex-mediated imine addition worked successfully in the
synthesis of compound 18, it was decided to attempt a more direct synthesis of
compound 21 in a similar way (Scheme 2.9) rather than trying the Heck reaction
pathway (Scheme 2.7), with the associated N-protection/deprotection steps.
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14

1
CH2Cl2

NBS
1.2 h

CH3CN

NaBr

20

17

Zn / THF

42 h

21

Scheme 2.9 : Synthesis of the 1-substituted stilbenyl target 21 via organo-zinc coupling
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To this end, (E)-4-chloromethyl stilbene 14, which was commercially available, was
first converted into (E)-4-bromomethyl stilbene 20 as the bromide is a better leaving
group and also because we had successfully formed the analogous bromo-zinc complex
earlier (Scheme 2.8) in the synthesis of 18. The bromide 20 was synthesised in high
yield from the chloride 14 by using an excess of sodium bromide and stirring overnight
in acetonitrile.

The 1H NMR spectrum showed the expected upfield shift in the

chemical shift of the proton signal for the -CH2Br group at 4.53 ppm and also some
(10%) of -CH2Cl at 4.61 ppm which indicated the complete formation of the desired
bromo compound was not achieved. Continuation of the reaction for a further 8 hours
showed evidence for complete conversion of the chloro compound 14 to the bromo
compound 20 as the 1H NMR signal for –CH2Cl was absent. The CI-MS gave evidence
for the formation of the desired bromo-intermediate by MH+ signals at m/z 273 (79Br)
and 275 (81Br).

The bromide 20 was then added to a cooled solution of 3,4-dihydroisoquinoline 17 and
activated Zn in THF and the reaction mixture was allowed to stir for 42 hours at room
temperature. TLC analysis of the reaction mixture showed one major product spot and
two minor spots along with evidence of some unreacted imine 17. The CI-MS on the
crude target compound 21 showed evidence for the addition product (m/z 326; MH+)
and some unreacted imine (m/z 132; MH+). The appearance of a one-proton triplet (1CH) at 3.42 ppm in the 1H NMR of the reaction product was consistent with the
presence of the desired addition product 21. The 1H NMR spectrum, however, also
showed signals for the imine 17. Unfortunately, attempted purification by acid / base
extraction was unsuccessful since the imine was also extracted along with the desired
compound as it is basic. The low resolution mass spectrum (CI+) of the base recovered
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after the extraction process was quite similar to the crude spectrum except that it also
showed, in addition to the signal at m/z 326, a strong signal at m/z 340 (MH+). This is
likely to be the oxidised compound 25, although attempted further purification of the
compound was not successful. This compound 25 could arise from a free radicallybased oxidation process as outlined in Scheme 2.10. Compound 21 may be more
susceptible to such aerial oxidation than 18, possibly due to increased benzylic free
radical stabilisation through extended delocalisation in the former case.

25
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21
1. O2

2. RH
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Scheme 2.10 : Suggested mechanism for the formation of 25

2.8.12 Synthesis of (E)-1-cinnamyl-1,2,3,4-tetrahydroisoquinoline 22
Another designed dopamine D4 receptor target ligand based on the refined
pharmacophore model was compound 22. Similar conditions were followed for the
synthesis of 22 as for the synthesis of compound 21 except that commercially available
cinnamyl bromide 13 was used instead of (E)-4-bromomethyl stilbene 20 (Scheme
2.11). TLC analysis of the crude product showed the presence of some unreacted imine
along with a major product spot. The CI-MS of the crude product gave evidence for the
desired compound with a signal at m/z 250 ascribed to the MH+ for the compound 22,
together with evidence for a dimer 26 derived from cinnamyl bromide (m/z 235; MH+).
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dichloromethane
NBS
1.2h
17

1

Zn / THF
42h
13

10

22

11

Scheme 2.11 : Synthesis of (E)-1-cinnamyl-1,2,3,4-tetrahydroisoquinoline 22

Surprisingly, acid/base extraction, column chromatography or preparative TLC did not
achieve purification of compound 22, and the neutral coupling product 26 was present.

26

Compound 26 was possibly formed from reductive coupling in the presence of zinc by a
free radical process involving the organozinc intermediate attacking the second
cinnamyl bromide to form the dimer.106 The reason why it could not be separated from
the amine 22 is not clear.
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2.9

TESTING OF DESIGNED SELECTIVE D4 RECEPTOR LIGANDS

This section includes discussion of the experimental dopamine D2 and D4 ligand
binding affinities and their comparison with the estimated Ki binding affinities using the
refined D2 and D4 pharmacophore models.

2.9.1

Pharmacological testing

The D2 and D4 receptor in vitro binding assay on the designed ligands was conducted by
Professor H. Hübner in the Department of Medicinal Chemistry, Friedrich-Alexander
University, Erlangen, Germany. The assay involved human dopamine D2long (the long
isoform of D2 receptor subtype that functions as a post-synaptic receptor) and D4
receptors which were heterologously expressed in the mammalian cell line (Chinese
Hamster Ovary (CHO)). Each experiment was carried out in triplicate using a series of
concentrations of the test compound from 0.1 to 100,000 nM measuring the
displacement of the radioligand [3H] spiperone from the receptor. The values for the
test compounds given in this section are mean Ki values of two or three independent
experiments presented in nM. The lower the Ki value, the more strongly the ligand
binds to the designated receptor. Only pure compounds were tested.

2.9.2

Comparison between predicted and experimental D2 and D4 receptor
affinities of the test set compounds

The first four minimal ligands of the test set (Table 2.9) (N-propyl 2, N-butyl 3, N-allyl
12 and N-phenethyl THIQ 4) were designed based on the preliminary pharmacophore
studies. The remaining test set ligands were then designed based on the dopamine D2
and D4 refined pharmacophore studies. The predicted affinities (Table 2.9) of all the
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test set ligands are based on the refined D2 and D4 pharmacophore mapping.

2.9.2.1 D2 comparison of the test set
The test set includes the minimal THIQ analogues (Table 2.9) designed and synthesised
based on the preliminary and refined pharmacophore (2-pyridyl amine 9 and transcyclopropyl amine 11) modelling. These molecules were not part of the training set
used

for

the

preliminary

and

refined

D2

pharmacophore

generation.

Table 2.9 : Experimental and estimated (refined pharmacophore) D2 affinities of
designed minimal ligands
Cmd.

Tested Minimal Ligands

No.

Experimental

Estimated Affinity

D2 Affinity

(refined D2 model)

Ki (nM)

Ki (nM)

2

N-propyl THIQ*

30000

100

3

N-butyl THIQ*

33000

100

12

N-allyl THIQ*

16000

100

4

N-Phenethyl THIQ*

5300

27

8

2-pyridyl amide

69000

110

9

2-pyridyl amine

100000

80

10

Trans-cyclopropyl amide

36000

150

11

Trans-cyclopropyl phenyl THIQ*

2000

21

* As their hydrochloride salts

The protonated test set THIQ amine ligands were predicted to bind poorly to the D2
receptor subtype and this was confirmed by the experimental results. The 2-pyridyl
amide 8 and trans-cyclopropyl phenyl amide 10 compounds were also predicted to bind
with poor affinity (Ki 110 nM and 150 nM respectively). As discussed in Section
2.3.1.2, an estimated D2 binding affinity of 100 nM and over mapped only two out of
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the four pharmacophore features and was therefore considered to bind poorly. These
amides were the intermediates in the synthesis of 2-pyridyl ethyl THIQ and methyl
trans-cyclopropylphenyl THIQ compounds 9 and 11.

8

10

Figure 2.17 : Amide synthetic targets

The poor affinity of the amides (Figure 2.17) was predicted as neither of these
compounds would have a positive charge on the THIQ nitrogen at physiological pH
thereby missing the positive charge feature. These two compounds were tested for
actual in vitro binding to assess whether the positive ionisable nitrogen group was
critical in D2 receptor binding. The actual experimental results (Table 2.9) of the 2pyridyl amide 8 confirmed the poor D2 receptor binding with a Ki of 69000 nM. The
trans-cyclopropyl amide 10 also showed poor in vitro D2 binding with a Ki of 36000
nM. These results confirmed that the positive ionisable nitrogen group was likely to be
important for good D2 receptor binding. The N-phenethyl THIQ 4 and transcyclopropyl phenyl THIQ 11 compounds were predicted to bind quite strongly based on
the D2 pharmacophore mapping. The actual experimental affinities (Ki) for these two
compounds were 5300 nM for 4 and 2000 nM for 11 which were the strongest amongst
the test set (Table 2.9). The 2-pyridyl amine 9 was predicted to bind weakly with an
estimated Ki of 80 nM. The actual in vitro result showed poor D2 binding with a Ki of
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100000 nM. In comparing 4 and 9 it is apparent that the pyridyl nitrogen had a
detrimental effect on D2 receptor binding.

2.9.2.2 D4 affinity comparisons of test set
As the refined D4 pharmacophore training set included very high affinity ligands with
most ligands having a Ki of less than 10 nM, an estimate of 110 nM based on such a
training set was poor and a Ki of 20-40 nM was considered a moderate estimate.

The N-propyl compound 2 fitted well on two features of the refined D4 pharmacophore
and was therefore predicted to bind with a moderate affinity of 58 nM. The actual
experimental activity (Table 2.10) was 23000 nM. This poor binding could suggest that
mapping of only two out of the four pharmacophore features may give poor binding
results. The N-propyl compound 2 was the first compound designed (preliminary
pharmacophore) to investigate the minimum features necessary to demonstrate high
binding affinity and selectivity for the D4 receptor subtype. This result prompted us to
design molecules that could fit more than two features (refined pharmacophore studies).
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Table 2.10 : Experimental and estimated D4 affinities of designed D4 minimal ligands
Cmpd.
No.

Tested Minimal
Ligands

D4 affinity

D4 over D2 Selectivity

Ki (nM)
Experimental

Estimated
(refined D4
model)

Experimental

Estimated

2

N-propyl THIQ*

23000

58

1.3

1.7

3

N-butyl THIQ*

7700

110

4.3

0.9

12

N-allyl THIQ*

19000

55

0.8

1.8

4

N-Phenethyl
THIQ*

1100

49

4.8

0.5

8

2-pyridyl amide

68000

260

1.0

0.4

9

2-pyridyl amine

1100

24

91.0

3.3

10

Transcyclopropyl
phenyl amide

48000

250

0.8

0.6

11

Transcyclopropyl
phenyl amine*

930

6.5

2.1

3.2

* Tested as their hydrochloride salts.

The N-butyl compound 3 was predicted to bind with relatively poor affinity as it only
strongly mapped two features out of the four.

The experimental affinity of 3 was 7700

nM which was poor but showed a three-fold improvement compared to the N-propyl
compound 2. This may suggest that, due to the longer flexible alkyl chain in 3, the
terminal methyl group may extend to map on the third hydrophobic pharmacophore
feature. Although the experimental D4 binding affinity improved for 3, the mapping of
the terminal methyl group on the hydrophobic feature of the refined D4 pharmacophore
was not observed.
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The N-phenethyl compound 4 has a phenyl group which could interact with the
aromatic hydrophobic D4 binding site, thus resulting in an improved Ki value.

The N-allyl THIQ 12, like compound 3, was predicted to bind with a Ki of 110 nM and
its experimental Ki was 19000 nM, somewhat better than the result observed for 3. The
reason for this improvement is not clear although it may be associated with the reduced
steric volume of the allyl group compared with the propyl group.

We were also interested at the time to investigate the importance of a basic nitrogen
group in D4 affinity and hence decided to test the two amides, 2-pyridyl amide 8 and
trans-cyclopropyl phenyl amide 10. Both these amides were predicted to bind poorly
with an affinity of 260 nM and 250 nM respectively as the nitrogen is no longer basic
and cannot be protonated. The experimental affinity of 68000 nM for 8 and 48000 nM
for 10 supported the hypothesis that the presence of a basic nitrogen group was critical
for high D4 receptor affinity.

In support of this view, the corresponding 2-pyridyl

amine 9 and trans-cyclopropyl phenyl amine 11, had much lower Ki values of 1100 nM
and 930 nM respectively. There was certainly a trend in improved D4 binding by
adding various substituents to the minimal ligands. Amongst all the compounds tested
in this group, compound 11 had the strongest D4 binding affinity and this result
correlated with the predicted affinity trends for all these compounds (Table 2.10) as
compound 11 was predicted to bind to the D4 receptor more strongly (Ki 6.5 nM) than
any other compound in this group.
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The 2-pyridyl amine 9 showed the highest D4 over D2 selectivity of 91, better than its
estimated D4 selectivity of 3 amongst the designed THIQ D4 ligands. This was due to
its very poor D2 experimental Ki of 100,000 nM.

While it would also have been of interest to undertake functional studies at the D4
receptor on the amines, 9 and 11, time constraints did not allow this.

2.9.3

Stilbenyl and Cinnamyl THIQ analogues

Further 1- and 2-substituted analogues of 1,2,3,4-tetrahydroisoquinoline (Section 2.6)
(21-24) were designed and mapped on the refined D2 and D4 receptor pharmacophores
in order to build on the minimal THIQ ligands to improve selective dopamine D4
receptor affinity.

21

23

22

24

Figure 2.18 : D4 receptor ligand synthetic targets
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As discussed earlier, only the cinnamyl and stilbenyl analogues 23 and 24 (Figure 2.18)
could be synthesized and they were then tested for experimental D2-D4 receptor subtype
binding in vitro. Both showed D4 binding with a Ki of 880 nM in each case, whereas
the D2 affinity of compound 23 was 2300 nM while compound 24 showed a D2 affinity
of Ki 4700 nM (Table 2.11). These two compounds were the most active and showed
significant improvement in D4 binding compared with the other THIQ analogues
synthesised. The best binding affinity in the previous THIQ analogues synthesised was
930 nM for compound 11 (Table 2.10). However, the D4/D2 binding selectivity ratios
were still low for the amines 23 and 24, with a value of 2.4 fold for the former
compound and 5 fold for the latter.

Table 2.11 : Experimental and estimated D4 and D2 affinities of designed D4 ligands
Cmpd. Tested THIQ Ligands
No.

Refined pharmacophore

Expt.
D4 Ki
(nM)

Predicted
D4 Ki
(nM)

Expt. D2
Ki (nM)

Predicted
D2 Ki
(nM)

21

(E)-1-(4-stilbenylmethyl)
THIQ

-

11

-

1200

22

1-cinnamyl THIQ

-

7

-

550

23

(E)-2-cinnamyl THIQ

880

7

2300

670

24

(E)-2-(4-stilbenylmethyl)
THIQ

880

10

4700

1150

100

2.9.4

Design and D4 pharmacophore mapping of potential high affinity D4 ligands

Along with the previous target ligands, other related compounds were also designed and
superimposed on the D4 and D2 models. SAR approaches including incorporating a
hydrophobic propyl side chain on the tetrahydroisoquinoline ring nitrogen of 21 were
also investigated.

28

27
Predicted D4 - 12 nM, D2 - 100 nM
D4/D2 Selectivity = 8.3

Predicted D4 - 20 nM, D2 - 100 nM
D4/D2 Selectivity = 5

..

29

30

Predicted D4 - 9.4 nM, D2 - 100 nM
D4/D2 Selectivity = 10.6

Predicted D4 - 11 nM, D2 - 35 nM
D4/D2 Selectivity = 3

Figure 2.19 : Designed D4 receptor target ligands
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Compounds 27, 28, 29 and 30 (Figure 2.19) had similar predicted D4 and D2 receptor
affinities to the previous targets 21, 22, 23 and 24 (Table 2.11).

No marked

improvement in the predicted D4 affinity of the amine 27 (the N-propyl analogue of 21)
was noted. This was probably because the propyl chain is flexible and does not map the
fourth feature (hydrophobic group) well but maps the other three features (positive
charge, hydrophobic and hydrogen bond acceptor) of the refined D4 pharmacophore
strongly, thereby being predicted to bind with an affinity of 12 nM. As explained in
Section 2.3.1.2, a binding affinity prediction of 100 nM in the refined D2
pharmacophore training set, meant the compound was estimated to bind poorly to the
D2 receptor.

Hence the D4/D2 selectivities for all these designed compounds are

moderate. Compound 30, on the other hand was not a suitable candidate for further
investigation since the imine nitrogen with the lone pair mapped the hydrogen bond
acceptor of the D2 pharmacophore, thereby increasing its D2 affinity (Ki 35 nM).
Further design work is needed to refine these targets in order to selectively map the
entire D4 pharmacophore model features.

2.10 SUMMARY
A reasonably robust new ligand based pharmacophore model (refined pharmacophore)
was developed for dopamine D4 receptor selective ligands. This formed the basis for
the design of new target ligands. Synthetic target compounds 11, 23, 24, that were
designed based upon the refined pharmacophores, showed modest D4 receptor affinity
ranging from 880 nM (compounds 23 and 24) to 930 nM (compound 11) in the in vitro
pharmacological testing. In line with the pharmacophore model predictions, the D4/D2
selectivity ratio of these four ligands also improved from 2.1-fold for 11 to 5-fold for
compound 24.
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3 CHAPTER 3
SECOND GENERATION DOPAMINE D4
SELECTIVE PHARMACOPHORE STUDIES
3.1

INTRODUCTION

After the generation of the preliminary and refined D4 and D2 pharmacophore models,
significant further research was reported on the synthesis and testing of D4 and D2
receptor ligands.108,113 It was also observed that some of these ligands were structurally
quite different from the previous training set ligands used in the initial work. It was
therefore decided to generate new pharmacophore models (second generation) to further
investigate the differences in the features that would eventually facilitate the design of
high affinity and selective D4 receptor ligands over D2 receptor subtype ligands. The
refined D2 pharmacophore model only contained 15 compounds in the training set as
few D2 selective ligands were reported at the time. There was certainly a need to
generate a robust next generation D2 model with several structurally different ligands
reported in the literature since the refined D2 pharmacophore generation. The second
generation D4 and D2 pharmacophore models were validated by superimposing
compounds not included in the training sets but of known experimental affinity107 and
comparing this affinity with the predicted value. The program CATALYST® version 4
was used for the second generation pharmacophore studies discussed in the following
sections.
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3.1.1

Second generation D4 model

3.1.1.1 Training set
The new training set consisted of 46 compounds as compared to the refined D4 training
set that contained 24 compounds. In Table 3.1 and Figure 3.1 the biological data and
structures of new compounds added to the original training set (Figure 2.10) are given.
There was a broad range of D4 receptor binding affinities selected for the second
generation pharmacophore and several structurally diverse compounds represented
including a fused bis-thieno-imidizo derivative (Newcompound 16) and pyrazolo
derivatives (Newcompounds 1, 2, and 26) (Figure 3.1), (Table 3.1).

Where

stereochemistry for the structures was not defined, they were included as
stereochemistry unknown during the 3D conformational search. The pharmacophore
was generated using the same features as previously used to generate the refined
pharmacophores. Also, the excluded volume feature was used in the second generation
D4 receptor pharmacophore. The automated excluded volume feature was used as a trial
feature in generating the second generation D4 pharmacophore with the intention of
extensive sampling of all possible space placement sites.
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Table 3.1 : Second generation D4 training set
Compounds

Experimental
D2 affinity Ki
(nM)

Experimental
D4 Affinity
Ki (nM)

Estimated
D4 Affinity

Reference

Ki (nM)

Newcompound 1

>10000

10000

290

108

Newcompound 2

176

2

280

108

Newcompound 3

580

5

11

109

Newcompound 4

14000

0.5

0.18

110

Newcompound 5

2112

0.66

3

110

Newcompound 6

4864

0.76

3.4

110

Newcompound 7

>5000

93

120

111

Newcompound 8

526

2

11

111

Newcompound 9

>5000

4

98

111

Newcompound 10

1212

2

8.5

111

Newcompound 11

>100000

4

210

112

Newcompound 12

5000

23

220

112

Newcompound 13

680

1.6

6.7

113

Newcompound 14

21

4

4.7

113

Newcompound 15

>10000

1511

80

113

Newcompound 16

>10000

301

330

108

Newcompound 17

>10000

3548

220

108

Newcompound 18

3000

100

160

109

Newcompound 19

90000

800

13

110

Newcompound 20

53000

4400

25

110

Newcompound 21

25000

200

4

110

Newcompound 22

>5000

160

94

111

Newcompound 23

>5000

434

110

111

Newcompound 24

404

397

210

112
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Compounds

Experimental
D2 affinity Ki
(nM)

Experimental
D4 Affinity
Ki (nM)

Estimated
D4 Affinity

Reference

Ki (nM)

Newcompound 25

800

187

210

112

Newcompound 26

Not determined

10000

250

108

JHH12

1734

0.51

8.9

79a

Rcmpd10a

1839

8.8

4.5

114

12.4

4.8

87

Rcmpd10d
Compound8c

3405

6.95

3.2

115

PD-172760

1290

4.3

5.8

90

API-103

3160

5

3.5

90

API-104

7938

6.3

4.8

90

Compound12

2560

8

3.4

90

Compound3b

2184

8.5

6.4

84

Compound46

227

1.3

2.9

90

PD-141977

500

26

5.6

90

Compound36

1100

1.4

14

90

Compound47

570

3.8

8.8

84

Cmpdno51

388

0.67

2.6

80

CP293019

3308

3.4

7.3

90

Compound5c

630

2.1

18

80

JHH6

3000

1.58

3.5

116

A-01-49

500

6.75

4.6

90

Fananserin

723

2.93

6.1

117

Note: The last 19 compounds of the above table are common to the refined D4 pharmacophore training set, the
structures of these compounds can be found in Figure 2.10), together with experimental D2 and D4 Ki values and
estimated D4 Ki values. The names starting with “Newcompound” were the names used in the pharmacophore
training set and the rest (apart from the API’s) are the names used in the respective literature.
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Newcompound1

Newcompound 2

Newcompound 3
Newcompound 4

Newcompound 6
Newcompound 5

Newcompound 7
Newcompound 8

Newcompound 9

Newcompound 10
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CH3
R

N

CH3
N

CH3

New compound 11

H3C

S

CH3

New compound 12

H3C

CH3
N
N
Cl

N

O

N

O

N

Cl

N

Newcompound 14

Newcompound 13

H3C

N
N

S

S

Cl

N

N

CH3
O

N

H3C
Newcompound 16

Newcompound 15

H3C

Cl

N

N

N
N

S

Cl

Newcompound 18

NH

Newcompound 17

N

N

COOCH3

N

N

H3COOC
N
H

N
H

Newcompound 20

Newcompound 19

108

Newcompound 22

Newcompound 21

R

Newcompound 23

Newcompound 24

S

Newcompound 25

Newcompound 26

Figure 3.1 : Structures additional to the training set compounds from the original
refined D4 pharmacophore development

3.1.1.2 Second generation D4 pharmacophore statistics
Features selected to generate the second generation pharmacophore models were similar
to the ones chosen to generate the preliminary and refined models, namely ring
aromatic, hydrogen bond acceptor, positive ionisable nitrogen, hydrophobic, and
hydrogen bond donor features. Out of the ten ranked hypotheses, the hypothesis ranked
1 was selected for all calculations. The total cost for this hypothesis was 251.38 and the
Null hypothesis cost was 300.30. The difference between the Null hypothesis cost and
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the hypothesis cost was 48.92 bits, which translated into 75%-90% statistical
probability.

3.1.2

Analysis and comparison with refined D4 pharmacophore

The second generation D4 pharmacophore (Hypothesis ranked 1) is shown in Figure 3.2,
superimposed on the previous refined D4 receptor ligand pharmacophore. Three out of
the total of four features (ring aromatic, hydrophobic and positive ionisable nitrogen)
mapped closely for the two pharmacophores (Figure 3.2) and the difference between
these three features in the two pharmacophores was not significant. The most striking
feature of the second generation pharmacophore was the mapping of a hydrogen bond
acceptor group at a distance of approximately 6.2 Å from the positive ionisable nitrogen
feature.

This feature was not mapped in the previously generated refined D4

pharmacophore (Figure 2.11).

The “excluded volume” feature was also used to

generate this pharmacophore in order to get a visual representation of the volume that is
inaccessible to other molecules (Figure 3.2).
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Characteristic
New D4

b

feature
6.2Å
a

a
Characteristic
Refined D4
feature

b
3.8Å

a
b

b

a

a – refined D4 features
b – second generation D4 features

Figure 3.2 : Second generation D4 pharmacophore and refined D4 pharmacophore
superimposition
This shows a characteristic hydrophobic group at a distance of 3.8 Å from the positive
ionisable nitrogen (a) of the refined D4 pharmacophore, and a characteristic hydrogen
bond acceptor of the second generation D4 pharmacophore at a distance of 6.2 Å from
the positive ionisable nitrogen (b).
Red sphere: positive ionisable nitrogen (second generation D4) or positive charge
(Refined D4), small green sphere: hydrogen bond acceptor group, large green sphere:
possible receptor binding direction & region of the receptor interaction, and blue sphere:
hydrophobic groups, black sphere: excluded volume- for the second generation D4
pharmacophore.

The most active compound from the training set, newcompound 4 (Ki = 0.5 nM) was
estimated to bind with a Ki of 0.18 nM (Table 3.1). One possible explanation for the
mapping of a hydrogen bond acceptor (HBA) feature in this pharmacophore was
because of the presence of an oxime (=NOH) functional group in the potent D4
antagonist newcompound 4 that was likely to fit the HBA region. Newcompound 5,
which has a D4 affinity of 0.66 nM was, however, underestimated to bind with an
affinity of 3 nM (Table 3.1). Even though this compound has a hydroxyl group capable
of acting either as a hydrogen bond donor or acceptor, this feature was not mapped,
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whereas the remaining three features that were common to newcompound 4 mapped
well on the pharmacophore. Following analysis of the training set compounds, it was
concluded that a map of all four features consistently gave an estimate of 0.6 nM - 1 nM
for the Ki while the mapping of three features gave an estimate of >5 nM. The
estimated activity with two features mapped was >150 nM and below two features gave
an estimate of >1000 nM for the Ki. This pharmacophore was useful to explain the poor
D4 affinity of the initial ‘minimal ligands’- the THIQ analogues, 2, 3 and 12 (Table 3.2).
These initial THIQ compounds were targeted to map two closer features – a
hydrophobic group and a positive ionisable nitrogen (Figure 2.5) (based on the
preliminary D4 pharmacophore studies) that was hypothesized to be the minimum two
features that would potentially be critical in selective D4 receptor binding. These two
features also were characteristic of the refined D4 pharmacophore. Another aspect was
that the minimal ligands were designed particularly to avoid groups that would map the
hydrogen bond acceptor feature and thus obviate binding with greater affinity to the D 2
rather than the D4 receptor.
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Table 3.2 : Comparison between estimated D4 binding of all the synthesised THIQ
analogues as predicted by the refined D4 and second generation D4 pharmacophores.

Cmd.
No.

Compounds

Experim
ental D4
Affinity
Ki (nM)

Estimated D4
Affinity Ki
(nM)

Estimated D4
Affinity Ki
(nM)

Refined D4
R

Ratio

Ratio

Second
generation
D4

Experime
ntal/Estim
ated
(Refined
D4)

Experime
ntal/Esti
mated
(Second
generation D4)

2

CH2CH2CH3

23000

58

2200

396

10

3

CH2CH2CH2CH3

7700

110

260

70

29

4

CH2CH2Ph

1100

49

220

22

5

12

CH2CH=CH2

19000

55

2300

345

8

8

COCH2C5H4N

68000

260

220

261

309

9

CH2CH2C5H4N

1100

50

90

22

12

10

48000

250

220

192

218

11

930

6.5

60

143

15

23

CH2CH=CHPh

880

7

90

126

10

24

CH2PhCH=CHPh

880

10

110

88

8
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There was generally an improved prediction (as indicated by generally lower
experimental/estimated Ki ratios) of all target compounds based on the second
generation D4 pharmacophore (Table 3.2). There was an apparent relative trend (with
some anomalies) in affinity for the N-substituted THIQ ligands with compound 11
predicted to bind with high affinity (60 nM, Table 3.2) and this was consistent with the
experimental affinity (980 nM) observed. In the case of 11, the pendant phenyl group
mapped the third feature (hydrophobic) and hence was predicted to bind with better
affinity than the initial minimal ligands. This hydrophobic feature was common to both
the second generation and the refined D4 pharmacophore (Figure 3.5), however the
latter had better predictive ability.

This new pharmacophore also predicted the

observed difference in binding affinity between N-propyl THIQ 2 and N-butyl THIQ 3
as the latter was estimated to bind with a Ki of 260 nM, whereas the former was
estimated to have a Ki of 2200 nM.

The second generation D4 pharmacophore did not map the hydrophobic group at a close
distance of 3.8 Å from the positive ionisable nitrogen feature, hence the estimated Ki
had a modest correlation with the experimental Ki for the N-propyl 2 and N-allyl 12
analogues. The experimental activities of these two compounds (Table 3.2) confirmed
that the two basic features at a shorter distance of roughly 3.8 Å may not be the critical
factor for higher D4 receptor binding although this feature may be one of the important
features in D4 receptor selectivity over the D2 receptor subtype.

The N-phenethyl compound 4, the 2-pyridyl amine 9 and the trans-cyclopropyl phenyl
amine 11 were synthesised in the second phase of the design and synthesis of the
minimal ligands. The aim of this work was to investigate if expanding the minimal
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ligands to map other D4 pharmacophore features would result in improved D4 affinity
by incorporation of more rigidly disposed N-substituted hydrophobic or aromatic
groups. All these compounds were predicted to bind better than the short-chain THIQ
analogues previously synthesised (Table 3.2).

The experimental results for these

compounds showed a reasonable correlation between their estimated (second generation
D4 pharmacophore) and experimental affinities compared to the estimated activities
using the refined D4 pharmacophore (ratios comparison in Table 3.2). For example, the
amines, 9 and 11, showing a ratio of measured: estimated affinity of 22 for the refined
D4 whereas the measured: estimated second generation ratio was 12 which was a result
of the somewhat better prediction of these two ligands on second generation D4
pharmacophore model. Also, compounds 23 and 24 showed a much better correlation
between measured and estimated ratios in the second generation D4 pharmacophore
compared to the refined D4 pharmacophore model (Table 3.2).

The second generation D4 pharmacophore had a unique feature – a hydrogen bond
acceptor (Figure 3.2), which was not previously mapped. None of the target ligands
synthesised had a hydrogen bond acceptor group, since this feature was specific to the
preliminary and refined D2 pharmacophore and was therefore avoided in the design /
selection of target ligands for synthesis and testing. However the intermediate amides,
8 and 10 were predicted on the basis of the refined D4 pharmacophore to bind with an
affinity of 260 nM and 250 nM while their experimental affinities were found to be
68000 and 48000 nM respectively. The poor experimental affinities for these two
compounds confirm the hypothesis that a basic nitrogen (positive ionisable group) is
likely to be one of the critical features necessary for high D4 receptor binding affinity.

115

Compounds 23 and 24 were designed ligands based on the minimal ligand features and
were intended to map more features to improve D4 affinity and selectivity over the D2
receptor subtype. Although the experimental D4 binding affinities for 23 and 24 were
better than the minimal ligands, no significant improvement in the predicted D4 affinity
(Ki 90 nM and 110 nM respectively) was observed. Since these two targets did not map
a hydrogen bond acceptor group (unique to the second generation D4 pharmacophore),
the binding predictions of these targets were no better than for compounds 9 and 11.

3.1.3

Validation of second generation D4 pharmacophore

In order to validate the second generation D4 pharmacophore, ligands apart from the
THIQ analogues, with known selective D4 binding affinity but which were not part of
the training set were superimposed on the pharmacophore and estimated Ki values
ascertained. There was a moderate correlation between the estimated and measured
binding affinity of these ligands (Compounds 3b, 3c and 3) indicative of a reasonable
D4 pharmacophore model (Table 3.3). Cloned human D4 and D2 receptors expressed in
Chinese hamster ovary (CHO) cells were used for the pharmacological binding studies
on these compounds.107,113
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Table 3.3 : Validation of second generation D4 pharmacophore
Compounds

N

N

Reference

Br

2.6

12

107

F

24

48

107

1511

275

113

N

N

N

Experimental Estimated
D4 affinity
D4
affinity*
(Ki nM)
(Ki nM)

Compound 3b

N
N
N
N

N

Compound 3c

O
N
N

N

Compound 3

*Second generation D4 pharmacophore

3.1.4

Second generation D2 pharmacophore model

3.1.4.1 Training Set
The second generation D2 pharmacophore model was generated using a total of 22
ligands in the training set as opposed to 15 for the refined D2 model (Section 2.3.1.1).
A total of 7 new compounds (Figure 3.3) from the more recent literature (up to 2009)
were incorporated in the original refined D2 pharmacophore training set (Figure 2.7) in
order to build a statistically significant training set (a training set of at least 17 ligands is
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considered statistically significant).

There was a good range of Ki values for the

training set with at least 3 ligands representing each of the three affinity ranges: high,
moderate and poor.

S

S-1

3-PPP

D2-cmpd-3

Mezilamine

D2-newtarget-2

D2-newtarget-1

D2-newtarget-4

Figure 3.3 : Second generation D2 pharmacophore training set
(Structures of only the new ligands of the second generation D2 pharmacophore training
set are shown. The remaining training set contained the refined D2 training set ligands
discussed in Section 2.3.1.1)
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Table 3.4 : Second generation D2 pharmacophore training set, together with
experimental and estimated D2 Ki values
Compounds

Raclopride

Experimental
D2 Activity

Estimated D2
Activity

Ki (nM)

Ki (nM)

Reference

3

1.4

118

Compound 3

10.4

11

119

(+)-Butaclamol

1.1

15

120

JHH10

2.4

7.9

121

Spiperone

0.05

0.004

76

Haloperidol

1.4

0.63

86

Nemonapride

0.16

0.35

122

Compound 12

9

8.2

77

Compound 22

0.67

2.1

123

Compound 5

7

5.8

124

Compound 19

1.4

11

76

Compound 2a

560

112

125

Compound 3d

3500

1100

126

Naxagolide

1.5

27

127

Quetiapine

310

10

128

3-PPP

8

10

112

D2-compound-3

21

24

113

5000

1100

112

D2newtarget-1

1.1

0.63

129

D2newtarget-2

0.31

3.5

129

D2newtarget-4

2.4

9.4

129

Mezilamine

5.4

8.4

130

S-1

Note: The names of compounds in this table are taken from their respective references except “D2-compound-3” and
“D2newtarget” are the names used during pharmacophore generation.
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3.1.4.2 Second generation D2 pharmacophore statistics
In order to maintain consistency across all pharmacophores generated as part of this
work, the features selected for hypothesis generation were the same as the ones used in
the refined models, namely ring aromatic, positive ionisable nitrogen, hydrophobic,
hydrogen bond acceptor and hydrogen bond donor groups. The difference between the
total cost of the hypothesis used for analysis and the Null hypothesis was 52 bits, which
translated to high statistical probability.

3.1.4.3 Analysis
The second generation D2 pharmacophore, which is shown in Figure 3.4 with the potent
D2 ligand spiperone, mapped two hydrogen bond acceptor groups (Figure 3.4) unlike
the refined D2 pharmacophore which mapped only one hydrogen bond acceptor group.
There was a reasonable correlation (0.62) between predicted and experimental binding
affinity of the training set compounds (Table 3.4). The most active compounds in the
training set, spiperone and nemonapride were predicted to bind with high affinity. The
least active molecules in the training set, Compound 3d and S-1, with experimental Ki
values of 3500 nM and 5000 nM respectively, were predicted to bind poorly to the
dopamine D2 receptor subtype with the lowest estimate for Ki of 1100 nM amongst all
the training set compounds.
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Figure 3.4 : Most active training set compound, spiperone (Ki 0.05 nM), mapped on the
second generation D2 pharmacophore
Red sphere: positive ionisable nitrogen, small green sphere: hydrogen bond acceptor group,
large green sphere: possible receptor binding direction & region of the receptor interaction, and
blue sphere: hydrophobic groups.

3.1.5

Validation of second generation D2 pharmacophore

Two selective and high D2 receptor affinity compounds that were not included in the
training set, chlorpromazine (Ki 0.74 nM) and Newcompound 14 (21 nM), were mapped
on the second generation D2 pharmacophore along with two other poorly binding
compounds, Newcompound 1 (>10000 nM) and Newcompound 4 (14000 nM) (Table
3.5).
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Table 3.5 : Validation of second generation D2 pharmacophore
Compounds

Experimental Estimated D2 Reference
D2 affinity
affinity
(second
Ki nM
generation)
Ki nM
CH3

0.74

11

131

>10000

1440

108

14000

500

110

21

20

113

N
CH3
N

Cl

S
Chlorpromazine

HN

N

Newcompound1

Newcompound 4

CH3
N

N

Cl

O

N
Newcompound 14

The estimated D2 binding affinity trend of all these compounds was generally consistent
with the measured affinity. High affinity Newcompound 14 mapped four out of the five
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pharmacophore features (hydrogen bond acceptor, two hydrophobic groups and a
positive ionisable nitrogen) and hence was predicted to bind with a Ki of 20 nM,
essentially the same as the experimental value.

3.1.6

Comparison between refined D2 and second generation D2 pharmacophores

The second generation D2 pharmacophore mapped two hydrogen bond acceptor groups
each at a distance of 4.1 Å and 5.6 Å from the positive ionisable nitrogen group
respectively. The refined D2 pharmacophore however mapped only one hydrogen bond
acceptor group at a distance of 5.2 Å from the basic nitrogen group. The training set of
the second generation pharmacophore (Table 3.4) gave a very good correlation of
predicted versus true experimental affinities for a range of ligands, especially the most
active, structurally different compounds: spiperone, nemonapride and Cmpd22. It can
be concluded that the two hydrogen bond acceptor groups in the right orientation with
respect to the basic nitrogen may be critical for high D2 receptor binding affinity. The
second generation D2 pharmacophore had a more structurally diverse training set and
still mapped all five features, whereas the refined D2 pharmacophore only had four
features (Figure 3.5).
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Figure 3.5A

Figure 3.5B

Spiperone (protonated)

Figure 3.5 : Protonated spiperone mapped on the D2 refined pharmacophore (A) and on
the second generation D2 pharmacophore (B).

The most active compound in the training set, spiperone, in its protonated form, mapped
all four features of the refined D2 pharmacophore (Figure 3.5A). The second generation
D2 pharmacophore mapped five features and spiperone mapped all of these five features
(Figure 3.5B).

There was consistency in Ki value prediction for the synthesised THIQ analogues in
general between the refined D2 and second generation D2 pharmacophores (Table 3.6).
The synthesised THIQ compound 24 (see Section 6.2.2.21) was estimated to bind with a
Ki value of 1100 nM, broadly consistent with its experimental affinity of 4700 nM.
Only two features (hydrogen bond acceptor and a hydrophobic group) of the second
124

generation D2 pharmacophore model were mapped (Figure 3.6) with this compound.
Compound 24 was also predicted to bind poorly based on the refined D2 pharmacophore
with an estimated Ki of 140 nM.

Figure 3.6 : Compound 24 mapped on the second generation D2 pharmacophore

As discussed earlier (Section 2.3.1.2), in refined D2 pharmacophore prediction, a value
of 100 nM or over was the maximum Ki generated by the pharmacophore which
correlated to poor D2 binding affinity. The second generation D2 pharmacophore was
significantly better in general prediction of the designed targets and the comparative
experimental/predicted ratios for D2 binding are given in Table 3.6. The minimal
ligands, 2, 3 and 4 were all predicted to bind poorly with an estimate of 1100 nM and
the ratio of the experimental/estimated Ki improved from 27 for compound 2 to 5 for
compound 4. The over-estimation of D2 binding affinity for the amides, 8 (140 nM) and
10 (80 nM) based on the second generation D2 pharmacophore could not be explained
by the modelling studies. There was a reasonably good correlation for compound 11
(Table 3.6) with a ratio of 2 for the experimental over estimated D2 Ki. This ratio was
also good for the ligands, 23 and 24.
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Table 3.6 : Comparison between estimated D2 binding values (Ki) as predicted by the
refined D2 and the second generation D2 pharmacophores

Cmd.

Compounds

Experim
ental

Estimated
Affinity

D2
Affinity

(Refined D2
model)

Estimated
Affinity
(Second
generation
D2

Ki (nM)

Ki (nM)

Model)

No.

R

Ratio

Ratio

Experim
ental/Est
imated
(Refined
D2)

Experiment
al/Estimate
d (Second
generation
D 2)

Ki (nM)
2

-CH2CH2CH3

30000

100

1100

300

27

3

-CH2CH2CH2CH3

33000

100

1100

330

30

4

-CH2CH2Ph

5300

27

1100

196

5

12

-CH2CH=CH2

16000

100

970

160

16

8

-COCH2C5H4N

69000

110

140

627

492

9

-CH2CH2C5H4N

100000

80

440

1250

227

10

36000

150

80

240

450

11

2000

21

1100

95

2

23

CH2CH=CHPh

2300

120

580

19

4

24

CH2PhCH=CHPh

4700

140

1100

33

4
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3.2

SUMMARY

Since the generation of the refined pharmacophore models, various structurally different
molecules containing different functional groups (e.g. groups that could map the
hydrogen bond acceptor feature of the new pharmacophore) were published with strong
D4 binding affinity. Thus the research described in this chapter evolved from the
preliminary work to identify minimal features to refined pharmacophores (to build on
minimal features to improve D4 binding over D2) and ultimately to creating a more
robust second generation model using a modest activity range of structurally dissimilar
training set molecules to generate D4 and D2 receptor ligand pharmacophore models.
The key features of this evolutionary process and the outcomes are summarized in Table
3.7. The second generation D4 model mapped a new hydrogen bond acceptor region
which may assist in the design of future target D4 selective ligands.
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Table 3.7 : Summary of findings from D2 and D4 pharmacophore studies
Pharmacophores

Key observations

Preliminary

Common feature hypothesis without binding affinity
data was used to generate the preliminary D2 and D4
models.
A very small D2 (n=4) and D4 (n=8) pharmacophore
training set.
An aromatic ring group at a distance of 3.8 Å from the
positive ionisable nitrogen was considered to be a D4
specific mapping in the design and synthesis of
minimal tetrahydroisoquinoline (THIQ) D4 selective
ligands.

Refined

The binding affinity of all the training set ligands was
used to generate the refined D2 and D4.
Emerging literature provided more data on D2 specific
and D4 specific ligands with a range of binding
affinity. This led to a modest number of D2 (n=15) and
D4 (n=24) training set for the refined pharmacophore
studies.
Further insight into the relative 3D orientation of
aromatic ring and hydrophobic groups with respect to
the positively charged nitrogen and avoiding a H-bond
acceptor group (a feature considered necessary for D2
receptor binding) led to the design and synthesis of
THIQ analogues by addition of further functional
groups.

Second Generation

Significant research in the SAR for dopamine
receptors, particularly structurally diverse class of
compounds, was published since the preliminary and
refined pharmacophores were generated.
It was decided to generate the second generation D2
(n=22) and D4 (n=46) pharmacophores using a much
broader structurally diverse compounds in the D2 and
D4 training set.
These pharmacophores showed a better trend in the
prediction of previously designed and synthesised
minimal ligands and the modified THIQ analogues.
The second generation D2 and D4 models are quite
unique as there is currently no published
pharmacophores that utilise structurally diverse
training set ligands.
These second generation models could be valuable
tools in the design of novel D4 selective ligands for
potential management of neurodegenerative disorders.
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4 CHAPTER

4

DESIGN, SYNTHESIS AND TESTING OF
DOPAMINE TRANSPORTER INHIBITORS
4.1

INTRODUCTION

The plasma membrane bound Dopamine Transporter (DAT) has been implicated in the
central mechanism of cocaine addiction and has been studied intensively in order to
understand the neurochemical actions of cocaine associated with this transporter.132
DAT is a presynaptically located protein (see Figure 1.2, Chapter 1) that regulates the
concentration of dopamine in the synaptic junction by translocating it into the
presynaptic neurons.133 The human DAT has 620 residues and is organised in 12
transmembrane domains connected by 5 intracellular and 6 extracellular loops, with the
amino and carboxy termini being in the cytoplasm.134 The transport of dopamine is
mediated by the consecutive binding and co-transport of Na+ and Cl- ions, with one
molecule of dopamine requiring two Na+ ions and one Cl- ion for transport. It is
suggested that the ions are involved in binding to an extracellularly aligned
conformation of the DAT and are then taken inwards through structural alterations of
the transmembrane domains.135,136 DAT inhibitors might act through competing with
substrates for binding or by modifying or preventing DAT conformational changes.
The development of novel high affinity DAT inhibitor ligands is the key in
understanding the mechanism of the stimulant and reinforcing effects of cocaine and
could ultimately lead to the development of future drugs that may serve the purpose of
combating cocaine abuse.
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Most commonly used computer-aided drug design methods for DAT inhibitors are
ligand-based and involve either quantitative structure activity relationship (QSAR) or
pharmacophore modelling.

Due to a restricted number of available transporter

templates, QSAR studies involving homology modelling have been restricted.137,158
Ligand-based design approaches150 have also been hampered by the lack of a crystal
structure of the transporter (although the crystal structure of a related bacterial Na+ dependent leucine transporter is known138) or of good homology models.

Thus a

number of ligand-based pharmacophore studies for this transporter have been
undertaken.

DAT pharmacophore studies were reported157 by Wang and Enyedy in

2003 and more recently by Griffith and co-workers.158 These studies are discussed in
Section 4.4.

We were also interested in ligand-based pharmacophore development as an aid to
designing specific and potent DAT inhibitors. At the time these studies began, no such
pharmacophores had been reported. The results of our studies and comparisons with
published data, together with the design, synthesis and evaluation of some new tropaneand benzothiophene-based inhibitors are described in this chapter.

4.2

LIGAND BASED PHARMACOPHORE STUDIES

We decided to develop pharmacophore models using a training set of a range of
structurally different high affinity ligands to better understand the features necessary for
target ligands to bind to DAT protein with high affinity. With knowledge of these
features we then intended to design target compounds which would be synthetically
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accessible and also be capable, potentially, of being used for PET and SPECT imaging
studies in order to give an insight into the role of the DAT in cocaine abuse.

4.2.1

Preliminary pharmacophore studies

In the past 15 years, a large number of cocaine analogues and other dopamine
transporter inhibitors, including analogues of WIN 35,065-2,139 GBR12909,140 methyl
phenidate141 and benztropines57 (Figure 4.1) have been developed and tested for their
importance in ameliorating cocaine abuse.

Among these, the benztropines have

received significant attention in clinical evaluation.

We wished to access

pharmacophore features quickly for the design and synthesis of target DAT ligands and,
since results on only a very limited number of high affinity ligands were available in the
literature at the time, the preliminary pharmacophore training set contained only a
limited number of compounds (Figure 4.2).

WIN 35,065-2

GBR 12909

Methyl phenidate
4,4-dichlorobenztropine

Figure 4.1 : Some dopamine transporter inhibitors
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The high-affinity tropane based benztropine analogues and WIN-analogues were used in
the training set to develop a DAT ligand-based pharmacophore model.

Like the

dopamine receptor pharmacophore development approach discussed earlier, the DAT
pharmacophore was developed with a view to identifying the minimal key ligand
functional group features required for strong binding to the DAT protein.

Target

ligands were then designed based on their superimposition characteristics on the
pharmacophore model. Each of the training set ligands was conformationally searched
in the 20 kcal/mol energy range. Using CATALYST ® software, a quick preliminary
pharmacophore was generated using a similar approach to that discussed in Chapter 2
(Section 2.2) in the design of dopamine D4 receptor ligands.

4.2.1.1 Training set for the preliminary DAT pharmacophore
The training set included six ligands with a range of tropane-based structures: a group
of three compounds of the benztropine-type142 with a 3α-diphenylmethoxy linkage (4,4dichlorobenztropine, compounds 2g and 2h), plus three other compounds based on the
isoxazole substituted tropanes144 (compounds 5a, 5b and 5c) as bioisosteres of the
methyl ester group in cocaine (Figure 4.2).
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4,4-dichlorobenztropine

Compound 2g

Compound 5c
Compound 2h

Compound 5b

Compound 5a

Figure 4.2 : Training set ligand structures
Note: Racemic mixtures in the modelling were used where literature data was not specific to particular enantiomers.
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Compounds 2g, 2h and 5c were 2- and 3- substituted high affinity analogues of cocaine
with compound 5a being the most active training set ligand with an IC50 of 0.59 nM
(Table 4.1). The IC50 (inhibitory concentration) value is a measure of the effectiveness
of a ligand.75 This quantitative measure indicated how much of the compound is needed
to inhibit the effectiveness of the dopamine transporter protein by half (50%). [3H]WIN
35428 was used as a standard reference and its monophasic displacement was
measured.142,143,144

Table 4.1 : Training set compounds (preliminary DAT pharmacophore)
Compounds

Experimental
Activity

Estimated
Activity

References

IC50 (nM)

IC50 (nM)

4,4'-dichlorobenztropine

24.0

30

142

Compound 2g*

13.2

56

143

Compound 2h*

15.8

3.4

143

Compound 5b*

0.93

0.6

144

Compound 5a*

0.59

0.5

144

Compound 5c*

0.73

1.2

144

*Compound numbers are from the respective references.
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4.2.1.2 Statistics – Preliminary DAT pharmacophore

Figure 4.3 : Experimental (True) and estimated activity (IC50,[nM]) correlation (0.97)
of the training set ligands using hypothesis ranked 5 for the preliminary DAT
pharmacophore
The green line represents the ideal situation where the experimental and estimated
activities are the same.

There was a good correlation (0.97) between the measured DAT affinity (true activity)
and the estimated affinity of the training set compounds (Figure 4.3 and Table 4.1).
This was possibly due to a small training set with a structurally somewhat similar class
of compounds.

4.2.1.3 Preliminary pharmacophore analysis
The preliminary pharmacophore studies generated 10 ranked hypotheses. Hypotheses 1,
2, 3 and 4 did not map the positive ionisable nitrogen and were therefore discarded.
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Hypothesis 5 mapped three hydrophobic groups, a positive ionisable nitrogen and a
hydrogen bond acceptor. There was not much difference between the total costs of
hypotheses 1 and 5. The difference in the null and total cost for hypothesis ranked 5 was
58.09.

The most active compound in the training set, compound 5a, mapped all five features of
the DAT pharmacophore hypothesis ranked 5 and was therefore predicted to bind with
an affinity of 0.5 nM (Table 4.1). Compounds 5b and 5c were also predicted to bind
with high affinity (IC50 value of 0.6 nM and 1.2 nM respectively). However 4,4'dichlorobenztropine was predicted to bind with an affinity of 30 nM as it did not have
the carboxylic ester functional group at the tropane 2-position to map the hydrogen
bond acceptor group. Thus three of the five features were strongly mapped with the
fourth feature close to mapping and the fifth feature (hydrogen bond acceptor) not
mapping at all. This is the reason for its predicted IC50 of 30 nM (about 50 fold weaker
to compound 5b), in line with the experimental IC50 of 24 nM.

From the preliminary DAT pharmacophore, it was tentatively indicated that for high
DAT binding, benztropine derivatives should ideally have a hydrogen bond acceptor
group and a para-chloro, iodo or bromo group on the 3α-substituted tropane with a
biaryl methyl ether group (see also Figure 4.9; Section 4.3).
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4.2.1.4 Limitations of the preliminary DAT pharmacophore
A major limitation in the preliminary pharmacophore studies was that only six
compounds formed the training set and all compounds were tropane-based analogues.
Also the pharmacophore obtained did not map a ring aromatic feature. As it mapped
three hydrophobic features, a range of groups like methyl, halogen or phenyl could each
map as a hydrophobic group and it was therefore not satisfactory for more specific
ligand design purposes.

Later in this work, data on more DAT inhibitors became available in the
literature,145,146,147 and we therefore decided to attempt to generate a refined
pharmacophore model from the larger and more structurally diverse ligand training set
in order to overcome the limitations of the preliminary pharmacophore, and then design
high affinity DAT targets.

4.2.2

Refined DAT pharmacophore model

4.2.2.1 Training set
The refined DAT pharmacophore was generated using a training set of 21 ligands
(Figure 4.4), including those used in the preliminary pharmacophore training set apart
from compound 2g. They were chosen from all classes of known DAT ligands:
benztropines (4,4'-dichlorobenztropine, compound 2h), structurally different piperidine
and piperazine based compounds (compounds 5A, GBR-12909, 22, 11b and 13b),
methyl m-bromo phenidate and some bicyclic compounds without a basic nitrogen
(compounds 12a, 12g, 12d, 14d and 14c) but showing significant affinity for the
dopamine transporter protein (Table 4.2). These training set ligands had a range of IC50
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values from 0.59 to 10000 nM inhibition of the DAT. The refined DAT pharmacophore
model was generated using the CATALYST® program.
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CH 3
N
N

COOCH 3
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O
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GBR-12909
Compound 13a
F
N

N

N
O

O

NH
NO 2

Compound 22

Compound 11b

N

N
O

S

O
F

F

Compound 5A

Compound 13b

CH3

CH 3

N

N

COOCH3
Cl

Cl

O

O

Compound 2h
Cl

4,4'-dichlorobenztropine
H3CO
H
N

O
Br

Methyl m-bromo phenidate

Figure 4.4 : Training set ligands for the refined DAT pharmacophore and their mapping
regions shown as filled spheres.
Note: Pharmacophore mapping regions are shown as spheres. Arrows indicate possible orientation for receptor
interaction (hydrogen bonding or π-stacking). Compounds are named as in the references quoted.
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4.2.2.2 Statistics – Refined DAT pharmacophore
Out of the ten ranked hypotheses generated, hypotheses 1 to 4 did not map a hydrogen
bond acceptor feature and were therefore discarded. Hypothesis 5 mapped five features:
2 hydrophobic groups, a ring aromatic feature, a positive ionisable group and a
hydrogen bond acceptor and was used for further analysis.

There was not much

difference between the total costs of the top hypothesis ranked 1 (93.9) and the
hypothesis ranked 5 (98.7). The difference between null cost and the total cost for
hypothesis 5 was 35 which was not ideal but was expected due to the structurally
diverse training set.

There was a moderate correlation (0.72) between the true

(experimental) IC50 and the predicted values of the training set ligands (Figure 4.5).

Figure 4.5 : True (experimental) and estimated activity (IC50, [nM]) correlation
(0.72) of the training set ligands for the refined DAT pharmacophore
The green line represents the ideal situation where the experimental and estimated IC50 values are the same.
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4.2.2.3 Analysis of refined DAT pharmacophore
The refined DAT pharmacophore mapped a ring aromatic feature which wasn’t
previously mapped in the preliminary DAT pharmacophore. Perhaps the extra aromatic
rings in some of the high affinity piperazine derivatives (e.g. compound 22) may have
helped define this aromatic ring feature of the refined DAT pharmacophore.
The most active ligand in the training set was the tropane derivative, compound 5a
which was estimated to bind with an IC50 of 0.34 nM whereas its experimental affinity
was 0.59 nM (Table 4.2). It mapped all five features of the pharmacophore consistent
with the estimated high DAT binding affinity. Compound 5b was quite similar to
compound 5a except for a para-substituted methyl group in place of a chloro group.
This compound mapped four out of the five features, although the fifth feature, the
hydrogen bond acceptor, mapped closely to the oxygen of the 3-isoxazolyl ring (Figure
4.6). This was still a very good superimposition and it was therefore estimated to bind
with an affinity of 0.97 nM, virtually the same as its experimental affinity of 0.93 nM.

Figure 4.6 : Compound 5b mapped on the refined DAT pharmacophore

Compound 5c belonged to the same class of tropane compounds and was predicted to
bind with an affinity of 11 nM whereas its experimental affinity was 0.73 nM. This
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compound mapped three features strongly (two hydrophobic features and the positive
ionisable nitrogen) and the fourth feature, the ring aromatic, was in the right space but
did not result in an exact fit. Somewhat unexpectedly, the oxazole oxygen (compound
5c) was not mapped as an H-bond acceptor feature of the refined DAT pharmacophore.
Also the aromatic ring feature did not map the aromatic group of compound 5c.
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Table 4.2 : Refined DAT pharmacophore training set ligands with experimental and
estimated affinities
Compounds

Experiment Estimated
al Activity
Activity
IC50(nM)

References

IC50(nM)

4,4'-dichlorobenztropine

24.0

8.2

142

compound 2h

15.8

9.9

143

compound 5c

0.73

11

144

compound 5b

0.93

0.97

144

compound 5a

0.59

0.34

144

compound5A

17.2

23

146

compound12a

10000

2400

145

compound12g

4.6

18

145

compound12d

62

19

145

compound14d

11

12

145

compound14c

7.1

8.6

145

compound13f

2.9

17

145

compound13d

1.16

4.9

145

compound12f

12.3

15

145

compound12l

19.7

10

145

compound13a

2590

210

145

GBR-12909

14

7.8

146

compound22

0.7

0.2

147

compound11b

16.4

34

146

compound13b

13.8

25

145

Methyl m-bromo
phenidate

4.2

8.3

148

Note: Compounds are named as in the references quoted.
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Compound 12a does not have a positive ionisable nitrogen and mapped only two
features, the carboxylic hydrogen bond acceptor and the hydrophobic (phenyl ring).
This was quite a poor fit compared to the other ligands in the training set and was
therefore predicted to bind with an affinity of 2400 nM, which correlated to some extent
with its experimental affinity of 10000 nM. Compound 12g, on the other hand, was
structurally similar to compound 12a except that it had meta and para substituted chloro
groups on the phenyl ring. This compound then mapped three features, the hydrophobic
group (the methoxy methyl group), ring aromatic group (phenyl ring) and another
hydrophobic group (the p-chloro group), well. The estimated affinity of compound 12g
was 18 nM whereas the experimental affinity was 4.6 nM. Compound 12d mapped
similarly to compound 12g with a predicted affinity of 19 nM whereas the experimental
affinity was 62 nM. It thus appears that in the latter case, the extra chloro substituent in
the meta position is increasing hydrophobic interactions in a site not considered in the
pharmacophore (Table 4.2, Figure 4.4).

Without a basic ionisable nitrogen, compounds 14d and 14c only mapped three features.
Compound13f also only mapped three features and was estimated to bind with 17 nM
affinity whereas its experimental affinity was 2.9 nM. Compound 13a, on the other
hand was predicted to bind poorly with an affinity of 210 nM and its experimental
affinity was 2590 nM. The only difference between this compound and compound 13f
was the presence of a phenyl ring instead of a naphthyl ring in the 3α-position (Figure
4.4). Two features mapped strongly while the third feature was aligned in the right
space but did not fit strongly. Compound 13d was similar to compound 13a except for
the presence of meta- and para-chloro groups on the phenyl ring, out of which the parachloro mapped the hydrophobic feature and the phenyl ring mapped the other
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hydrophobic feature. Compounds 12f and 12l did not have a basic nitrogen function
(Figure 4.4) but mapped three features well consistent with the predicted IC50 value of
15 nM and 10 nM respectively.

Among the piperazine- or piperidine-based GBR series, GBR-12909 mapped three
features strongly with the fourth feature aligned in the right space but not in the correct
orientation for a good interaction. It was therefore predicted to bind with an IC50 of 7.8
nM and its experimental affinity was 14 nM. Compound 22 was estimated to bind with
an IC50 of 0.2 nM as it mapped four features. Further mapping of another conformer of
compound 22 (conformational energy of 14.79 kcal) mapped all five pharmacophore
features

(estimate of IC50 1 nM). The ester m-bromophenidate mapped four features

and was estimated to bind with an IC50 of 8.3 nM and its experimental affinity was 4.2
nM. Compounds 11b and 13b (GBR series) mapped three features out of the five
features. Their estimated affinities were 34 nM and 25 nM respectively. The tropane
derivative, compound 5a mapped five features and was estimated to bind at 0.34 nM
while its experimental affinity was 0.59 nM. The inhibitor 4,4'-dichlorobenztropine
mapped three features and was estimated to bind with an affinity of 8.2 nM while its
experimental affinity was 24 nM.
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4.2.2.4 Validation of the refined DAT pharmacophore
The refined DAT pharmacophore was validated by mapping some known ligands (Table
4.3, Figure 4.7) that were not part of the original training set that was used to generate
the pharmacophore. These ligands had a significant range of IC50 values from 0.5 nM to
78 nM.

Compound 2d

Compound 16d

Compound 17

Compound 22
Compound 5

Figure 4.7 : Chemical structures of test ligands for the refined DAT
pharmacophore validation
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Table 4.3 : Validation of the refined DAT pharmacophore
Compounds

Experimental
binding
affinity

Estimated
binding
affinity

IC50(nM)

IC50(nM)

Ccompound 2d*

0.75

1.9

149

Ccompound 17

0.8

0.59

149

Compound 22

0.5

2.6

149

Compound 16d

12.9

5.6

150

78

8

150

Compound 5

Reference

* Compound names used are as noted in the respective references.

A moderate correlation (0.87) was observed with the experimental and predicted DAT
binding affinities of the compounds listed above in Table 4.3. Compound 5 was overestimated with a binding affinity of 8 nM as opposed to its experimental affinity of 78
nM probably due to its para-substituted methoxy group in the 3α- substituted tropane
with a biaryl methyl ether group. The methoxy group of compound 5 mapped the
hydrogen bond acceptor feature of the pharmacophore, while the rest of the mapping
was similar to other tropane analogues used in the training set and hence the predicted
DAT binding affinity was significantly better than the experimental affinity. Compound
17 mapped all features of the pharmacophore and hence was predicted to bind well to
the DAT (Table 4.3). Compound 2d mapped four out of five features strongly and
hence was predicted to bind with an IC50 of 1.9 nM (Figure 4.8) and its experimental
IC50 was 0.75 nM.
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Figure 4.8 : Compound 2d superimposed on the refined DAT pharmacophore
Red sphere: positive ionisable nitrogen, small green sphere: hydrogen bond acceptor
group, large green sphere: possible receptor binding direction & region of the receptor
interaction, and blue spheres: hydrophobic groups, brown sphere: ring aromatic group
with an arrow pointing to possible receptor interaction orientation.

Although CATALYST® was able to generate a reasonable DAT pharmacophore using a
structurally different training set, the effects of some specific functional groups (e.g.
halo groups) in the tropane analogues could not be adequately explained.

4.3

COMPARISION BETWEEN THE PRELIMINARY AND REFINED DAT
PHARMACOPHORE

While the refined and the preliminary DAT pharmacophores were similar, the major
difference was the mapping of an aromatic ring feature in the refined pharmacophore
which

was

not

mapped

in

the

preliminary

pharmacophore

(Figure

4.9,

Table 4.4). Instead the preliminary pharmacophore had mapped an extra hydrophobic
group, which was observed to be non-specific and would have led to an over-estimation
of binding affinity (Figure 4.9). An aromatic group is more rigid and groups with
aliphatic carbon chains like methyl or ethyl groups do not map ring aromatic features.
149

Based on this observation and the validation with non-training set ligands, the refined
DAT pharmacophore was considered to be more robust.

Table 4.4 : DAT pharmacophore comparisons
Preliminary DAT pharmacophore

Refined DAT pharmacophore

The training set included only 6
compounds
Structurally similar compounds in the
training set

The training set included 21
compounds
Different classes of compounds
with a range of affinities in the
training set
Aromatic ring feature was mapped

Aromatic ring feature was not mapped

Possibly less biased pharmacophore
due to range of training set
compounds
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Figure 4.9 : Superimposition of preliminary and refined DAT pharmacophores
Red sphere: positive ionisable nitrogen, small green sphere: hydrogen bond acceptor group,
large green sphere: possible receptor binding direction & region of the receptor interaction, and
blue sphere: hydrophobic groups, brown sphere: ring aromatic group with an arrow pointing to
possible receptor interaction orientation.

4.4

COMPARISION
BETWEEN
PUBLISHED
DAT
INHIBITOR
PHARMACOPHORES AND THE REFINED DAT PHARMACOPHORE

Wang151 and co-workers proposed a DAT inhibitor pharmacophore using the CHARMm
program within QUANTA software for conformational analysis and minimization.
Along with the global minimum conformation, other conformations within 5 kcal/mol of
the global minimum were also considered. This range was much smaller than the
CATALYST® energy range of 20 kcal/mol that was used for building the refined DAT
pharmacophore model.
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Wang et al included two ligands, cocaine and WIN-35065-2, both tropane-based
ligands, in the training set. The objective of this study was to determine 3D-geometric
relationships of these two ligands. Three crucial binding features, namely the nitrogen
atom, the carbonyl group and the aromatic ring centre,152,153 formed the basis of this
pharmacophore model (Figure 4.10). The 3D-orientation of these three binding features
in the low energy conformations of both the training set ligands were discussed with
respect to their distances from each other (d1, d2 and d3). Based on this model, 3Ddatabase searching was carried out for compounds that “hit” the DAT model, and a
novel

compound,

4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl-4-

methylphenylketone with a Ki value of 492 nM for DAT binding affinity was
discovered in this way.151

Chemical modifications were carried out on this lead

compound to afford a high affinity analogue with a DAT Ki of 11 nM. Unlike the Ki
values used in this literature pharmacophore study, the refined DAT pharmacophore
studies used IC50 values (determined using the same radioligand standard in each case)
for all the ligands in the training set. These values are related however through the
Cheng-Prusoff equation.154

152

4-hydroxy-1-methyl-4-(4-methylphenyl)-3piperidyl-4-methylphenylketone

WIN 35,065-2

Cocaine

Figure 4.10 : DAT pharmacophore model taken from Wang et al,151 and structures of
some DAT ligands

In comparison to the Wang study, our refined DAT pharmacophore was less biased as
the training set included high affinity inhibitor ligands of structurally different classes of
compounds but assumed to be binding at the same binding site: e.g. benztropine, methyl
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phenidate and the GBR piperidine series. Some twenty one ligands formed the training
set of the refined pharmacophore model as against two for the Wang pharmacophore
model.151 Only three features were mapped and discussed in the literature model151 and
the nitrogen atom, similar to the refined DAT pharmacophore, was one of the features
mapped. Our refined DAT model, however, consisted of five features.

Previously reported SAR studies155, 156 indicated that high affinity DAT ligands, where
the nitrogen atom was replaced by oxygen or carbon, high DAT activity was still
retained. This can be supported by our refined model which included in the training set
used to generate the refined DAT pharmacophore some compounds without a basic
nitrogen group (compounds 12a, 12g, 12d, 14d,14c, 12f and12l, Figure 4.4). Compound
12a was estimated to bind with and IC50 of 2400 nM and its experimental affinity was
10000 nM. The rest of this class of compounds (without a basic nitrogen group),
namely compounds 12g,12d, 14d, 14c, 12f and 12l were all predicted to bind with
moderate to good IC50 values and this was consistent with their experimental affinity
(Table 4.2). Thus, although the positive ionisable nitrogen feature was not mapped, a
moderate-high IC50 estimate in these compounds would be as a result of a high
weighting on the remaining four pharmacophore features. The first pharmacophore
model proposed by Wang et al did not specifically discuss this point.

In 2003, the Wang group published157 a second pharmacophore model (CHARMm
program) following identification of several potent DAT inhibitors that did not contain a
carbonyl group as specified in the previous pharmacophore model.151

Only four

compounds formed the training set for this second pharmacophore, which featured one
nitrogen and two phenyl groups. The authors showed that the carbonyl group at the 2154

position of the cocaine analogues may not be essential in the design of potent DAT
inhibitors and that it could be replaced by an aromatic hydrophobic group. They also
showed that the nitrogen group in cocaine analogues may not be critical for high affinity
DAT binding – it could be replaced by a group that can act as a hydrogen bond
acceptor.157

N-ring,
HB ACC

Phenyl group
D1= 5.1-6.7 Å

D3= 4.0-6.5 Å

D2= 3.7-6.1 Å

Phenyl group

Figure 4.11 : DAT pharmacophore model adapted from reference 157
Note: D = distance; N-ring – nitrogen ring; HB ACC – hydrogen bond acceptor.

This second generation model (Figure 4.11) was still different from the refined DAT
pharmacophore model from our work as the refined pharmacophore identified two extra
features that may be important in determining the overall strength with which ligands
bind at the DAT site. Both the pharmacophores discussed above were generated using a
very limited number of structurally similar compounds in the training sets.
Two other new DAT pharmacophores were also published recently158 by MacDougall
and Griffith using the CATALYST® program.

One was based on a GBR-derived

training set (the GBR series were piperazine derivatives that are widely used in mapping
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dopamine pathways in the brain159), while the other was based on tropane derivatives.
These training sets (one containing 32 GBR analogues and the other with 31 tropane
analogues) were used to generate three common pharmacophores for the neuronal
monoamine transporters (MAT) of dopamine, noradrenaline and serotonin. The two
DAT pharmacophore models (1a and 2a; Figure 4.12) when superimposed showed three
common features: two hydrophobic aromatic groups and one hydrogen bond acceptor
group, while the positively charged (positive ionisable nitrogen) group was absent in the
pharmacophore generated using tropane analogues only. These DAT pharmacophores
were validated using correlations with serotonin transporter (SERT) and noradrenaline
transporter (NET) inhibitor ligands as the same training set was used to generate the
three pharmacophores (DAT, SERT and NET).

Figure 4.12 : Overlay of two DAT pharmacophore models from MacDougall and
Griffith158
1a: GBR-12909 (see compound used in preliminary DAT pharmacophore training set
Figure 4.1) based pharmacophore, 2a: tropane based pharmacophore. The blue
coloured spheres are hydrophobic groups, green spheres are hydrogen bond acceptor
groups and the red spheres are positive ionisable nitrogen groups. The two black
spheres on either side are excluded volume spheres.
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In comparison to our refined DAT pharmacophore model, the literature DAT
pharmacophores (Figure 4.12, 1a and 2a) did not map the aromatic ring group but
mapped the rest of the features. There appeared to be a similarity between the refined
pharmacophore with the two DAT pharmacophores (Figure 4.12, 1a and 2a) with
respect to the orientation of at least three features: the positive ionisable group, a
hydrogen bond acceptor and one of the hydrophobic groups. The objective of the
MacDougall-Griffith pharmacophore work158 was to generate multiple pharmacophore
models using the same training set to identify common features for ligand binding and
also explain selective affinity to one of the MAT sites over others by using the excluded
volume feature in CATALYST®; hence it was different from our refined DAT
pharmacophore approach. Also by generating multiple pharmacophore models it was
hoped to maximize the number of structurally diverse compounds that were assessed
during database mining, which would otherwise not be picked. A summary of the key
features of the three literature DAT inhibitor pharmacophores and the refined DAT
pharmacophore from the present work is given in Table 4.5.
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Table 4.5 : Key Features of literature DAT pharmacophores and the refined DAT
pharmacophore.
. Pharmacophores

Training Set

Wang et al.151

2 ligands- tropanes

Enyedy et al.157

Four ligands- 2β-alkyl Carbonyl group at 23β-phenyltropanes.
position may not be
essential for potent DAT
inhibitors. 3 features: 1
nitrogen and 2 phenyl
groups.

MacDonald and
Griffith158

32 GBR analogues,

Refined DAT

21 ligands from range A single robust DAT
of structural classes
pharmacophores generated
based on a comprehensive
training set. 5 features:
positive ionisable nitrogen,
aromatic ring, hydrogen
bond acceptor and 2
hydrophobic groups. Good
prediction with this refined
pharmacophore for
structurally different classes
of compounds.

31 tropane analogues

Key Observations
3D geometric relationship
of the two training set
ligands as a basis for 3Ddatabase searching. 3
features: nitrogen, aromatic
and carbonyl groups.

Two different
pharmacophores generated
for each class of
compounds. Similarity in 3
features: (positive
ionisable, hydrogen bond
acceptor and hydrophobic
groups) of the two
pharmacophores with the
refined DAT.
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The purpose of the work described in this chapter of the thesis was to generate a robust
pharmacophore using a structurally diverse training set that gave a reliable prediction of
affinity that strongly correlated with experimental binding affinity for the training set
ligands as well as the designed ligand targets. The DAT pharmacophore generated by
us is the first such pharmacophore based on a single comprehensive training set (Table
4.5).

4.5
4.5.1

DESIGN OF TARGET DAT LIGANDS
Design based on the DAT refined pharmacophore

In order to investigate the structure-activity relationships of the benztropines further, we
initially designed, synthesized and tested 8-azabicyclic compounds (31, 32) (Figure
4.13), which were similar to 4,4-dichlorobenztropine except that our designed
compounds were 6,7-dehydro benztropines.

The experimental procedure for the

synthesis of the dehydro benztropines was available from other work in our
laboratory.166

The 6,7-dehydro benztropine analogues would have reduced steric

volume at the 6,7 positions that may influence stronger DAT binding. Also increased
binding might possibly result through -bond interactions, even though this was not a
featured region in the preliminary pharmacophore.

The predicted affinity (IC50) of 31 and 32 based on the refined DAT pharmacophore
were 90 and 32 nM respectively. In order to explore the effect of stereochemistry at the
3-position, it was decided to also synthesise the 3β-substituted isomeric compounds (33,
34) of 31 and 32.

These 3β-analogues were also predicted on the refined DAT

pharmacophore to bind to the DAT with good affinity.
159

32
31

34

33

35

Figure 4.13 : 6,7-dehydro benztropine target ligands
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4.5.2

Design of a phenyl/pyridyl benztropine analogue

As compounds 31 and 32 did not map the hydrogen bond acceptor feature, we also
designed the 6,7-dehydro target ligand 35 (Figure 4.13) containing a pyridyl group. The
DAT refined pharmacophore mapping showed (Figure 4.14) that the pyridyl nitrogen in
this compound maps as a hydrogen bond acceptor and four features (hydrogen bond
acceptor, positive ionisable nitrogen and two hydrophobic groups) map strongly. This
resulted in an estimated DAT binding affinity of 9.5 nM.

Figure 4.14 : Compound 35 DAT refined pharmacophore mapping
The pyridyl nitrogen maps the hydrogen bond acceptor (green sphere) group of the
refined DAT pharmacophore.

4.5.3

Design of oscine target 36

Another tropane derived compound 36 based on oscine (scopoline) was also mapped on
the refined DAT pharmacophore and it was predicted to bind with an IC 50 of 17 nM.
Oscine was chosen as the base for this new target compound because of the more rigid
tricyclic core compared with the tropane core. However it would place the 3α-3-pyridyl
161

phenyl methoxy group in a different spatial arrangement compared with the benztropine
analogue 35.

36

On the refined DAT pharmacophore, three features (positive ionisable nitrogen,
hydrogen bond acceptor group and ring aromatic) mapped strongly for 36 and the fourth
feature (hydrophobic group) was close to mapping. The pyridyl nitrogen in 36 mapped
the hydrogen bond acceptor group of the refined DAT pharmacophore.

4.5.4

Design of benzothiophene analogues

In an effort to broaden the known structural base for DAT inhibitors further,
[1]benzothiophene analogues different from the tropane analogues were also designed.
From other work, we had ready access in our laboratory to 3-chloro-[1]benzothiophene2-carbonyl chloride 55 and it was thought that this compound might form the basis of a
new type of DAT inhibitor based on the aromatic [1]benzothiophene nucleus (Figure
4.15) if a group containing a protonatable nitrogen and/ or amidic nitrogen was added.
The targets thus designed included the piperidine 37, morpholine 38 and phenyl
piperazine 39 moieties in the substituted [1]benzothiophenes.

The refined DAT

pharmacophore superimposition of these benzothiophene targets indicated that
compound 39 in particular should bind very well to the DAT (IC50 of 22 nM). This
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piperidine amide mapped the positive ionisable nitrogen and the ring aromatic binding
site (via the [1]benzothiophene moiety) in the pharmacophore.

38

37
Estimated DAT binding affinity: 147 nM

Estimated DAT binding affinity: 185 nM

Estimated DAT binding affinity: 22 nM

39

Figure 4.15 : Designed [1]benzothiophene analogues as potential DAT inhibitors with
their estimated binding affinities (IC50) from mapping on the refined DAT
pharmacophore.

4.6

4.6.1

SYNTHEIS
LIGANDS

OF

DOPAMINE

TRANSPORTER

(DAT)

INHIBITOR

Synthesis of 31 and 32

A large number of compounds have been synthesised that bind at the cocaine-binding
site of the dopamine transporter in order to better understand the pharmacological
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properties of this drug.160 Of these, tropane based compounds161,162,163,164 including the
3α– (diphenylmethoxy) tropane analogues142 as well as GBR analogues165 have gained
importance.
In the current work, the target 6,7-dehydrotropane derivatives 31 and 32 were
synthesised from scopolamine 40 as outlined in Scheme 4.1. Scopolamine was kindly
made available through Dr R. J. Smith, Phytex Australia Pty Ltd., Sydney.

The

individual steps in Scheme 4.1 are discussed in the following sections.
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Zn-Cu couple
ethanol, reflux

41

40

NaOH, H 2O/M eOH
reflux

SOCl2
N2 reflux

42

44

43

160 oC
30min

160 oC
30min

45

31
32

Scheme 4.1 : Synthesis of 6,7-dehydrotropane derivatives 31 and 32

4.6.2

Synthesis of 8-methyl-8-azabicyclo[3.2.1]oct-6-en-3-yl ester 41

Previous work in our laboratory by Tarrant166 had shown that deoxygenation of
scopolamine 40 yielded 41 in high yield in the presence of freshly prepared zinc-copper
couple in ethanol.
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In the current study, the work of Tarrant was followed. Thus reaction of scopolamine
with freshly prepared zinc-copper couple167 in refluxing ethanol afforded a near
quantitative conversion of scopolamine to the 6,7-dehydrohyoscyamine 41 (Scheme
4.2).

Zn-Cu couple
ethanol, reflux

40

41

Scheme 4.2 : Synthesis of 6,7-dehydrohyoscyamine 41

The spectral details of 41 were consistent with the reported data.166 An alternative
synthesis of 41 has also been reported.168 In this alternative approach, compound 41
was obtained by reaction between the p-toluenesulfonic acid salt of dehydrotropine and
O-acetyl tropylchloride. This alternative synthesis constituted part of the total synthesis
of scopolamine.

4.6.3

Synthesis of 8-methyl-8-azabicyclo[3.2.1]oct-6-en-3α-ol 42

The ester 41 was then converted in good yield to the alcohol 42 by base hydrolysis.166
(Scheme 4.3).

166

NaOH, H2O/M eOH
reflux

42
41

Scheme 4.3 : Synthesis of 8-methyl-8-azabicyclo[3.2.1]oct-6-en-3α-ol 42

The structure of 42 was confirmed by mass spectrometry and 1H and

13

C NMR

spectroscopy, and comparison with the reported data.168 Simplification of the 1H NMR
and

13

C NMR spectra in compound 42 as compared to compound 41 was consistent

with the loss of the ester derivative. The

13

C NMR spectrum gave evidence for the

structure of 42 as there were no aromatic carbon signals present and no signal for an
ester carbonyl group. The retention of the 6,7 double bond was evident by the sp2
carbon signal at 134.2 ppm as well as the characteristic 1H NMR singlet signal at 6.24
ppm.
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4.6.4

Synthesis of 6,7-dehydro-3α-(diphenylmethoxy) tropane 31

N2 160 oC
30min

42

44

31

SOCl2

43

Scheme 4.4 : Nucleophilic displacement for the synthesis of the 3α tropane analogue 31

At this stage of the synthesis, it was necessary to prepare benzhydryl chloride 44 before
coupling with the alcohol 42. Access to 44 was readily achieved by reaction of the
alcohol 43 with thionyl chloride (Scheme 4.4). The NMR spectroscopic data for 44
were consistent with those reported in the literature.142 The next step involved addition
of benzhydryl chloride dropwise to 42 in a melt at 160 ˚C for nucleophilic displacement
to yield 31. Subsequent acid-base extraction resulted in the realisation of the new
compound 31 as a light brown coloured oil (78% yield). The CI MS gave evidence for
the desired compound with an m/z signal at 305 (MH+). The HR-MS (CI+) data for the
M+ signal was consistent with the molecular formula C21H23NO.

1

H NMR data was

consistent with the expected structure with a singlet peak for –CH-(Ph)2 at 5.31 ppm and
a multiplet at 7.22-7.51 ppm for 10 aromatic protons and a singlet at 6.11 ppm assigned
to the two vinylic protons at the 6,7 positions. A multiplet at 3.85 ppm was assigned to
H3 which was consistent with this proton being in the β position.166 A singlet at 2.85
168

ppm was assigned to the N-methyl group. In the

13

C NMR spectrum, the vinylic

carbons were assigned to a signal at 133.8 ppm.

4.6.5

Synthesis of 6,7-dehydro-3α-(4-chloro-diphenylmethoxy) tropane 32

160 o C
30min

42

45

32

Scheme 4.5 : Nucleophilic displacement for the synthesis of the 3α tropane analogue 32

Chloro(4-chlorophenyl)phenyl methane 45 was obtained commercially and was added
dropwise to the alcohol 42 in a melt at 160 ˚C (Scheme 4.5) and then the same
procedure (as for 31) was followed to purify the product, 32. The EI-MS of 32 gave an
M+ signal at m/z 339 consistent with the desired compound, while the HR-MS signal at
m/z 339.1388 was consistent with the molecular formula of 32. The 1H NMR provided
further confirmatory evidence for 32 with a downfield singlet at 5.31 ppm characteristic
of the aliphatic methine proton in the dibenzylether moiety. A singlet integrating for
two protons at 6.22 ppm was assigned to the double bond protons. A multiplet at 2.152.30 ppm was assigned to H2a and H4a. A singlet signal at 3.42 ppm for the 3-H was
supportive of the configuration for a 3α-substituted compound.166

The

13

C NMR

spectrum of 32 had a characteristic signal at 134.5 ppm which was assigned to the 6,7vinylic carbons.
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4.6.6

Synthesis of the 3β - tropane analogues 33 and 34

The proposed overall scheme for the synthesis of 33 and 34 involved the initial
formation of the key 3β-substituted compound, 6,7-dehydrotropacocaine 47 by a
Mitsunobu reaction of the alcohol 42 with benzoic acid 46 (Scheme 4.6).

DEAD, TPP
THF, 0oC

47
46

42

10%KOH, M eOH
reflux

44
160o 30min

48
33
160o
30min

45

34

Scheme 4.6 : Synthesis of 3β-tropane analogues 33 and 34 via the Mitsunobu reaction

The Mitsunobu reaction is known to occur primarily by inversion of configuration.169
Hydrolysis of 47 was then planned to give the 3β-hydroxy tropane 48, which on
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reaction with benzhydryl chloride 44 or with the chloro-substituted analogue 45 was
expected to provide access to the required racemic 3β-tropane ethers 33 and 34
respectively. The outcomes of the individual steps are discussed below.

4.6.7

Synthesis of 6,7-dehydrotropacocaine 47

DEAD, TPP
THF, 0 oC

42

46

47

Scheme 4.7 : Synthesis of 6,7-dehydrotropacocaine 47

Treatment of a mixture containing tropenol 42, benzoic acid and triphenyl phosphine
(TPP) in tetrahydrofuran at 0 ˚C with diethyl azodicarboxylate (DEAD) gave, after
purification, 6,7-dehydrotropacocaine 47 in high yield (Scheme 4.7). The EI-MS of 47
gave a molecular ion signal at m/z 243 which was consistent with the molecular weight
of the desired compound. Consistent with the structure proposed, two major fragments
at m/z 121 and m/z 122, arising from the loss of PhCOO˙ and PhCO2H respectively from
the molecular radical cation, were also seen in this mass spectrum. The 1H NMR
spectrum of 47 confirmed signals for the five aromatic, two allylic and ten aliphatic
protons. The characteristic 3α-H signal appeared as a doublet of doublet at 5.09 ppm.166
The 13C spectrum showed eleven signals, comprising two quaternary carbons: the ester
carbonyl group at 165.9 ppm and the aromatic carbon at 130.5 ppm, three aromatic C-H
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(132.8 ppm, 129.7 ppm, 128.4 ppm), one vinylic (129.2 ppm), two methines (68.6 ppm,
66.4 ppm), one methylene (32.2 ppm) and one methyl group carbon (40.5 ppm).

4.6.8

Synthesis of 8-methyl-8-azabicyclo[3.2.1]oct-6en-3β-ol 48

10%KOH, M eOH
reflux

47

48

Scheme 4.8 : Synthesis of 8-methyl-8-azabicyclo[3.2.1]oct-6en-3β-ol 48

In order to access the alcohol 48, the ester 47 was heated at reflux in the presence of
potassium hydroxide in methanol. Evaporation of the volatile material and extraction of
the aqueous layer with dichloromethane gave the alcohol 48 as an oil (70%) (Scheme
4.8). The characteristic signal for the 3α-proton (CH) appeared as a multiplet at 4.42 –
4.52 ppm, consistent with the presence of a 3β-OH group; in the isomeric 3α-OH
compound 42, the 3α-equatorial proton signal appeared as a triplet at 3.85 ppm. The
rest of the chemical shifts were similar to those observed in the 1H NMR spectrum of
compound 42.
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4.6.9

Attempted synthesis of 3β-benztropine analogues 33 and 34

44
X
160 oC 30min

48

33

Scheme 4.9 : Attempted nucleophilic displacement for the synthesis of the 3β-tropane
analogue 33

A synthetic approach similar to that previously used for the successful synthesis of 31
and 32 was attempted in the case of the ether 33. This involved heating the alcohol 48
with benzhydryl chloride 44, but none of the desired product 33 (Scheme 4.9) was
obtained. Mostly unreacted 48 was recovered from the reaction mixture.

Similarly, addition of the chloride 45 to the melt of compound 48 at 160 ˚C (Scheme
4.10) did not give the desired product 34 and mainly starting alcohol 48 was again
recovered. Further reactions at higher temperatures were also tried but none gave any
evidence of the desired product. An attempt was also made to convert the 3β-OH group
in 48 into the oxide anion by using sodium hydride and then adding the chloride 45,
followed by heating the mixture at reflux (THF) for 6 hours. Again, there was no
evidence (MS, 1H NMR) for the desired product 34 (Scheme 4.10) following this
reaction, and mainly unreacted starting materials were detected, although the analogous
tropane derivative without the 6,7- double bond was obtained by using this method.142
The lack of nucleophilic displacement products from these reactions is probably due to
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the increased steric hindrance about the 3β oxygen nucleophile from the axial
hydrogens at C2 and C4.

160 oC
X

48

45

34

Scheme 4.10 : Attempted nucleophilic displacement for the synthesis of the 3β-tropane
analogue 34

4.6.10 Attempted synthesis of the 3α-tropane analogue 35
Synthesis of the tropane ether 35 was attempted based on the proposed reactions
outlined in Scheme 4.11. The key reaction was again a nucleophilic displacement on
chloro-(3-pyridyl)-phenyl methane 51 with the alkoxide anion derived from the alcohol
42.
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NaBH4, M eOH

49
50
SOCl2
CH2Cl2

42

51
a. NaH, DM F, N 2

b. , DM F, N2

35

Scheme 4.11 : Synthesis of 35 involving nucleophilic displacement via the formation of
alkoxide anion

The halide 51 was obtained from the commercially available ketone 49 via reduction
with NaBH4 then conversion of the alcohol 50 to the desired chloride with SOCl2. The
1

H NMR spectrum gave evidence for the formation of the desired chloride 51 by the

disappearance of the methine signal at 5.62 ppm (CH-OH) and the appearance of a
singlet signal ascribed to the CH-Cl group downfield at 6.32 ppm. Mass spectrometric
data also supported the formation of 51. For the final step, a solution of tropenol 42 in
dry DMF was stirred at room temperature under nitrogen. To this was added sodium
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hydride and the reaction mixture was further stirred at room temperature to ensure
alkoxide ion formation. The chloride 51 in dry DMF was then added slowly to the
above reaction mixture and the resultant mixture was heated at 80 °C overnight. The
EI-MS of the crude product gave evidence for the desired product 35 with a weak signal
at m/z 306 (for M+), however purification attempts failed and thus further
characterisation of this compound could not be completed.

One of the possible

difficulties in the purification may be due to self-reaction of 51 by quarternization to
afford 52 and higher oligomers.

Cl-

52

4.6.11 Attempted synthesis of oscine target 36
In the preparation of 36, the starting compound, oscine 53, was first synthesised from
scopolamine by hydrolysis in the presence of a base.170 The proposed synthesis then
envisaged a nucleophilic substitution reaction involving the alkoxide anion from oscine
and the chloride 51 (Scheme 4.12). In the event, EI-MS of the crude reaction mixture
showed some evidence (small M+˙ peak at m/z 322) for the desired compound 36, but
attempts to purify it using preparative TLC failed. Unfavourable steric factors170 about
the secondary hydroxyl group may well be influencing the poor reaction outcome in this
case.
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10% KOH, MeOH
reflux, 2hrs

53
40
NaH, DMF
N2 , 60°C


51

36

Scheme 4.12 : Synthesis of oscine target 36 involving nucleophilic displacement via
formation of alkoxide anion

4.6.12 Synthesis of substituted [1]benzothiophene analogues
Structurally different to the tropane analogues, the benzothiophene analogues 37, 38 and
39 were also synthesised as potential DAT inhibitors since they were predicted to bind
with moderate to good affinity when mapped on the refined DAT pharmacophore
(Section 4.5.4). Also the starting compound 3-chloro-[1]benzothiophene-2-carbonyl
chloride 55 was readily available from other work in our laboratory. Utilisation of the
reactive acid chloride functionality in 55 was expected to allow ready access to the
amino amide targets (Scheme 4.13).
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SOCl2 , pyridine
Toluene

54

55

THF
K2CO3
reflux

piperidine;
morpholine;
N-phenylpiperazine

37

R=
38

Ph 39

Scheme 4.13 : Synthesis of amino amide targets 37, 38 and 39 via reactions with acid
chloride 55

4.6.13 Synthesis of 3-chloro-[1] benzothiophene-2-carbonyl chloride 55
The acid chloride 55 was synthesised according to Wright’s method171 from cinnamic
acid 54, but with slight modifications172 to improve yields. Using toluene as a solvent
instead of chlorobenzene, the yield was improved to 64%.

One of the possible

pathways for the formation of 55, as proposed by Higa and co-workers,173 is shown in
Scheme 4.14. A key step in this mechanism is the cyclisation with the SCl functionality
to afford the 5-membered ring.
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SOCl2, Pyridine
HCl

Toluene

54
SOCl2

HCl

-2 HCl

55

Scheme 4.14 : Formation of the acid chloride 55 using Wright’s method

4.6.14 Synthesis of 1-(3-chloro-[1]benzothiophene-2-carbonyl)piperidine 37

piperidine, THF
K2CO3, reflux

55

37

Scheme 4.15 : Synthesis of the piperidine amide 37

The amide 37 was the first of the three benzothiophene derivatives synthesised, and
involved reaction of 55 and piperidine in hot THF in the presence of potassium
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carbonate (Scheme 4.15).

Purification of the reaction product by column

chromatography then gave 37 in 81% yield. An ES-MS of 37 gave an MH+ signal at
m/z 279 and a fragment ion at m/z 195 (from loss of the piperidine moiety) that was
consistent with the desired compound. The 1H NMR spectrum of 37 showed signals for
the two piperidine CH2 groups adjacent to the nitrogen at 3.22-3.41 ppm as triplets and
the remaining six protons of the piperidine ring at 1.52-1.64 ppm as multiplets. The 13C
NMR spectral data gave further evidence for the desired structure with key features
being the signal at 161.6 ppm, which was ascribed to the amide carbonyl carbon and the
C-2 and C-3 carbon signals of the thiophene system at 137.5 ppm and 135.9 ppm
respectively. The quaternary carbons C-3' and C-7' were assigned to signals at 133.8
ppm and 130.5 ppm respectively.

4.6.15 Synthesis of 1-(3-chloro-[1]benzothiophene-2-carbonyl)morpholine 38

morpholine, THF
K2CO3, reflux

55

38

Scheme 4.16 : Synthesis of the morpholine amide 38

The amide 38 was synthesised in good yield (76%) by heating at reflux a solution of
morpholine and the acid chloride 55 in THF in the presence of base (Scheme 4.16). The
mass spectrum of 38 gave evidence for the molecular formula, and in the EI+ mass
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spectrum, peaks were observed at m/z 281, 283 (M+, Cl35 70%, Cl37 30%), 246 (M+37

Cl, 25%) and 195 (M+- C4H8NO, 100%). Apparent triplets for the two symmetrical

methylene groups of the morpholine at 2.79 ppm (4H) and 3.6 ppm (4H) confirmed the
structure. The 13C NMR gave evidence for the carbonyl carbon at 162.4 ppm, while the
four methylene carbon signals appeared upfield at 67.7 ppm and 46.2 ppm. The two
carbons of the thiophene ring (C2 and C3) were ascribed to signals at 137.3 ppm and
135.4 ppm.

4.6.16 Synthesis of 1-(3-chloro-[1]benzothiophene-2-carbonyl)-4-phenylpiperazine
39

N-phenylpiperazine, THF
K2CO3, reflux

55

39

Scheme 4.17 : Synthesis of the phenylpiperazine amide 39

The amide 39 was also synthesised by heating at reflux a solution of the acid chloride
55 and N-phenylpiperazine in THF in the presence of potassium carbonate (Scheme
4.17). Purification of the crude reaction product by preparative TLC gave 39 as a pale
yellow coloured oil (76%).

The HR-MS gave evidence for the correct molecular

formula of 39 and its molecular weight (with correct proportions of the chlorine isotopic
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peaks). The 1H NMR spectrum gave further evidence for the structure with the correct
number of aromatic protons and clear signals for the two sets of four methylene protons
at 3.36 ppm and 4.16 ppm. The

13

C NMR spectrum was also consistent with the

structure with the amide carbonyl carbon signal appearing at 165.4 ppm. The signals
for the methylene carbon pairs of the piperazine ring were assigned to those at 65.7 ppm
(C-9 and C-12) and 50.1 ppm (C-10 and C-11).

4.7

TESTING OF TARGET LIGANDS

The compounds 31, 32, 37, 38 and 39 (Table 4.6), were tested by Dr. Andrew Katsifis
at the Australian Nuclear Science and Technology Organisation, Lucas Heights, NSW
Australia for in vitro dopamine transporter binding.
Of the tested target compounds, two promising new lead compounds (32 and 39) were
identified that had good to moderate nanomolar DAT binding affinity (Table 4.6). The
dehydrotropane analogue, 32 was predicted to bind to the DAT with an IC50 of 32 nM
and its experimental affinity was 49 nM, thus showing a good correlation between the
estimated and predicted DAT binding affinities (Table 4.6). Due to time and other
constraints, other functional studies and comparative binding studies to the serotonin
and noradrenaline transporters were not undertaken.

32

39
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Table 4.6 : Estimated (refined DAT pharmacophore) and experimental DAT binding
affinity of all tested DAT target compounds
Cmpd.
No.

Compound

Experimental
DAT binding
affinity

Estimated DAT binding
affinity

IC50(nM)

IC50(nM)

1500

90

49

32

1000

175

645

151

320

83

31

32

37

38

39
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It is of interest to note that the 3α-(4-chloro-diphenylmethoxy)tropane174 (similar to 32
in structure but without the 6,7 double bond), was predicted, on the refined DAT
pharmacophore, to bind with an IC50 of 12 nM and its experimental IC50 has been
reported as 36 nM.174 This binding was nearly 1.5 fold greater than for 32. Another
dehydrotropane analogue, 31 was tested and its experimental IC50 was found to be 1500
nM, much larger than its 4-chloro analogue 32 (49 nM). Compound 31 was similar to
benztropine itself except for the double bond in the tropane nucleus in 31. The reported
DAT IC50 for benztropine175 is 213 nM which is poor compared to that of its 4-chloro
analogue (IC50 36 nM). There appeared to be a significant improvement of DAT
binding with 4-chloro substitution in the case of 32 compared to 31, consistent with the
trend observed with benztropine and its 4-chloro analogue.

3-(4-chloro-diphenylmethoxy)tropane
Predicted DAT IC50 = 12 nM
Experimental DAT IC50 = 36 nM

32
Predicted DAT IC50 = 32 nM
Experimental DAT IC50 = 49 nM
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From this data it was difficult to generalise on the effect of the 6,7-double bond in the
tropane derivatives on DAT binding, with the presence of this feature being apparently
significantly less detrimental in the case of 32 than 31. It was noteworthy that the
[1]benzothiophene-based amide derivative 39 exhibited moderate DAT binding of 320
nM although somewhat weaker than its estimated binding affinity of 83 nM. Of the
three [1]benzothiophene amides, 39 was estimated to have the strongest binding affinity
and this was confirmed experimentally.

4.8

DESIGN OF A FURTHER [1]BENZOTHIOPHENE BASED INHIBITOR

In order to map all five features in the DAT inhibitor pharmacophore, we also designed
a novel benzothiophene analogue 56 with a GBR-like piperazine linkage (Figure 4.16).

O

N
Cl
N

S

O

56
Estimated Affinity: 1.5 nM

Figure 4.16 : Designed high affinity DAT benzothiophene target
Note: The refined DAT pharmacophore mapping is shown as spheres.

This possible target was predicted to bind with a strong affinity of 1.5 nM. It closely
mapped all five features of the pharmacophore and was thus considered a good
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candidate for future synthesis. However time constraints prevented synthesis of this
compound.

4.9

SUMMARY

The refined DAT inhibitor ligand pharmacophore generated was different from the
literature reported DAT pharmacophores as it was the only pharmacophore that used, in
the training set, a variety of skeletally different ligands with various ranges of affinities
to DAT protein. Two new tropane target compounds, 31 and 32, were synthesised and
the latter compound demonstrated promising DAT binding affinity with a predicted
DAT binding affinity of 14 nM while the experimental affinity was 49 nM. Although
the benzothiophene amide derivatives 37, 38 and 39 did not show high DAT affinity,
compound 39 was promising as it showed modest DAT binding and provided a new
lead analogue for further studies.

One proposed development from this lead was

compound 56, which was predicted to have high DAT binding affinity with an IC50 of
1.5 nM. Another new target 35 was also designed in order to map the hydrogen bond
acceptor group of the refined DAT pharmacophore and was estimated to bind with an
affinity of 9.5 nM.

35

56
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5 CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
5.1

DOPAMINE D4 RECEPTOR ANTAGONISTS

In view of the implication of D4 receptor subtype involvement in schizophrenia, D4
receptor ligand pharmacophores were generated to form the basis for the design,
synthesis and subsequent testing of new D4 receptor antagonists. The preliminary and
refined dopamine D4 pharmacophore studies resulted in useful ligand-based
pharmacophore models. The preliminary modeling studies enabled us to design simple
ligands with a view to ascertaining the minimal features that may be critical in selective
dopamine D4 receptor binding over D2 receptor binding. The refined pharmacophore
models were then generated with a larger training set with a range of published ligands
(at the time) with different binding affinities in an attempt to generate an unbiased and
statistically significant pharmacophore (Figure 5.1). This work enabled us to build on
the initial designed set of minimal ligands by incorporating different groups in an
attempt to map other features of the pharmacophore.
tetrahydroisoquinoline

analogues

synthesized,

the

Based on the designed
new

N-substituted

tetrahydroisoquinolines 11, 23 and 24 showed promising D4 receptor affinity with
experimental binding affinities (Ki) of 930 nM for 11, and 880 nM for compounds 23
and 24 (Figure 5.2). The D4/D2 receptor binding selectivity ranged from 2-fold for
compounds 11 and 23 to 5-fold for compound 24. Enantiomers of 11 could be good
candidates for future studies in exploring their D4 binding affinity and selectivity and
associated functional studies.
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Figure 5.1 : Superimposition of refined D4 and D2 pharmacophore models
(features to the right hand side are common to both pharmacophores and the features to
the left are unique to each. Red sphere: positive ionisable nitrogen, Blue sphere:
hydrophobic group, Brown sphere: ring aromatic group and Green sphere: hydrogen
bond acceptor group)

11

23

24

Figure 5.2 : Designed tetrahydroisoquinoline analogues with promising experimental
D4 binding affinity
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The second generation pharmacophore studies were conducted after a significant
number of new high affinity D4 selective ligands had been published subsequent to the
earlier pharmacophore studies. These compounds were structurally different to the
original training set used for generating the refined pharmacophores.

The second

generation pharmacophores gave new information (an additional hydrogen bond
acceptor group) on the key features necessary for selective dopamine D4 receptor
binding over D2 receptor binding. The hydrogen bond acceptor group was not mapped
in the earlier refined D4 pharmacophore and was mapped only in the refined D2
pharmacophore. The experimental binding affinities of all D4 ligands synthesised,
especially the minimal ligands, could be explained better by mapping these on the
second generation D4 pharmacophore (Section 3.1.2, Table 3.2). The robust second
generation D2 and D4 pharmacophore models were used to design further new high
affinity D4 receptor target compounds. These second generation models were validated
by comparing the estimated and measured binding affinity of literature compounds that
were not used in the pharmacophore training set.

5.1.1

Future directions – selective D4 ligands

Future pharmacophore studies focused on excluded volumes of ligands could provide
additional information on the nature and orientation of features in new target
compounds for high affinity and selectivity for the dopamine D4 receptor. Synthesis of
a series of 1-substituted N-alkyl tetrahydroisoquinoline analogues could potentially
provide high affinity and selective dopamine D4 receptor ligands also suitable for
radioisotopic-labelling. There is also a need to investigate binding affinity of target D4
selective ligands at other G-protein coupled receptor (GPCR) sites including dopamine
D1, D3, 5-HT and adrenergic receptors as more research in understanding the complex
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signaling pathway of the GPCR system in various neurodegenerative diseases,
including schizophrenia, unfolds.

5.2

LIGANDS AS INHIBITORS OF DOPAMINE TRANSPORTER (DAT)
PROTEIN

A refined DAT inhibitor-based pharmacophore was developed which used a structurally
diverse training set. This pharmacophore was validated by the mapping of known
reported DAT ligands that were not part of the training set. Two structurally different
classes of compounds, [1]benzothiophene and aza-bicyclooctane derivatives, were
synthesised by compact routes and tested for their DAT binding. The aza-bicyclo DAT
target ligand, 32, showed the most promising DAT binding with an experimental
affinity (IC50) of 49 nM.

The [1]benzothiophene morpholine 38 and piperazine 39

derivatives showed moderate DAT binding, with IC50 values of 645 nM and 320 nM
respectively. Although these benzothiophene-based analogues showed moderate DAT
affinity, this structural class provided the basis for the design of a new type of high
affinity target compound, 56, with an estimated DAT affinity of 1.5 nM.

This

compound also has the potential for incorporation of radioisotopic labels for future PET
and SPECT studies.
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56

5.2.1

Future directions – DAT inhibitor ligands

The ready synthesis of new benzothiophene-based amino amide analogues could
provide new high affinity DAT inhibitors of potential value in the treatment of cocaine
addiction and Parkinson’s disease.175
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6 CHAPTER 6
EXPERIMENTAL
6.1
6.1.1

PHARMACOPHORE GENERATION (CHAPTERS 2, 3 AND 4)
INSIGHT II – DISCOVER Experiments

The preliminary and refined pharmacophore modelling experiments described in
Chapters 2 and 3 were carried out on Silicon Graphics Indy workstations using Biosym
software of Molecular Simulations, Inc. under an IRIX 5.2 operating system.
The preliminary training set ligands for the D2 (Figure 2.1) and D4 (Figure 2.3) receptor
pharmacophore generation were built using the BUILDER module of the software
package. The next steps were carried out using the DISCOVER module, starting with
an initial minimisation to relieve any strain on the molecules before the dynamics was
started. This minimisation invoked 100 steps of steepest descent minimisation followed
by 100 steps of conjugate gradients until the maximum derivative was less than 0.0001
kcal/mol. The dynamics was initialised at 900K for 1ps (1000ps of 1 fs). During the
initialisation process, the system was raised to, and partially equilibrated at, the target
temperature. The major conformational changes were seen in this process. The first
step in the loop was to resume the dynamics at 900 K for 2 ps, then a sample
conformation was saved to an archive file, and finally the dynamics was resumed for
another step and so on for a total of 10 cycles. The ten conformations sampled were
minimised again until the maximum derivative was less than 0.0001 kcal/mol by using
the same method as the initial minimisation process. Finally the global minimum
energy conformations were determined.
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The global minimum conformers thus obtained were exported to another software
system, CATALYST®, where these conformers were used as input.

6.1.2

CATALYST® experiments

The preliminary and refined pharmacophore studies were performed on a Silicon
Graphics O2 workstation using the CATALYST® version 3.1 package by Molecular
Simulations Inc., under an IRIX 5.2 operating system.

All second generation

pharmacophore studies were carried out using CATALYST® version 4.5 from
Accelrys®. A generalised CHARMM-like69 force field was used throughout.

The preliminary D2 and D4 pharmacophore models were generated by using the global
minimum conformers (obtained from the INSIGHT II/ DISCOVER module) of the
training set ligands (Figure 2.1, Figure 2.3) and then carrying out another
conformational search on these conformers using CATALYST®. CATALYST® uses
all the conformers generated by default, although conformers can also be manually
selected and discarded.

All conformers were used throughout the CATALYST ®

experiments in this project. The “Common Feature Hypothesis” module was used to
generate the pharmacophore models for the preliminary D2 and D4 ligands. This feature
uses the common features in the training set ligands to generate the pharmacophore
model, instead of the binding affinity data used by the “CatHypo” module which
generates pharmacophore models based on the binding affinity data of the training set
ligands.

The “Common Feature Hypothesis” was used for the preliminary pharmacophore
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models because some of the D2 training set ligands were reported to have an affinity for
the D2-like receptors. Thus the D2 binding affinity data for such ligands was of no use
and therefore the “CatHypo” module was not used.

The refined D2 and D4

pharmacophore models however are generated using the “CatHypo” command. The
training set ligands of the refined pharmacophore models were built and
conformationally searched in CATALYST® software, unlike the preliminary training
set ligands, where the global minimum conformers were first generated using the
INSIGHT-BUILDER module and these global minimum conformers were then used as
input for CATALYST® and were conformationally searched again in CATALYST®.

The best quality conformational search is recommended for hypothesis generation as it
provides the most comprehensive treatment of flexible ring systems, as well as the
greatest conformational coverage within CATALYST®.65 The conformational search
was carried out in the default range of 20 kcal/mol and conformational models for each
compound were generated automatically using the poling algorithm.70 The training set
of molecules along with their conformational models were submitted to CATALYST®
by using the generate “common feature hypothesis” command. The chemical functional
groups used in this generation step included hydrogen bond acceptor, hydrophobic, ring
aromatic, positive ionisable and hydrogen bond donor groups. Hydrogen bond acceptor
and donor groups are composed of a heavy atom on the ligand and a vector projecting to
the point of a complementary receptor atom. This provides directionality and further
discrimination in the search query. The ring aromatic group specifically describes the
π-π interaction between aromatic features, by restricting the plane of the aromatic
system instead of just defining the centre point of the aromatic ring system. A vector is
also projected to the centre point of the aromatic system of the receptor in this feature.
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A positive ionisable feature (used for preliminary D2 and D4 pharmacophore models)
represents a functional group, such as a tertiary amine, that can be protonated under
physiological conditions. A positive charge feature was used instead of a positive
ionisable feature to generate the refined pharmacophore models as all the training set
ligands were used as their protonated forms.

Based on these features used, CATALYST® generates ten ranked hypotheses (using
generate hypothesis feature) depending on how well the training set ligands fit the
features used. Cost analyses of the hypotheses are calculated to determine the ranking
of the hypotheses. The cost analysis and the selection of the best hypothesis for
calculations and the statistics is discussed in Chapter 2 Section 2.1.3.

The null

hypothesis generated assumes that there is no statistically significant structure within
the data, and that the experimental activities are randomly distributed about their mean.
The hypotheses were then used to predict the activities of the target compounds. These
activities are derived from those conformers displaying the smallest root-mean square
(RMS) deviations projected onto the hypothesis.

In the case of the preliminary

pharmacophore models, however, mapping of the target compounds on the hypothesis
was important as activity data was not used to generate the models. The purpose of the
preliminary pharmacophore modelling was to identify the minimal features necessary
for selective D4 binding. The distance of 3.4 Å - 3.8 Å between the positively ionisable
nitrogen and aromatic ring was found to be critical for selective D4 binding and minimal
ligands were designed based on these two minimal features.
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The preliminary and refined DAT pharmacophore studies were carried out using the
“CatHypo” feature of the CATALYST® software (Chapter 4). Both the training sets
included ligands with their IC50 values (nM). Features used to generate hypotheses
were: hydrogen bond acceptor, hydrophobic, ring aromatic, hydrogen bond donor and
positive ionisable nitrogen groups.

6.2
6.2.1

SYNTHESIS (CHAPTERS 2 AND 4)
General procedures

General
All synthetic work was carried out using standard laboratory equipment and glassware.
A vacuum Kugelruhr distillation apparatus was used specifically to obtain freshly
distilled starting material, 3,4-dihydroisoquinoline (17). Melting points were carried out
using a Reichert Melting Point apparatus and are uncorrected.

Temperatures are

expressed in degrees Celsius (ºC).

NMR Spectroscopy
Nuclear magnetic resonance (NMR) spectra were obtained using a Varian Unity 300
MHz, operating at 300.1 MHz for 1H and 75.5 MHz for

13

C nuclei, or a Varian Inova

500 MHz spectrometer, where proton NMR (1H NMR) spectra and carbon NMR (13C
NMR) spectra were acquired at 500 and 125 MHz respectively. All 1H and

13

C NMR

spectra are recorded in deuterochloroform (CDCl3) and chemical shifts () were
reported as parts per million (ppm) and referenced against 0.5% tetramethylsilane
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(TMS), obtained from Cambridge Isotope Laboratories Inc., as internal reference (0.00
ppm).

The 1H NMR is reported as chemical shift followed by relative integral,

multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, br
= broad), and assignment. Note: Numbering on structures shown in the experimental is
that used for the assignment of the 1H and 13C signals, it differs in some cases from the
systematic nomenclature numbering with respect to specification of substituent atoms.

Mass Spectrometry
Chemical ionisation (CI+) and electron impact (EI) low-resolution mass spectra (CI-MS
or EI-MS) were recorded on a Shimadzu QP-5000 MAT-44 quadrupole spectrometer
using a direct insertion probe and with a 70eV electron beam. iso-Butane was used as
the reactant gas for the chemical ionization spectra.

Electrospray ionisation low

resolution mass spectra (ESI-MS) were recorded on a Micromass Platform LCZ
spectrometer and high resolution ESI on a Micromass QTOF2 spectrometer. High
resolution mass spectra (HR-MS EI+ and CI+) were obtained using a Fisons/VG
Autospec-TOF mass spectrometer.

Polyethylene glycol was used as the internal

standard for ESI-HR-MS. Perfluorokerosene was used as the internal standard for CIHR-MS and EI-HR-MS. All mass (%) spectra were run in the positive ion mode, and
relative abundances are shown in brackets.

Chromatography
Analytical thin layer chromatography (TLC) was carried out using Merck Kieselgel 60
F254 silica on aluminium backed sheets. Rf values were recorded from the centre of the
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spots and a UV lamp (λ 254 nm) was used for detection. Reaction products were
separated and purified by flash silica column chromatography using Merck Silica gel 60
(0.040-0.063 mm; 230-400 mesh) and medium pressure.

Preparative TLC was

attempted for purification of some compounds using Merck Silica gel 60 (thickness of
about 1mm) on the TLC plate. Solvent ratios refer to v/v. Reagents and solvents were
purified with reference to procedures outlined in Perrin and Armarego.176

Solvents
Dry solvents were prepared as follows:


DCM was freshly distilled from calcium chloride.



Tetrahydrofuran was used freshly distilled from sodium wire in the presence of
benzophenone as an indicator.



Anhydrous DMF was purchased from Sigma Aldrich Chemical Co. Inc., in a
Sure-seal™ bottle and was stored under an inert atmosphere.



Diethyl ether was distilled and then kept over calcium chloride for 24 h. It was
then freshly distilled from sodium wire/benzophenone.



Methanol was used freshly distilled and stored in a Schott bottle over activated
4Å molecular sieves.



Chloroform was first washed with water to remove the ethanol, shaken and left
overnight over anhydrous calcium chloride and finally distilled from and stored
over activated 4 Å molecular sieves.
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Solvents were removed under reduced pressure at 40 ºC in a Büchi rotary evaporator.
Pre-drying of solvent extracts was done over anhydrous sodium sulfate.

Light

petroleum had a b.p. range of 40-60 ºC.

The elemental microanalysis was undertaken by the Queensland Microanalytical
service, Brisbane, Queensland 4072.

Other Chemicals and Reagents
Scopolamine hydrochloride, the starting material for all the benztropine analogues
(Sections 6.2.3.4, 6.2.3.5), was generously supplied by Dr. R.J. Smith, Phytex Australia
Pty Limited, Sydney.

Other starting compounds were obtained from commercial

sources and were used as received.

Zinc powder used for the nucleophilic alkylation reactions was first activated by an acid
wash177,178 using 10% HCl, then washed with distilled water and finally by anhydrous
diethyl ether. Formation of hydrochloride salts of bases was achieved by passing
hydrogen chloride gas through a solution of the respective compound in anhydrous
diethyl ether and the precipitated hydrochloride salt separated by filtration.

Anhydrous potassium carbonate (K2CO3) was used for the N-alkylation and acylation
experiments.
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6.2.2

Experimental (For Chapter 2)

6.2.2.1 Preparation of 2-propyl-1,2,3,4-tetrahydroisoquinoline 2
To a solution of commercially acquired (Aldrich)
5
6

4'

4

1,2,3,4-tetrahydroisoquinoline (1, 1 g, 7.5 mmol) in

3

N

7
8

8'

1

2

10

ethanol (25 mL), was added K2CO3 (1.8 g, 13 mmol)
9

11

and the solution stirred at room temperature for 15 min.

To this was added 1-

iodopropane (1.3 g, 7.5 mmol) in absolute ethanol (20 mL). The above reaction mixture
was heated at reflux for 16 h with stirring. The reaction mixture was cooled to room
temperature and then filtered. Solvent was removed from the filtrate in vacuo, and 2M
HCl (15 mL) was added to the crude product and the mixture stirred for 30 min. This
solution was extracted with DCM (3x15 mL) and the remaining aqueous phase was then
basified with concentrated aqueous ammonia and extracted with DCM (3 x 15 mL).
The combined organic extracts were evaporated to give a dark brown coloured crude
product. This was purified by column chromatography using DCM/methanol (98:2) as
the eluent to give the known amine 2 (1 g, 86%)179 as a pale yellow oil. The resultant
base was converted to its corresponding hydrochloride salt, m.p. 237.5 - 238.5 ˚C
(Lit.180 m.p. 238.5 – 239.5 ˚C).
CI-MS: m/z 176 (100% MH+), 146 (40%).
HR-MS (CI+) (HCl salt): m/z measured MH+ 176.1433, calculated for C12H18N,
176.1439.
1

H NMR (HCl salt) (CDCl3):  1.01 (3H, t, J = 6.8 Hz, H-11), 1.98 – 2.11 (2H, m, H-

10), 2.95 (2H, t, J = 6.2 Hz, H-9), 3.20 (2H, t, J = 9.6 Hz, H-4), 3.42 (2H, t, J = 9.3 Hz,
H-3), 4.20-4.30 (2H, s, H-1), 7.10-7.25 (4H, m, Ar-H).
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13

C NMR (CDCl3):  131.6 (C-8), 130.4 (C-4), 128.8 (C-8), 128.3 (C-7), 127.3 ,

126.8 (C-6 and C-5), 56.3 (C-9), 51.96 (C-1), 48.7 (C-3), 24.1 (C-4), 17.5 (C-10), 11.1
(C-11).

6.2.2.2 Preparation of 2-butyl-1,2,3,4-tetrahydroisoquinoline 3179
To a solution of 1,2,3,4-tetrahydroisoquinoline (1,
5
6

4'

4

1 g, 7.5 mmol) in ethanol (25 mL), was added

3

N

7
8

8'

1

2

12

10

9

K2CO3 (1.8 g, 13mmol) and the mixture stirred at

11

room temperature.

To this was added 1-

iodobutane (1.38 g, 7.5 mmol) in absolute ethanol (20 mL). The above reaction mixture
was heated at reflux overnight (16 h) with stirring. The reaction mixture was cooled
and then filtered. Solvent was removed from the filtrate in vacuo, and 2M HCl (15 mL)
was added to the crude product and was stirred for 30 min. This solution was extracted
with DCM (3 x 15 mL) and the remaining aqueous phase was then basified with
concentrated aqueous ammonia and was extracted with DCM (3 x 15 mL).

The

combined organic extracts were evaporated to give the crude product. This crude
product was then purified by recrystallisation using diethyl ether/methanol to give the
known amine 3 (1.24 g, 88%)179 as pale yellow crystals. The resultant purified base was
then converted into its corresponding hydrochloride salt, m.p.(HCl salt) 222 – 224 ˚C.
CI-MS: m/z 190 (90%, MH+), 146 (45%).
HR-MS (ESI+) (HCl salt): m/z measured 190.1574 (MH+), calculated for C13H20N,
190.1594.
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1

H NMR (CDCl3):  0.96 (3H, t, J = 7 Hz, H-12), 1.34-1.40 (2H, m, H-11), 1.64-1.69

(2H, m, H-10), 2.60 (2H, t, J = 9.8 Hz, H-4), 2.85 (2H, t, J = 9.2 Hz, H-3), 2.98 (2H, t, J
= 5.4 Hz, H-9), 3.78 (2H, s, H-1), 7.11-7.20 (4H, m, Ar-H).
13

C NMR (CDCl3):  133.6 (C-8), 133.1 (C-4), 128.6 (C-8), 126.6 (C-7), 126.5 (C-6),

125.9 (C-5), 57.3 (C-9), 55.1 (C-1), 50.3 (C-3), 28.4 (C-4), 27.8 (C-10), 20.5 (C-11),
13.9 (C-12).

6.2.2.3 Preparation of 2-(2-phenylethyl)-1,2,3,4-tetrahydroisoquinoline 4
A mixture of 1,2,3,4-tetrahydroisoquinoline
5

'

4

(1 g, 7.5 mmol), phenethyl bromide (1.36 g,

4

6

3

N

7

2

10

'

8

8

7.5 mmol), K2CO3 (1.8 g, 13 mmol) and 1-

12
13

1

9

11

butanol (30 mL) was heated at reflux for 12

16

14
15

h. The reaction mixture was cooled, filtered

and the solvent was evaporated to dryness to give a crude red coloured viscous oil
which was purified by column chromatography (ethyl acetate / hexane 1:1) to give a
pale yellow oil which on trituration with diethyl ether afforded 4 (530 mg, 30%) as
light brown needles; m.p. 93 – 95 ˚C (m.p. HCl salt: 155-157 ˚C). Anal: Found, C,
86.15; H, 8.37; N, 5.85 %. C17H19N requires C, 86.03; H, 8.07; N, 5.90 %.
CI-MS: m/z 238 (MH+), 146.
HR-MS (CI+) (HCl salt): m/z measured 238.1591 (MH+), calculated for C17H20N
238.1596.
1

H NMR (CDCl3):  2.81 – 2.84 (4H, m, H-4 and H-9), 3.05 – 3.13 (4H, m, H-10 and

H-3), 3.90 (2H, s, H-1), 7.10-7.45 (9H, m, aromatic H).
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13

C NMR (CDCl3):  140.3 (C-11), 134.6 (C-8), 134.2 (C-4); 128.6, 128.6, 128.3,

126.5, 126.1, 126.0, 125.5 (9 aromatic carbons; some overlapping signals), 60.2 (C-1),
56.0 (C-9), 50.9 (C-3), 33.9 (C-10), 29.1 (C-4).

6.2.2.4 Preparation of 3-bromophenylacetyl chloride 5 (R = m-BrPhCH2, Scheme
2.3)
Thionyl chloride (25 mL) was added to 3bromophenylacetic acid (1 g, 4.65 mmol) with
stirring and the mixture then heated at reflux for
40 min. Excess thionyl chloride was then removed by distillation to give the acid
chloride 5 (0.92 g). This acid chloride was then used without further purification.

6.2.2.5 Preparation of 2-(3-bromophenylacetyl)-1,2,3,4-tetrahydroisoquinoline 6
To
5

'

4

6

N
8

8'

mixture

of

1,2,3,4-

tetrahydroisoquinoline (600 mg, 4.5 mmol)

3

7

a

4

2

10

12

Br

9
11

1

O

16

13

and K2CO3 (1 g, 7.24 mmol) in dry

14

distilled THF (20 mL) was added the

15

appropriate acid chloride 5 (1.05 g, 4.5 mmol) with stirring. The above reaction mixture
was warmed to 45 °C and stirred continuously for 2 h. The mixture was allowed to cool
and was then filtered. The solvent was removed from the filtrate in vacuo to give the
crude amide as a red coloured viscous oil. The amide was then purified by column
chromatography (DCM / methanol 96:4) to collect 12 fractions. Fractions 1-7 were
combined and concentrated to give the amide 6 as a reddish brown viscous oil (1.01 g,
68%).
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CI-MS: m/z 330, 332 (MH+) (79Br, 81Br).
HR-MS (EI+): m/z measured 329.0411, calculated for C17 H1679BrNO (M+), 329.0415.
1

H NMR (CDCl3):  2.54 (2H, t, J = 8.76 Hz, H-4), 2.75 (2H, t, J = 9.0 Hz, H-3), 3.82

– 3.88 (2H, m, H-10), 4.12 (2H, s, H-1), 7.22-7.64 (8H, m, Ar-H).
13

C NMR (CDCl3):  168.8 (C-9, C=O), 137.6 (C-11), 134.4 (C-13), 133.7 (C-8),

133.2 (C-4), 132.6, 132.3, 131.5, 131.0, 128.7, 127.6, 126.5, 125.4 (8-ArCH), 56.6 (C1), 52.2 (C-3), 42.5 (C-10), 29.2 (C-4).

6.2.2.6 Preparation of 2-[2-(3-bromophenyl)ethyl]-1,2,3,4-tetrahydroisoquinoline
7
To a stirred solution of the amide 6 (400
5

'

4

mg, 1.2 mmol) in dry, freshly distilled

4

6

3

N

7

2

10

'

8

8

1

9

12

Br

11

13

16

14

THF (20 mL) was added 2M boranemethyl sulfide complex (3 mL) and the

15

mixture heated at reflux for 4 h.

The

reaction was quenched by adding EtOH (12 mL) and the solvent removed in vacuo.
The residue was dissolved in methanol (20 mL) and K2CO3 (160 mg, 1.2 mmol) was
added and the resultant solution was heated at reflux for about 2 h. The reaction
mixture was then cooled and filtered to remove K2CO3 and the solvent removed in
vacuo to give crude product 7 which was then purified by column chromatography
using DCM /methanol (99:1) to give the amine 7 (0.26 g, 69%) as a reddish brown
powder, m.p. 141 – 143 ˚C.
CI-MS: m/z 316, 318 (MH+, 79Br, 81Br), 146 (40%), 134 (100%), 107 (30%).
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HR-MS (EI+): m/z measured 315.0620, calculated for C17 H1879BrN (M+), 315.0623.
1

H NMR (CDCl3):  2.64 (2H, t, J = 8.84 Hz, H-4), 2.77 (2H, t, J = 9.2 Hz, H-3), 2.82-

3.02 (4H, m, H-9 and H-10), 3.68 (2H, s, H-1), 7.02-7.30 (8H, m, Ar-H).
13

C NMR (CDCl3):  137.9 (C-11), 134.6 (C-13), 133.9 (C-8), 132.7 (C-4), 131.1,

130.7, 128.5, 127.9, 127.8, 127.2, 126.5, 125.5 (8-ArCH), 61.6 (C-1), 55.7 (C-9), 50.6
(C-3), 33.6 (C-10), 28.7 (C-4).

6.2.2.7 Preparation of 2-(2-pyridyl)acetyl-1,2,3,4-tetrahydroisoquinoline 8
1,3-Dicyclohexylcarbodiimide (0.93 g, 4.5
5

'

4

4

6

mmol) was added to a cooled solution of

3

N

7
8

'
8

2

10

N
15

1,2,3,4-tetrahydroisoquinoline (0.6 g, 4.5

11

12

14

mmol), 1-hydroxybenzotriazole (0.608 g, 4.5

9

1

O

13

mmol) and 2-pyridylacetic acid (0.78 g, 4.6
mmol) in dry THF (24mL). The above mixture was warmed with stirring overnight (16
h). The THF was removed in vacuo to give a crude light brown coloured product which
was acidified by 2M HCl and extracted with DCM (3 x 20mL) to give the crude amide
which was purified further by column chromatography (DCM : methanol 96:4) to give
the amide 8 as a light brown powder (0.6 g, 53%), m.p. 198 - 200 ˚C.
CI-MS: m/z measured 253 (100%, MH+), 134 (10%).
HR-MS (EI+): m/z measured 252.3110, calculated for C16 H16N2O (M+), 252.3116.
1

H NMR (CDCl3):  3.16 (2H, t, J = 8.76 Hz, H-4), 3.45 – 3.52 (4H, m, H-3 and H-

10), 4.18 (2H, s, H-1), 7.01-7.25 (7H, m, H-5, H-6, H-7, H-8, H-12, H-13 and H-14),
8.44 (1H, d, J = 4.7 Hz, H-15).
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13

C NMR (CDCl3):  169.2 (C-9, C=O), 149.2 (C11), 146.4 (C-15), 137.7 (C-12 and

C-14), 134.6 (C-8), 132.7 (C4), 120.9, 121.2, 122.7, 125.5, 132.2 (C-5, C-6, C-7, C-8,
C-13), 40.8 (C-1), 40.5 (C-3), 38.2 (C-10), 32.2 (C-4).

6.2.2.8 Preparation of 2-[2-(2-pyridyl)ethyl]-1,2,3,4-tetrahydroisoquinoline 9
To a stirred solution of the amide 8 (0.1 g,
5
6

4'

4

0.396 mmol) in dry THF (15 mL) was added

3

N

7
8

8'

1

2

10

9

N

an excess of 2M borane-methyl sulfide

11

15

12

14
13

complex in THF (0.9 g, 11.9 mmol) and the
mixture was heated at reflux for 4 h. The

reaction mixture was quenched by adding ethanol (12 mL) and allowed to stir for a
further 25 min. The excess solvent was removed in vacuo and the residue was dissolved
in MeOH (20 mL). To this was added K2CO3 (0.2 g, 1.45 mmol) and the above reaction
mixture was heated at reflux for 2 h. The reaction mixture was allowed to cool and was
then filtered. Excess solvent was removed in vacuo to give the crude product which
was purified by column chromatography (MeOH : DCM 3:97) to give the amine 9 (45
mg, 48%) as an oil.
CI-MS: m/z 239 (MH+), 161, 146, 132.
HR-MS (ESI+): m/z measured 239.1547 calculated for C16H18N2 (MH+), 239.1548.
1

H NMR (CDCl3):  2.98 (2H, t, J = 9.2 Hz, H-4), 3.28 (2H, t, H-10), 3.60 (2H, t, J =

8.8 Hz, H-3), 3.68 (2H, t, J = 6.9 Hz, H-9), 4.60 (2H, s, H-1), 7.22-7.31 (7H, m, H-5, H6, H-7, H-8, H-12, H-13 and H-14), 8.42 (1H, d, J = 4.6 Hz, H-15).
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13

C NMR (CDCl3):  148.6 (C-11 and C-15), 137.3 (C-12 and C-14), 132.7 (C-

8),131.6 (C-4), 131.1. 129.1, 127.8, 126.9, (C-5, C-7, C-8 and C-13), 121.1 (C-6), 54.4
(C-1), 39.8 (C-9), 38.5 (C-10), 25.5 (C-3), 24.9 (C-4).

6.2.2.9 Preparation

of

2-(trans-2-phenyl-1-cyclopropyl)carbonyl-1,2,3,4-

tetrahydroisoquinoline 10

.
To

a

stirred

solution

of

1,2,3,4-

tetrahydroisoquinoline (1 g, 7.5 mmol) in
dry THF (25 mL) and K2CO3 (700 mg, 5.06
mmol)

was

phenylcyclopropane-1-

added

trans-2-

carboxylic

chloride (5, Rˈ= cyclopropylphenyl; Scheme 2.3) (1.36 g, 7.6 mmol).

acid

The above

reaction mixture was warmed (50 °C) and stirred for 3 h. The reaction mixture was then
cooled, filtered and excess solvent removed in vacuo to give the amide which was
recrystallised from diethyl ether and methanol to give the racemic amide 10 as a light
brown powder (1.6 g, 77%), m.p. 149 - 150 ˚C.
CI-MS: m/z 278 (90%, MH+), 145(30%), 132(50%), 117(100%).
HR-MS (EI+): m/z measured 277.1462, calculated for C19 H19NO (M+), 277.1467.
1

H NMR (CDCl3):  1.22 - 1.31 (1H, m, H-12), 1.56 – 1.61 (1H, m, H-11a), 1.82 –

1.91 (1H, m, H-11b), 2.52 – 2.58 (1H, m, H-10), 3.18 (2H, t, J = 8.9 Hz, H-4), 3.42 (2H,
t, J = 9.0 Hz, H-3), 4.18 (2H, s, H-1), 7.08 –7.36 (9H, m, Ar-H).
13

C NMR (CDCl3):  178.0 (C-9, C=O), 139.6 (C-8), 138.1 (C-4), 134.4 (C-13),

128.9, 128.8, 128.5, 127.9, 127.1, 126.7, 126.6, 126.2, 126.1 (C-5, C-6, C-7, C-8, C-14,
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C-15, C-16, C-17, C-18), 44.1 (C-1), 41.8 ( C-10), 31.5 (C-3), 26.8 (C-4), 25.3 (C-12),
17.3 (C-11).

6.2.2.10 Preparation

of

2-(trans-2-phenyl-1-cyclopropyl)methyl-1,2,3,4

tetrahydroisoquinoline 11 ....................................
To a stirred solution of the amide 10 (600
mg, 2.2 mmol) in dry THF under nitrogen,
was added an excess of 2M boranedimethyl sulfide in THF (1.6 g, 22 mmol)
by a syringe and the resultant solution was
heated at reflux for 4 h. The solvent was removed in vacuo and the residue was
dissolved in MeOH (20 mL). K2CO3 (276 mg, 2 mmol) was added to this and the
reaction mixture was further heated at reflux for 4 h. The resultant mixture was cooled,
filtered and MeOH was removed in vacuo and the crude product was dissolved in DCM
(20 mL) washed with water (2 x 15mL) and the dried organic layer collected and
concentrated to give racemic 11 as an oil (0.38 g, 65%); hydrochloride salt m.p. 171 172 ˚C.
CI-MS: m/z 264 (100%, MH+), 134 (50%).
HR-MS (HCl salt) (ESI+): m/z measured 264.1754, calculated for C19 H22N (MH+),
264.1752.
1

H NMR (CDCl3):  0.94 – 1.12 (1H, m, H-12), 1.42 – 1.54 (2H, m, H-11), 1.90 –

1.98 (1H, m, H-10), 2.95 (2H, t, J = 8.9 Hz, H-3), 3.72 (2H, t, J = 8.5 Hz, H-9), 4.15
(2H, s, H-1), 7.05-7.30 (9H, m, Ar-H).
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13

C NMR (CDCl3):  134.6 (C-8), 133.5 (C-4), 133.1 (C-13), 129.5, 128.5, 128.1,

127.8, 127.5, 127.1, 126.9, 126.5, 125.7 (ArCH), 46.3 (C-1), 44.5 (C-9), 42.6 (C-10),
36.6 (C-3), 26.5 (C-4), 25.8 (C-12), 18.2 (C-11).

6.2.2.11 Preparation of 2-allyl-1,2,3,4-tetrahydroisoquinoline 12
A solution of 1,2,3,4 - tetrahydroisoquinoline (1 g, 7.5
5
6

4'

4

mmol) in absolute ethanol (24 mL) and K2CO3 (1.1 g,

3

N

7
8

8'

1

2

10

8 mmol) was stirred under nitrogen. Allyl bromide
9

11

(0.9 g, 7.5 mmol) in ethanol (15 mL) was then added and the resultant mixture was
heated at reflux for 18 h. The reaction mixture was cooled, filtered and the solvent
removed in vacuo to give crude compound 12. The crude product was then passed
through a silica gel column (MeOH: DCM 4:96) to give the desired pure compound
12181 as a pale yellow oil (1.02 g, 78%); hydrochloride salt m.p. 219 – 221 ˚C.
ESI-MS: m/z 174 (100%, MH+).
HR-MS (EI+): m/z measured 173.1202, calculated for C12H15N (M+), 173.1204.
1

H NMR (CDCl3):  2.70 (2H, t, J = 9.5 Hz, H-43), 2.90 (2H, t, J = 9.2 Hz, H-3), 3.05

(2H, d, J = 5.3 Hz, H-9), 3.60 (2H, s, H-1), 5.08-5.17 (2H, m, H-11), 5.80-5.98 (1H, m,
H-10), 7.10-7.22 (4H, m, Ar-H).
13

C NMR (CDCl3):  135.7 (C-11), 134.8 (C-8), 130.1 (C-4), 127. 3 (C-8), 127.1 (C-

7), 125.5 (C-10), 117.4 (C-6), 114.9 (C-5), 56.5 (C-1), 55.5 (C-9), 50.0 (C-3), 29.5 (C4).
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6.2.2.12 Preparation of 2,2-bisallyl-1,2,3,4-tetrahydroisoquinolinium bromide 19
5

'

4

6

9'

3

10

8

Br

1

stirred

solution

of

2-allyl-1,2,3,4-

absolute ethanol (30 mL) was added an equimolar

2

8'

a

tetrahydroisoquinoline (12) (1.1 g, 6.35 mmol) in

10'

N+

7

To

11'

4

11

9

portion of allyl bromide (0.77g, 6.35 mmol) and the
reaction mixture was heated at reflux under an atmosphere of nitrogen for 20 h. The
reaction mixture was then cooled, the solvent removed in vacuo, and the crude product
was precipitated in cold diethyl ether. The separated viscous oil was dissolved in 15ml
of water. The organic phase was washed with ether (30 mL) and the water was
evaporated gently to give the known quarternary salt 19 as white crystalline solid (1.25
g, 92%). The spectral data was consistent with the reported data in the literature.182
ESI-MS: m/z 215 (MH+-Br˙, 98%), 174 (215 -

H2CH=CH2, 54%), 117 (174 –

H2NCH2CH=CH2, 30%).
HR-MS (ESI+): m/z 215.1674, calculated for C15H21N , 215.1674.
1

H NMR (CDCl3):  3.14 (2H, t, J = 9.9 Hz, H-4), 3.92 (2H, t, J = 9.7 Hz, H-3), 4.20

(4H, d, J = 8.4 Hz, H-9 and H-9΄), 4.74 (2H, s, H-1), 5.62 (4H, t, J = 7.2 Hz, H-11 and
H-11΄), 6.19-6.03 (2H, m, H-10 and H-10΄), 7.08-7.30 (4H, m, Ar-H).

6.2.2.13 Preparation of N-(2-phenylethyl)-4-bromophenylacetamide 15
1,3-Dicyclohexylcarbodiimide (5.16 g, 0.025
4

3

'

mol) was added to a cooled solution of 2-

3

5

2

phenylethylamine

1
6

NH

8
7

O
9

(3

g,

0.025

mol)

and

commercially available 4-bromophenylacetic acid

16
15

10
11
14

Br

12
13
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(5.72 g, 0.025 mol) in THF (30 mL). The above reaction was warmed with stirring for
1 h and then left overnight (12 h) with stirring at room temperature. The solution was
filtered and the solvent was removed in vacuo to give the crude product as a colourless
solid (6.9 g, 87%), which was recrystallised from ethyl acetate to give 15 as colourless
crystals (6.6 g, 86%), m.p. 179 - 182 ˚C.
ESI-MS: m/z 318, 320 (MH+, 79Br, 81Br).
HR-MS (EI+): m/z measured 317.2003, calculated for C16H1579BrNO (M+), 317.2005.
1

H NMR (CDCl3):  2.68 (2H, t, J = 9.2 Hz, H-3), 3.21-3.37 (2H, m, H-2), 3.81 (2H,

bs, H-10), 5.39 (1H, bs, NH), 7.02-7.48 (9H, m, Ar-H).
13

C NMR (CDCl3):  168.7 (C-9), 134.7, 134.2 (C-11 and C-14), 131.4 (C-3), 130.7,

129.8, 129.4, 128.9, 128.2, 126.9, 126.6, 125.5, 125.0 (ArCH), 62.1 (C-10), 47.5 (C-2),
30.4 (C-3).
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6.2.2.14 Attempted Bischler-Napieralski cyclisation on amide 15
A hot (70 °C) solution of the amide 15 (0.5g, 1.5
mmol) in dry butyronitrile (12 mL) was added

N

dropwise to a stirred and refluxing solution of freshly
distilled phosphorous oxychloride (0.9g, 4.7 mmol), in
Br

butyronitrile (10 mL) under nitrogen.

heating the reaction mixture to reflux was continued for 14 h.

Stirring and

TLC (DCM: 1%

methanol) on this crude reaction mixture did not give evidence of the cyclised imine 16.

6.2.2.15 Preparation of 3,4-dihydroisoquinoline 17
N-Bromosuccinimide (2.65 g, 0.015 mol) was added portionwise
N

over a period of 20 min to a stirred solution of 1,2,3,4tetrahydroisoquinoline (1, 2.02 g, 0.015 mol) in DCM (30 mL)

under nitrogen. Stirring was continued for a further 1 h. Aqueous NaOH (30%w/v, 50
mL) was added and the two phase mixture was stirred for a further 20 min. Water (15
mL) was then added and the organic phase was separated. The organic phase was
further washed with water (2 x 25 mL) and extracted with 2M HCl (2 x 50 mL). The
combined aqueous extract was washed with DCM (20 mL), then basified with
concentrated aqueous ammonia solution (15 mL). The basified solution was extracted
with DCM (3 x 25mL), dried and concentrated in vacuo to give a dark coloured oil.
The oil was then distilled (bath temp 137 °C, in vacuo) using a vacuum Kugelruhr
distillation apparatus to give pure 17 as a colourless oil (1.64 g), which was used
immediately for the zinc coupling reaction in the preparation of compound 18 as it
tended to polymerize readily. The 1H NMR spectral data for 17 was consistent with that
given in the literature.183
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6.2.2.16 Preparation of 1-(4-bromobenzyl)-1,2,3,4-tetrahydroisoquinoline 18
5

4-Bromobenzyl bromide (9.5 mmol, 2.38 g) was added

4

'
4

6

3

at room temperature to a stirred suspension of

2
7
8

'

NH

*

8

activated zinc powder (15 mmol, 0.98 g) in dry THF

1
15

(30 mL) under nitrogen. The mixture was cooled to 0

9
14

10

˚C and to this cooled solution was added portionwise,

11
13
12

Br

3,4-dihydroisoquinoline 17 (8.8 mmol, 1.15 g) in dry
THF (15 mL). Stirring was continued for a further 24 h. To this was then added
saturated aq. NaHCO3 (15 mL). The reaction mixture was filtered through celite and
the organic layer separated by extraction with DCM (3 x 30 mL). The combined
organic fractions were again extracted with 2M HCl (3 x 30 mL), the acid extract
washed with DCM (15 mL), and then the aqueous layer was basified using 10 M NaOH
(16 mL). The basified solution was then extracted using DCM (3 x 30 mL), dried and
excess solvent removed in vacuo to give a crude residue. Purification by column
chromatography (using DCM: MeOH 95:5) gave 18 as a light yellow coloured solid
(2.16 g, 81%), m.p. 103 - 105 ˚C
CI-MS: m/z 302, 304 (MH+, 79Br, 81Br).
HR-MS (ESI+): m/z measured 302.0432, calculated for C16H1679BrN (MH+), 302.0436.
1

H NMR (CDCl3):  2.67 (2H, t, J = 9.2 Hz, H-4), 3.08 (2H, t, J = 8.8 Hz, H-3), 3.54

(1H, t, J = 6.6 Hz, H-1), 3.91-3.96 (2H, m, H-9), 7.11-7.28 (8H, m, Ar-H).
13

C NMR (CDCl3):  134.5 (C-13), 133.3 (C-10), 132.4 (C-8), 131.5 (C-4), 130.6,

129.6, 129.2, 128.7, 128.1, 125.8, 125.2, 124.6 (Ar-C), 62.2 (C-1), 53.5 (C-9), 48.6 (C3), 29.5 (C-4).
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6.2.2.17 Preparation of (E)-4-bromomethyl stilbene 20
7

To a stirred solution of (E)-4-chloromethyl

6
15

5
1

Br

2

stilbene 14 (106 g, 4.63 x 10-4 mol) in dry

14

8
3

13
4

9

10
11

acetonitrile (25 mL) was added an excess of

12

NaBr (2.2 g) and the mixture was allowed to stir
with warming to 45˚C for about 2 h. Further NaBr (1 g) was then added and the
reaction mixture then stirred for 18 h at 40 ˚C. The reaction mixture was then cooled to
room temperature, filtered, and concentrated through solvent evaporation in vacuo to
give known 20 as a white crystalline solid (119 mg, 95%), m.p. 114 – 115 ˚C (Lit.184
m.p. 117 – 118 ˚C).
CI-MS: m/z 273, 275 (MH+, 79Br, 81Br).
HR-MS (EI+): m/z measured 272.0200, calculated for C15H1379Br (M+), 272.0201.
1

H NMR (CDCl3):  4.42 (2H, s, H-1), 6.98 (1H, d, J = 14.2 Hz, H-8), 7.18 (1H, d, J =

14.0 Hz, H-9), 7.31-7.60 (8H, m, Ar-H).
13

C NMR (CDCl3):  140.2 (C-2), 137.5 (C-8), 135.8 (C-5), 135.1 (C-10), 132.4,

132.1, 131.1, 128.8, 128.1, 127.9, 127.5, 127, 125.7 (9-Ar), 123.2 (C-9), 54.3 (C-1).
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6.2.2.18 Preparation of (E)-1-(4-stilbenyl)methyl-1,2,3,4-tetrahydroisoquinoline 21
A suspension of activated zinc powder
(0.2 g, 3.07 mmol) in dry THF (30 mL)
under nitrogen was allowed to stir for 2 h.
To this was added a solution of (E)-4bromomethyl stilbene 20 (0.83 g, 3.05
mmol) in THF (20 mL) and the resultant
mixture was stirred for 3 h at room
temperature.

The mixture was then

cooled to 0 ˚C in an ice bath and to this
cooled solution was added slowly 3,4-dihydroisoquinoline 17 (8.8 mmol, 1.15 g) in dry
THF (15 mL). Stirring was continued for a further 36 h at room temperature. To this
stirred solution was then added saturated aqueous NaHCO3 solution (15 mL). The
reaction mixture was filtered through celite and the organic layer separated by
extraction with DCM (3 x 30 mL).

The combined organic fractions were again

extracted with 2M HCl (3 x 30 mL), the combined acid extract washed with more DCM
(15 mL) and then the aqueous extract was basified using 10M NaOH (16 mL). The
basified solution was then extracted with DCM (3 x 30 mL), dried and excess solvent
removed in vacuo to give the crude amine 21 (0.8 g), for which the following spectral
data were obtained. Purification of the desired compound 21 was not achieved as it was
unstable. Formation of some oxidation product 25 was suggested from the CI-MS (m/z
340, 40%, MH+)
CI-MS: m/z 326 (82%, MH+, amine 21), 193 (59%, +CH2PhCH=CHPh), 132 (42%,
MH-H, PhCH=CHPhCH2 or MH+, imine 17).
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1

H NMR (CDCl3):  2.84 (2H, t, J = 9.54 Hz, H-4), 3.18 (2H, t, J = 8.38 Hz, H-3),

3.42 (1H, t, H-1), 3.96-4.01 (2H, m, H-9), 6.98-7.57 (15H, m, H-16, H-17, Ar-H).

6.2.2.19 Preparation of (E)-1-cinnamyl-1,2,3,4-tetrahydroisoquinoline 22
5

A suspension of activated zinc powder (0.16 g, 2.4

4
4'

6

3

mmol) in dry THF (30 mL) under nitrogen was

2
7
8

NH

*

8'

allowed to stir for 2 h.

To this was added a

1

9

solution of cinnamyl bromide 13 (0.48 g, 2.4

10

mmol) in THF (20 mL) and the resultant mixture

17
11
16

12

was stirred for 3 h. The mixture was then cooled to
15

13
14

0 ˚C in an ice bath and to this cooled solution was

added slowly 3,4-dihydroisoquinoline 17 (0.3 g, 2.3 mmol) in dry THF (15 mL).
Stirring was continued for a further 36 h at room temperature. To this solution was then
added a saturated solution of sodium bicarbonate (15 mL). The reaction mixture was
filtered through celite and the organic layer separated by extraction with DCM (3 x 30
mL). The combined organic fractions were again extracted with 2 M HCl (3 x 30 mL),
the combined acid extract washed with more DCM (15 mL), and then the aqueous
extract was basified using 10 M sodium hydroxide (16 mL). The basified solution was
then extracted using DCM (3 x 30mL), dried and excess solvent removed in vacuo to
give the crude amine 22 (0.25g), for which the following spectral data were obtained. A
contaminating product with the amine 22, was believed to be the coupled diene 26 on
the basis of a peak at m/z 235 (MH+, C8H19) in the CI-MS.
CI-MS: m/z 250 (MH+, compound 22)
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1

H NMR (CDCl3):  2.38 (2H, t, J = 9.3 Hz, H-4), 2.61 (2H, t, J = 8.7 Hz, H-3), 3.41

(1H, t, J = 5.7 Hz, H-1), 4.90-5.15 (2H, m, H-9), 6.02-6.20 (1H, m, H-10), 6.38-6.52
(1H, m, H-11), 7.10-7.52 (9H, m, Ar-H).

6.2.2.20 Preparation of (E)-2-cinnamyl-1,2,3,4-tetrahydroisoquinoline 23
Cinnamyl bromide (0.18 g, 1.88
5
6

4'

4
14

3

N

7
8

8'

1

mmol) was added to a stirred solution

13

2

15

10
12

9

of 1,2,3,4-tetrahydroisoquinoline (1,

11

16
17

0.13 g, 1.87 mmol) and K2CO3 (0.56

g) in absolute ethanol (30 mL) and the above reaction mixture was heated at reflux
overnight (16 h). The mixture was then cooled to room temperature, filtered and
concentrated to give a crude pale yellow solid which was recrystallised from diethyl
ether/MeOH to afford 23 as pale yellow crystals (0.30 g, 65%), m.p. 167 - 169 ˚C.
CI-MS: m/z 250 (100%, MH+), 148 (15%), 134 (30%).
HR-MS (CI+): m/z measured 250.1594, calculated for C18H20N (MH+), 250.1596.
1

H NMR (CDCl3):  2.81 (2H, t, J = 9.8 Hz, H-4), 2.94 (2H, t, J = 8.8 Hz, H-3), 3.36

(2H, d, J = 7.4 Hz, H-9), 3.72 (2H, s, H-1), 6.42-6.31 (1H, m, H-10), 6.62 (1H, d, J =
18.2 Hz, H-11), 7.14-7.44 (9H, m, Ar-H).
13

C NMR (CDCl3):  136.6 (C-12), 134.2 (C-8), 133.8 (C4), 132.8 (C-11), 128.3,

128.2, 127.2, 126.321 (Ar, C-5, C-6, C-7, C-8), 126.3, 126.054, 125.9, 125.9, 125.8 (Ar,
C-13, C-14, C-15, C-16, C-17), 125.5 (C-10), 60.4 (C-9), 55.7 (C-1), 50.4 (C-3), 28.6
(C-4).
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6.2.2.21 Preparation of (E)-2-(4-stilbenyl) methyl-1,2,3,4-tetrahydroisoquinoline 24
(E)-4-Chloromethylstilbene

20
19

21

(0.1 g, 0.37 mmol) was
5

'

4
3

11

2

10

N

7
8

8'

18
22

4

6

16

12

1

13

14

9

17

23

added to a stirred solution
of

1,2,3,4-

15

tetrahydroisoquinoline

(1,

50 mg, 0.37 mmol) and K2CO3 (22 mg) in absolute ethanol (20 mL) and the above
reaction mixture was heated at reflux for 16 h. The mixture was then cooled to room
temperature, filtered and concentrated to give a crude pale yellow coloured solid which
was recrystallised from diethyl ether/MeOH to afford 24 as pale yellow crystals (89 mg,
74%), m.p. 137 - 139 ˚C.
CI-MS: m/z measured 326 (100%, MH+), 193 (95%, +CH2PhCH=CHPh), 134 (75%).
HR-MS (EI+): m/z measured 325.1828, calculated for C24H23N (M+), 325.1831.
1

H NMR (CDCl3):  2.84 (2H, t, J = 8.8 Hz, H-4), 3.08 (2H, t, J = 9.2 Hz, H-3), 3.96

(2H, s, H-1), 4.50 (2H, s, H-9), 6.42 (1H, d, J = 17.9 Hz, H-16), 6.64 (1H, d, J = 18.2
Hz, H-17), 7.04-7.59 (13H, m, Ar-H).
13

C NMR (CDCl3):  139.2 (C-10), 136.7 (C-16), 134.4 (C-13), 133.8 (C-18), 131.7

(C-8), 131.3 (C-4), 130.6, 129.0, 128.9, 128.7, 128.6, 128.1, 128.0, 127.9, 127.4,
127.3, 127.2, 127.1, 126.6 (Ar), 126.4 (C-17), 57.8 (C-1), 51.4 (C-9), 48.2 (C-3), 25.3
(C-4).
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6.2.3

Experimental for Chapter 4 (Section 4.6)

6.2.3.1 Preparation of [3(S)-(1α,5α,3β)]-α-(hydroxymethyl)benzeneacetic acid 8methyl-8-azabicyclo[3.2.1]oct-6-en-3-yl ester 41
From Tarrant,166,185 a solution of scopolamine 40
(12.17 g, 40.2 mmol; derived from scopolamine
hydrochloride by basification) in ethanol (140 mL),
was added dropwise to a refluxing suspension of
freshly prepared zinc/copper couple167 (50 g) and
ethanol (200 mL). The resulting mixture was further
heated at reflux for 14 h. The zinc dust was then
removed by decanting followed by filtering. Evaporation of the solvent yielded the
ester 41166 as a colourless oil (11.50 g, 40.1 mmol, 99%).
ESI-MS: m/z 288 (MH+).
EI-MS: m/z 287 (70%, M+), 164, 150, 138, 121 (100%) and 103.
HR-MS (EI+): m/z measured 287.1519, calculated for C17H21NO3 (M+), 287.1521
1

H NMR (CDCl3):  1.55 (1H, d, J = 11.1 Hz, H-2e), 1.72 (1H, d, J = 11.4 Hz, H-4e),

2.91 (5H’s, m, NCH3, H-2 and H-4a), 3.34 (1H, s, H-1), 3.45 (1H, s, H-4), 3.72 – 3.76
(1H, m, H-2′), 3.80 – 3.84 (1H, m, H-3’), 4.13 (1H, dd, J = 8.4, J = 6.6 Hz, H-3′), 5.02 –
5.11 (1H, m, H-3), 5.40 (1H, dd, J = 4.5 Hz, J = 1.5 Hz, H-6), 5.83 (1H, dd, J = 4.5 Hz,
J = 1.5 Hz, H-7) and 7.37-7.22 (5H, m, Ar-H).
Note: ‘e’ refers to equatorial and ‘a’ refers to axial hydrogens.
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13

C NMR (CDCl3):  171.6 (C=O), 135.8 (Ar), 131.0 (C-6 and C-7), 128.6 (Ar), 128.1

(Ar), 127.5 (Ar), 66.9 (C-3), 65.4 (C-1 or C-5), 65.4 (C-1 or C-5), 63.8 (C-3′), 54.3
(C2′), 41.9 (NCH3), 32.7 (C-2 or C-4), 32.5 (C-2 or C-4).

6.2.3.2 Preparation of 8-methyl-8-azabicyclo[3.2.1]oct-6-en-3α-ol 42
From Tarrant,166,185 a solution of the ester 41 (30 g, 105 mmol),
methanol (150 mL) and 10% sodium hydroxide solution (200 mL)
was heated at reflux for 2 h. The excess organic solvent was
evaporated and the solution was then extracted with chloroform (3
x 250 mL). The combined chloroform extracts were dried and evaporated to yield
42166,185 as an oil (10.71 g, 77.1 mmol. 74%).
EI-MS: m/z 139 (M+).
HR-MS (EI+): m/z measured 139.1000, calculated for C8H13NO (M+), 139.0997.
1

H NMR (CDCl3):  1.81 (2H, d, J=12.6Hz, H-2e and H-4e), 2.16-2.26 (5H, m, NCH3,

H-2a and H-4a), 3.43 (2H, s, H-1 and H-5), 3.85 (1H, t, J = 11.0 Hz, H-3), 6.24 (2H, s,
H-6 and H-7). Note: ‘e’ refers to equatorial and ‘a’ refers to axial hydrogens.
13

C NMR (CDCl3):  134.2 (C-6 and C-7), 66.0 (C-1 and C-5), 65.1 (C-3), 41.5

(NCH3) and 37.3 (C-2 and C-4).
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6.2.3.3 Preparation of benzhydryl chloride 44
Cl

To thionyl chloride (25 mL, 12 mmol) at 0 ˚C was added
benzhydrol 43 (2 g, 11 mmol) under an atmosphere of
nitrogen. The reaction mixture was then heated at reflux

with stirring for 15 h. The reaction mixture was then cooled to room temperature and
the volatiles removed in vacuo. Addition of dry toluene (2 x 20 mL) and removal of the
solvent in vacuo ensured complete removal of thionyl chloride, to afford 44 as white
needles (87%) on cooling, m.p 18 – 20 °C (Lit.186 m.p. 15 - 17 °C). The spectral data
were consistent with those published.186

6.2.3.4 Preparation of 3α-(1,1-diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]oct6-ene 31
Benzhydryl chloride 44 (1.2 g, 7.2 mmol) was added
in small portions to 8-methyl-8-azabicyclo[3.2.1]oct6-en-3α-ol 42 (1 g, 7.2 mmol) as a melt at 160 ˚C in
an oil bath over a period of 2 min.

Heating the

reaction mixture at 160 ˚C for a further 15 min
resulted in evolution of HCl gas and the formation of
a dark brown viscous oil which then solidified upon cooling. This crude product was
dissolved in chloroform (25 mL) and transferred to a separating funnel. Separation of
the desired product was achieved by extraction with 2M HCl (3 x 25 mL) to remove
residual starting material 44, followed by basification of the combined acidic extract
and then extraction with chloroform (2 x 25 mL). The combined organic fractions were
evaporated to give crude 31 which upon purification by column chromatography (DCM:
2% MeOH) gave 31 as a light coloured thick liquid (1.42 g, 65%).
221

EI-MS: m/z 305 (70%, M+), 167, 138.
HR-MS (EI+): m/z measured 305.1778, calculated for C21H23NO (M+), 305.1781.
1

H NMR (CDCl3):  2.01 (2H, d, J = 12.1 Hz, H-2e and H-4e), 2.85 (3H, s, NCH3),

2.91 (2H, d, J = 10.7 Hz, H-2a and H-4a), 3.85 – 3.88 (1H, m, H-3), 4.01 (2H, s, H-1
and H-5), 5.31 (1H, s, H-9), 6.11 (2H, s, H-6 and H-7), 7.22-7.51 (10H, m, Ar-H).
13

C NMR (CDCl3):  136.2 (C-10), 135.4 (C-10’), 133.8 (C-6 and C-7), 130.4, 129.8,

129.4, 127.8, 127.5, 127.2, 126.6, 125.5 (ArCH), 66.1 (C-1 and C-5), 64.7 (C-3), 41.2
(NCH3), 37.2 (C-2 and C-4).

6.2.3.5 Preparation

of

3α-[1-(4-chlorophenyl)-1-phenyl]methoxy-8-methyl-8-

azabicyclo[3.2.1]oct-6-ene 32
Commercially available 1-(4-chlorophenyl)-1-phenyl
chloromethane 45 (0.57 g, 2.24 mmol) was added
dropwise to the alcohol 42 (0.29 g, 2.24 mmol) melt at
160 ˚C in an oil bath over a period of 5 min. Evolution
of hydrogen chloride gas over 30 min resulted in a light
brown viscous oil which solidified upon cooling. TLC
analysis indicated that all the alcohol 42 had reacted.
The crude product was dissolved in chloroform (25 mL) and transferred to a separating
funnel. The chloroform solution was extracted with 2M HCl (3 x 25 mL; to remove
residual starting material 45) followed by basification with concentrated aqueous
ammonia and extraction of the basic aqueous solution with chloroform (2 x 25mL). The
combined organic fractions were dried and evaporated in vacuo to give a light brown
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solid which upon crystallisation from diethyl ether gave 32 (0.57 g, 71%) as cream
coloured flakes, m.p. 161 - 163 ˚C.
EI-MS: m/z 339 (80%, M+), 201, 138.
HR-MS (EI+): m/z measured 339.1386, calculated for C21H22ClNO (M+), 339.1390.
1

H NMR (CDCl3):  1.84 (2H, d, J = 12.3 Hz, H-2e and H-4e), 2.15-2.30 (5H, m,

NCH3, H-2a, and H-4a), 3.42-3.54 (2H, m, H-1 and H-5), 3.9-4.10 (1H, m, H-3), 5.31
(1H, s, H-9), 6.22 (2H, s, H-6 and H-7), 7.18-7.52 (9H, m, Ar-H).
13

C NMR (CDCl3):  137.4 (C-10 or C-10’), 135.7 (C-10 or C-10’), 134.5 (C-6 and C-

7), 131.4, 130.8, 129.4, 127.9, 126.6, 126.4, 126.1, 125.5 (Ar-C), 65.5 (C-1 and C-5),
64.7 (C-3), 40.2 (NCH3), 36.6 (C-2 and C-4).

6.2.3.6 Preparation of 3β-8-methyl-8-azabicyclo[3.2.1]oct-6-en-3-yl benzoate 47
Diethyl azodicarboxylate (0.25 g, 1.44 mmol) was added
to a stirred solution of 42 (0.2 g, 1.44 mmol),
triphenylphosphine (0.37 g, 1.44 mmol), benzoic acid 46
7

(0.18 g, 1.5 mmol) and dry THF (15 mL). This reaction
mixture was cooled to 0 ˚C and allowed to stir at that

temperature for 3 h and was then stirred overnight (14 h) at room temperature. The
solvent was evaporated and the resulting oil was purified by flash chromatography
using 6% MeOH in 94% DCM to yield the crude ester as white crystals which were
recrystallised from ethyl acetate/light petroleum to yield the ester 47 as colourless
needles (0.25 g, 72%), m.p. 134 – 136 ˚C
EI-MS: m/z 243 (M+), 122, 121.
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HR-MS (ESI+): m/z measured 244.1342, calculated for C15H18NO2 (MH+), 244.1338.
1

H NMR (CDCl3):  1.90 – 1.98 (2H, m, H-2e and H-4e), 2.11 – 2.22 (2H, m, H-2a

and H-4a), 3.21 (2H, s, H-1 and H-5), 5.09 (1H, dddd, J2e-3 = 6.96 J2a-3 = 6.96 J4a-3 =
9.64, H-3), 5.99 (2H, s, H-6 and H-7), 7.41 – 7.50 (2H, m, Ar), 7.53 – 7.68 (1H, m, ArH), 8.00 - 8.33 (2H, m, Ar-H).
13

C NMR (CDCl3):  165.9 (C=O), 132.8 (Ar), 130.5 (Ar), 129.7 (Ar), 129.2 (C-6 and

C-7), 128.4 (Ar), 68.6 (C-3), 66.4 (C-1 and C-5), 40.5 (NCH3), 32.2 (C-2 and C-4).

6.2.3.7

Preparation of 8-methyl-8-azabicyclo[3.2.1]oct-6-en-3β-ol 48
To a stirred solution of methanol (30 mL) and 10% aqueous
KOH (19 mL) was added the ester 47 (0.85 g, 3.5 mmol) and the
reaction mixture was heated at reflux for 2 h. Methanol was then
removed in vacuo and the aqueous solution was extracted with

DCM (3 x 25 mL) and the combined organic fractions were concentrated to give the
alcohol 48 as a colourless oil (0.29g, 60%). The NMR spectral details for 48 were
consistent with that reported in literature187 for an impure sample.
HR-MS (EI+): m/z measured 139.0094, calculated for C8H13NO (M+), 139.0097.
1

H NMR (300MHz, CDCl3):  1.90 – 2.00 (2H, m, H-2e and H-4e), 2.11 – 2.31 (2H,

m, H-2a and H-4a), 2.34 (3H, s, NCH3), 3.55 (2H, s, H-1 and H-5), 4.42-4.52 (1H, m,
H-3), 5.99 (2H, s, H-6 and H-7),
13

C NMR (75MHz, CDCl3):  132.8 (C6 and C7), 65.6 (C1 and C5), 64.9 (C3), 41.2

(NCH3) and 37.5 (C2 and C4).
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6.2.3.8 Attempted

of

preparation

3β-(1,1-diphenylmethoxy)-8-methyl-8-

azabicyclo[3.2.1]oct-6-ene 33
Benzhydryl chloride 44 (1.2 g, 7.2 mmol) was
added

in

small

portions

azabicyclo[3.2.1]oct-6-en-3β -ol

to

8-methyl-848 (1 g, 7.2

mmol) as a melt at 160 ˚C in an oil bath over a
period of 2 min. Heating the reaction mixture at
160 ˚C for a further 15 min did not give evidence
for the formation of the desired product using TLC. Further heating of this reaction
mixture at 160 ˚C for 30 min did not give any MS evidence for the formation of 33.

6.2.3.9 Attempted preparation of 3β-[1-(4-chlorophenyl)-1-phenyl]methoxy-8methyl-8-azabicyclo[3.2.1]oct-6-ene 34

Commercially

available

1-(4-chlorophenyl)-1-phenyl

chloromethane 45 (0.57 g, 2.24 mmol) was added
dropwise to the alcohol 48 (0.29 g, 2.24 mmol) melt at
160 ˚C in an oil bath over a period of 5 min.

The

reaction mixture was heated at 160 ˚C for 30 min. TLC
analysis did not give evidence for the desired 34 and
mostly unreacted alcohol 48 was recovered.
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6.2.3.10 Synthesis of 1-(3-pyridyl)-phenyl methanol 50
3-Benzoylpyridine 49 (1.5 g, 8.19 mmol) was dissolved in
2
1

3

6

4

methanol (25 mL) with stirring and the stirring was
continued for a further 15 min while the reaction mixture

5

was cooled to 0 °C. To this mixture was added sodium
borohydride (0.31 g, 8.19 mmol) portionwise over 5 min. The reaction mixture was
stirred for 1 h at room temperature. Solvent was then evaporated in vacuo to give a
crude residue, which was extracted with ethyl acetate (3 x 40 mL) to give 50, after
solvent evaporation in vacuo, as a semisolid mass (1.44 g, 94%).
EI-MS: m/z 185 (100%, M+), 168 (25%, M+-OH), 106 (80%)
HR-MS (EI+): m/z measured 185.0839, calculated for C12H11NO (M+), 185.0841.
1

H NMR (CDCl3):  5.62 (1H, s, CH-OH), 7.01-7.28 (7H, m, Ar), 8.02 (1H, d, J = 4.3

Hz, H-6), 8.25 (s, 1H, H-2).

6.2.3.11 Synthesis of 1-[(3-pyridyl)-1-phenyl] chloromethane 51
A solution of the alcohol 50 (1 g, 5.4 mmol) and DCM (40
2
1

3

mL) was stirred for 15 min at room temperature. Thionyl
chloride (1.5 mL) was then added to this mixture and the

6

4
5

resultant mix was heated at reflux for 1 h. The reaction

mixture was cooled, basified with 5% aqueous NaHCO3 solution and the organic layer
separated and concentrated to give 51188 as off white coloured flakes, m.p. 146 – 148 ˚C
(Lit.188 m. p. 145 – 146 ˚C) (0.85 g, 78%).
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HR-MS (EI+): m/z measured 203.0500, calculated for C12H1035ClN (M+), 203.0502.
1

H NMR (CDCl3):  6.32 (1H, s, CH-Cl), 7.24-7.41 (7H, m, Ar), 8.35 (1H, d, J = 4.4

Hz, H-6), 8.75 (1H, s, H-2).

6.2.3.12 Attempted synthesis of 3α-[1-(3-pyridyl)-1-phenyl]methoxy-8-methyl-8azabicyclo[3.2.1]oct-6-ene 35
Sodium hydride (60%) (0.1 g) was washed with dry
dioxan and to the solid was added dry DMF (2 mL)
under a nitrogen atmosphere. The alcohol 42 (100 mg)
was added and the mixture was stirred for 30 min. To
this was added 51 (68 mg) in DMF (3 mL). The
resultant reaction mixture was then stirred at room
temperature for 16 h, and then heated at 80 ˚C for 5 h.
The reaction mixture was diluted with water and extracted with EtOAc (3 x 10 mL).
The solvent layer was separated, dried over Na2SO4 and concentrated under vacuum to
give the crude product. Purification of this crude material was attempted with a silica
gel column using 2 % MeOH-CHCl3 as the eluting solvent but no pure product was
obtained.

6.2.3.13 Synthesis of oscine 53
Scopolamine hydrobromide (0.87 g, 2.27 mmol) was dissolved
in methanol (25 mL). A 10% KOH solution (25 mL) was

1

2

5
7

4

3

added to form scopolamine 40 and the solution was then

6
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heated at reflux for 2 h. The reaction mixture was then cooled and extracted with DCM
(3 x 50 mL) and the organic extract dried and concentrated in vacuo to give oscine 53 as
a white solid (0.28 g, 80%), m.p. 103 - 105 ˚C (Lit.189 m.p. 107 – 109 ˚C)
EI-MS: m/z 155 (50%, M+).
HR-MS (EI+): m/z measured 155.0943, calculated for C8H13NO2 (M+), 155.0946.
1

H NMR (CDCl3):  1.44 (2H, d, J = 13.8 Hz, H-4), 1.80-1.91 (1H, m, H-2), 2.33 (1H,

d, J = 12 Hz, H-2), 2.58 (3H, s, NCH3), 2.98 (1H, s, H-5), 3.68-3.81 (2H, m, H-1 and
H-7), 4.24 (1H, s, H-3), 4.48(1H, s, H-6).

6.2.3.14 Attempted synthesis of oscine ether 36
Sodium hydride (60%) (0.48 g, 1.29 mmol) was washed with
N
CH3

dry 1,4-dioxane and to the solid was added dry DMF (2.3

N

mL) under a nitrogen atmosphere. Oscine 53 (100 mg, 0.65

O
O

mmol) was added to this solution and stirred for 30 min. To
this solution was added 51 (0.155 g, 0.65 mmol) in DMF (3

mL). The resultant reaction mixture was stirred at room temperature for 16 h, and then
heated at 80 ˚C for 5 h. The reaction mixture was cooled, diluted with water (10 mL)
and extracted with EtOAc (3 x 12 mL). The organic solvent layer was separated, and
concentrated in vacuo. The residue was passed through a silica gel column using
MeOH-CHCl3 (2:98) as the eluting solvent to give a mixture of unidentified products
but none of the desired ether 36.
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6.2.3.15 Preparation of 3-chloro-[1]benzothiophene-2-carbonyl chloride 55
Thionyl chloride (11.1 mL, 90 mmol) was added to a solution
Cl
Cl

of (E)-cinnamic acid 54 (4.5 g, 3 mmol) in toluene (50 mL)
and pyridine (0.5 mL, 3 mmol). The above reaction mixture

S

O

was then heated at reflux for 48 h. The reaction mixture was
then cooled to room temperature and then filtered. The filtrate was concentrated in
vacuo to give a crude residue. This residue was purified by column chromatography
using 2% ethyl acetate: n-hexane as the eluent to give the pure compound which was
recrystallised from DCM to afford the acid chloride 55 (4.5 g, 64%) as yellow needles,
m.p. 114 - 116 C (Lit.190 m.p. 114.4 - 115.1 C). The MS and NMR spectral data and
m.p. were consistent with that reported in the literature.190

6.2.3.16 Preparation of 1-(3-chloro-[1]benzothiophene-2-carbonyl)-piperidine 37
The acid chloride 55 (0.4 g, 1.7 mmol) was added
slowly to a stirred solution of piperidine (0.15 g, 1.7
mmol) and K2CO3 (0.5 g) in dry THF (20 mL). The
mixture was heated at reflux using an oil bath for 2 h.
The reaction mixture was then cooled, filtered and the
filtrate was concentrated in vacuo to give a pale yellow oil which was purified by
column chromatography (MeOH : DCM 3:97) to collect 10 fractions (15 mL each).
The first 6 fractions were combined and concentrated to give 37 (0.38 g, 81%) as pale
yellow crystals, m.p. 181 - 183 ˚C.
EI-MS: m/z 279, 281 (60%, 30%, 35Cl, 37Cl) (M+), 244 (80%, M+-Cl), 160 (90%, 244C5H10N).
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HR-MS (EI+): m/z measured 279.0482, calculated for C14H1435ClNOS (M+), 279.0485.
1

H NMR (CDCl3):  1.52-1.64 (6H, m, H-10, H-11 and H-12), 3.22 (4H, t, J = 5.9 Hz,

H-9 and H-13), 7.22-7.42 (4H, m, Ar-H).
13

C NMR (CDCl3):  161.6 (C-8), 137.5 (C-2), 135.9 (C-3), 133.8 (C-7΄), 130..5 (C-

3΄), 126.6, 125.6, 122.9, 122.6 (4 x ArCH), 48.7 (C-9 and C-13), 26.8 (C10 and C-12),
24.6 (C-11).

6.2.3.17 Preparation of 4-(3-chloro-[1]benzothiophene-2-carbonyl)-morpholine 38
The acid chloride 55 (0.4 g, 1.7 mmol) was added slowly
to a stirred solution of morpholine (0.15 g, 1.7 mmol)
and K2CO3 (0.3 g) in dry THF (25 mL). The mixture
was heated at reflux for 2 h. The reaction mixture was
then cooled, filtered and the filtrate was concentrated in vacuo to give a pale yellow oil
which was purified by column chromatography (MeOH : DCM 1:99) and combined
fractions were concentrated to give the amide 38 (0.36 g, 76%) as a pale yellow oil.
EI-MS: m/z 281, 283 (70%, 30%, 35Cl, 37Cl) (M+), 246 (25%, M+-Cl), 160 (100%, 246
– C4H8NO).
HR-MS (EI+): m/z measured mass 281.0275, calculated for C13H1235ClNO2S (M+),
281.0277.
1

H NMR (CDCl3):  2.78 (4H, t, J = 5.3 Hz, H-10 and H-11), 3.59 (4H, t, J = 5.1 Hz,

H-9 and H-12), 7.41-7.82 (4H, m, Ar-H).
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13

C NMR (CDCl3):  162.4 (C-8), 137.3 (C-2), 135.4 (C-3), 132.5 (C-7΄), 132.1 (C-3΄),

126.5, 125.3, 122.5, 122.4 (4 x ArCH), 67.7 (C-9 and C-12), 46.2 (C10 and C-11).

6.2.3.18 Preparation

of

1-(3-chloro-[1]

benzothiophene-2-carbonyl)-4-

phenylpiperazine 39
A solution of the acid chloride 55 (0.4 g, 1.7
mmol), phenyl piperazine (0.35 g, 2 mmol) in
dry THF (25 mL) was stirred with warming in
the presence of K2CO3 (0.34 g) for 30 min. The
solution was then heated at reflux for 3 h. The
mixture was cooled, filtered and the filtrate was
concentrated in vacuo to give a pale yellow gelatinous mass which upon purification
using preparative TLC (DCM : MeOH 95:5) gave the amide 39 (0.46 g, 76%) as an oil.
EI-MS: m/z 356, 357 (65%, 30%, M ˙,

35

Cl,

37

Cl) (100%), 195, 197 (50%, M+-

C10H13N2)
HR-MS (EI+): m/z measured 356.0746, calculated for C19H1735ClN2OS (M+), 356.0750.
1

H NMR (CDCl3):  3.34 (4H, t, J = 5.2 Hz, H-9 and H-12), 4.14 (4H, t, J = 5.7 Hz, H-

10 and H-11), 7.18–7.31 (9H, m, Ar-H).
13

C NMR (CDCl3):  165.4 (C-8), 135.3 (C-2), 133.4 (C-3), 132.1 (C-7΄), 131.7 (C-3΄),

129.6, 129.4, 129.1, 128.4, 127.1, 126.5, 125.3, 122.5, 122.4 (9 x ArCH), 65.7 (C-9 and
C-12), 50.1 (C10 and C-11).
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6.3

PHARMACOLOGICAL TESTING (CHAPTERS 2 AND 4)

The D2 and D4 receptor in vitro binding assay on the designed ligands (Chapter 2) was
conducted by H. Hübner191 in the Department of Medicinal Chemistry, FriedrichAlexander University, Erlangen, Germany. The assay involved human dopamine D2long
(the long isoform of D2 receptor subtype that functions as a post-synaptic receptor) and
D4 receptors which were hererologously expressed in the mammalian cell line (Chinese
Hamster Ovary (CHO)). These expressed receptors were then used for competition
binding analysis measuring radioligand [3H] spiperone displacement.

The in vitro dopamine transporter binding studies of the synthesised target ligands
(Chapter 4) were conducted at the Australian Nuclear Science and Technology
Organisation, Lucas Heights, NSW Australia through Dr. A. Katsifis.
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